Mrgprx2 inhibitor compounds

WO2026213351A3PCT designated stage Publication Date: 2026-11-19EVOMMUNE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/021985
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-05
Filing Date
2026-04-01
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

MrgprX2 receptors, when overactivated, contribute to inflammatory and allergic diseases such as pseudoallergic reactions and anaphylaxis, and existing treatments are inadequate.

Method used

Development of MrgprX2 inhibitor compounds, including MrgprX2 antagonist compounds, to inhibit the receptor and prevent inappropriate activation.

Benefits of technology

The MrgprX2 inhibitor compounds effectively reduce inflammation and allergic responses, providing a therapeutic avenue for treating inflammatory disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are MrgprX2 inhibitor compounds. In some embodiments, the MrgprX2 inhibitor compound is a compound of formula (Ia). Also provided are pharmaceutical compositions including a MrgprX2 inhibitor compound and a pharmaceutically acceptable excipient. Further provided are methods of use of such compounds, including, e.g., methods of treating a subject for an inflammatory disorder.
Need to check novelty before this filing date? Find Prior Art

Description

Atty Dkt No.: EVOM-008WOMRGPRX2 INHIBITOR COMPOUNDSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] Pursuant to 35 U. S. C. §119(e), this application claims priority to the filing date of United States Provisional Application Serial No. 63 / 782,444 filed April 2, 2025, and to the filing date of United States Provisional Application Serial No. 63 / 876,626 filed September 5, 2025, the disclosures of which applications are incorporated herein by reference in their entirety.INTRODUCTION

[0002] Mas-related G protein-coupled receptors (Mrgprs) are a subfamily of receptors that play an important role in various physiological processes including, e.g., inflammation, immune responses and sensory processes (e.g., itch and pain sensations). One member of the subfamily is Mas-related G protein-coupled receptor X2 (MrgprX2), which is expressed in humans and predominantly found on mast cells. Mast cells are an integral part of the immune system, and are found in various tissues, including the skin, lungs and digestive tract.

[0003] Activation of MrgprX2 leads to degranulation and histamine release. While this immune response is essential to protect the body, overactivation is associated with inflammatory and allergic diseases such as pseudoallergic reactions, anaphylaxis, chronic urticaria and other inflammatory reactions (see, e.g., Ogasawara et al., Cells 2021, 10(11), 2906).

[0004] MrgprX2 is a promiscuous receptor that is able to bind to a variety of ligands including, e.g., basic secretagogues, neurokinin peptides, host defense antimicrobial peptides and small molecule compounds. As such, inhibitors of the MrgprX2 receptor provide a promising avenue to prohibit inappropriate activation of MrgprX2. Accordingly, compounds able to inhibit MrgprX2 are highly desired to address unmet need to treat inflammatory and allergic diseases.SUMMARY

[0005] Provided are MrgprX2 inhibitor compounds. Also provided are methods of use of such compounds (e.g., methods of treating inflammatory disorders), as well as pharmaceutical compositions thereof.Atty Dkt No.: EVOM-008WODETAILED DESCRIPTION

[0006] Provided are MrgprX2 inhibitor compounds. Also provided are methods of use of such compounds (e.g., methods of treating inflammatory disorders), as well as pharmaceutical compositions thereof.

[0007] Before the present invention is described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0008] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0009] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and exemplary methods and materials may now be described. Any and all publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.

[0010] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, forAtty Dkt No.: EVOM-008WOexample, reference to "a droplet" includes a plurality of such droplets and reference to "the discrete entity" includes reference to one or more discrete entities, and so forth. It is further noted that the claims may be drafted to exclude any element, e.g., any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely", "only" and the like in connection with the recitation of claim elements, or the use of a "negative" limitation.

[0011] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. To the extent the definition or usage of any term herein conflicts with a definition or usage of a term in an application or reference incorporated by reference herein, the instant application shall control.

[0012] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.DEFINITIONS

[0013] " Alkyl" refers to a monoradical, branched or linear, non-cyclic, saturated hydrocarbon group. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, cyclopentyl, and cyclohexyl. In some cases, the alkyl group has 1 to 24 carbon atoms, e.g. 1 to 12, 1 to 6, or 1 to 3.

[0014] " Alkenyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon double bond. Exemplary alkenyl groups include ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, and tetracosenyl.

[0015] " Alkynyl" refers to a monoradical, branched or linear, non-cyclic hydrocarbonyl group that comprises a carbon-carbon triple bond. Exemplary alkynyl groups include ethynyl and n-propynyl.Atty Dkt No.: EVOM-008WO

[0016] " Cycloalkyl" refers to a monoradical, cyclic, saturated hydrocarbon group. Exemplary cycloalkyl groups include cyclooctyl and bicyclopentyl. Similarly, "cycloalkenyl" refers to a monoradical and cyclic group having carbon-carbon double bond whereas "cycloalkynyl" refers to a monoradical and cyclic group having carbon-carbon triple bond.

[0017] " Heterocyclyl" or "heterocycloalkyl" refers to a monoradical, cyclic group that contains at least one heteroatom (e.g. 0, S, N) as a ring atom and that is not aromatic (i.e. distinguishing heterocyclyl groups from heteroaryl groups). Exemplary heterocyclyl groups include piperidinyl, tetrahydrofuranyl, di hydrofuranyl, and thiocanyl.

[0018] " Aryl" refers to an aromatic group containing at least one aromatic ring, wherein each of the atoms in the ring are carbon atoms, i.e. none of the ring atoms are heteroatoms (e.g. O, S, N). In some cases, the aryl group has a second aromatic ring, e.g. that is fused to the first aromatic ring. Exemplary aryl groups are phenyl, naphthyl, biphenyl, diphenylether, diphenylamine and benzophenone.

[0019] " Heteroaryl" refers to an aromatic group containing at least one aromatic ring, wherein at least one of the atoms in the aromatic ring is a heteroatom (e.g. O, S, N). Exemplary heteroaryl groups include those obtained from removing a hydrogen atom from pyridine, pyrimidine, furan, thiophene, or benzothiophene.

[0020] The term "substituted" refers the removal of one or more hydrogens from an atom (e.g. from a C or N atom) and their replacement with a different group. For instance, a hydrogen atom on a phenyl (-CeHs) group can be replaced with a methyl group to form a -C6H4CH3 group. Thus, the -C6H4CH3 group can be considered a substituted aryl group. As another example, two hydrogen atoms from the second carbon of a propyl (-CH2CH2CH3) group can be replaced with an oxygen atom to form a -CH2C(O)CH3 group, which can be considered a substituted alkyl group. However, replacement of a hydrogen atom on a propyl (-CH2CH2CH3) group with a methyl group (e.g. giving -CH2CH(CH3)CH3) is not considered a "substitution" as used herein since the starting group and the ending group are both alkyl groups. However, if the propyl group was substituted with a methoxy group, thereby giving a -CH2CH(OCH3)CH3 group, the overall group can no long be considered "alkyl", and thus is "substituted alkyl". Thus, in order to be considered a substituent, the replacementgroup is a different type than the original group. In addition, groupsAtty Dkt No.: EVOM-008WOare presumed to be unsubstituted unless described as substituted. For instance, the term "alkyl" and "unsubstituted alkyl" are used interchangeably herein.

[0021] Exemplary substituents include alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, acyl, alkoxy, amino, azido, carbonyl, carboxy, cyano, ether, halo, hydroxy, nitro, and substituted versions thereof.

[0022] In some cases, the substitutions can themselves be further substituted with one or more groups. For example, the group -C6H4CH2CH3 can be considered as substituted aryl, i.e. an aryl group substituted with the ethyl, which is an alkyl group. Furthermore, the ethyl group can itself be substituted with a pyridyl group to form -C6H4CH2CH2C5H5N, wherein -C6H4CH2CH2C5H5N can also be considered as a substituted aryl group as the term is used herein. In some cases, the substituents are not substituted with any other groups.

[0023] Diradical groups are also described herein, i.e. in contrast to the monoradical groups such as alkyl and aryl described above. The term "alkylene" refers to the diradical version of an alkyl group, i.e. an alkylene group is a diradical, branched or linear, cyclic or non-cyclic, saturated hydrocarbon group. Exemplary alkylene groups include diylmethane (-CH2-, which is also known as a methylene group), 1,2-diylethane (-CH2CH2-), and 1,1-diylethane (i.e. a CHCH3 fragment where the first atom has two single bonds to other two different groups). The term "arylene" refers to the diradical version of an aryl group, e.g. 1,4-diylbenzene refers to a C6H4 fragment wherein two hydrogens that are located para to one another are removed and replaced with single bonds to other groups. The terms "alkenylene", "alkynylene", "heteroarylene", and "heterocyclene" are also used herein.

[0024] " Acyl" refers to a group of formula -C(O)R wherein R is alkyl, alkenyl, alkynyl, or substituted versions thereof. For example, the acetyl group has formula -C(O)CH3. " Carbonyl" refers to a diradical group of formula -C(O)-.

[0025] " Alkoxy" refers to a group of formula -O(alkyl). Similar groups can be derived from alkenyl, alkynyl, aryl, heteroaryl, and other groups.

[0026] " Amino" refers to the group -NRXRYwherein Rxand RYare each independently H or a non-hydrogen substituent. Exemplary non-hydrogen substituents include alkyl groups (e.g. methyl, ethyl, and isopropyl).Atty Dkt No.: EVOM-008WO

[0027] " Carbonyl" refers to a diradical group of formula -C(O)-.

[0028] " Carboxy" is used interchangeably with carboxyl and carboxylate to refer to the -CO2H group and salts thereof.

[0029] " Cyano" or "nitrile" refers to the group -CN.

[0030] " Ether" refers to a diradical group of formula -O-. For instance, if the ether group is connected to an alkyl group, then the overall group is an alkoxy group (e.g. -OCH3 or methoxy). If the ether is connected to a carbonyl group, then the overall group is an ester group of formula -OC(O)-.

[0031] " Halo" and "halogen" refer to the chloro, bromo, fluoro, and iodo groups.

[0032] " Haloalkyl" refers to an alkyl group that is substituted with at least one halogen. Stated in another manner, a haloalkyl group is a substituted alkyl group wherein at least one substituent is a halogen. Trifluoromethyl is an exemplary haloalkyl group.

[0033] " Nitro" refers to the group of formula -NO2.

[0034] " Bicycloalkyl" refers to a cyclic group containing two rings that share at least two common atoms and wherein the rings are cycloalkyl rings. Bicycloalkyls include, e.g., fused bicycloalkyls and bridged bicycloalkyls. " Fused bicylcoalkyl" refers to compounds where two rings share two common atoms. Examples of fused bicycloalkyls include, e.g., bicyclo[4.4.0]decane, bicyclo[1.1.0]butane, etc. " Bridged bicycloalkyl" refers to compounds where two rings share three or more common atoms. Examples of bridged bicycloalkyls include, e.g., bicyclo[4.3.1]decane, bicyclo[2.1.1]heptane, bicyclo[2.2.2]octane, etc.

[0035] " Heterobicycloalkyl" has the structure of the above described "bicycloalkyl", except that the cyclic group contains at least one heteroatom (e.g. O, S, N) as a ring atom.

[0036] The term "spirocycloalkyl" or "spiroalkyl" refers to a cyclic group of two or more rings in which two of the rings share one common atom, and wherein the rings are cycloalkyl rings. Examples include, e.g., spirocyclopentane (e.g., spiro[2.2]pentane), spirocyclohexane (e.g., spiro[2.3]hexane), spirocyclooctane (e.g., spiro[3.4]octane, spiro[2.5]octane), spirocyclodecane (e.g., spiro[4.5]decane, spiro[6.3]decane), dispirodecane (e.g., dispiro[3.1.36.l4]decane), etc.Atty Dkt No.: EVOM-008WO

[0037] " Heterospirocycloalkyl" or "heterospiroalkyl" has the structure of the above described "spirocycloalkyl", except that the cyclic group contains at least one heteroatom (e.g. 0, S, N) as a ring atom.

[0038] Unless otherwise specified, reference to an atom is meant to include all isotopes of that atom. For example, reference to H includes1H,2H (i.e. D or deuterium) and3H (i.e. tritium), and reference to C is includes both12C and all other isotopes of carbon (e.g.13C).

[0039] A compound as disclosed herein, or a pharmaceutically acceptable salt thereof, may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. A compound as disclosed herein is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-) or (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0040] " Solvate" refers to a complex formed by combination of solvent molecules with molecules or ions of the solute. The solvent can be an organic compound, an inorganic compound, or a mixture of both. Some examples of solvents include, but are not limited to, methanol, / V, / V-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water. When the solvent is water, the solvate formed is a hydrate.

[0041] A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are non-superimposable mirror images of one another.Atty Dkt No.: EVOM-008WO

[0042] " Tautomer" refers to alternate forms of a molecule that differ only in electronic bonding of atoms and / or in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a -N=C(H)-NH- ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. A person of ordinary skill in the art would recognize that other tautomeric ring atom arrangements are possible.

[0043] It will be appreciated that the term "or a salt or solvate or stereoisomer thereof" is intended to include all permutations of salts, solvates and stereoisomers, such as a solvate of a pharmaceutically acceptable salt of a stereoisomer of subject compound.

[0044] The term "pharmaceutically acceptable salt" means a salt which is acceptable for administration to a patient, such as a mammal (e.g., salts with counterions having acceptable mammalian safety for a given dosage regime). Such salts can be derived from pharmaceutically acceptable inorganic or organic bases and from pharmaceutically acceptable inorganic or organic acids. " Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, formate, tartrate, besylate, mesylate, acetate, maleate, oxalate, and the like. " Pharmaceutically acceptable salt" includes both acid and base addition salts.COMPOUNDS

[0045] As discussed above, compounds of the present disclosure include MrgprX2 inhibitor compounds (i.e., compounds that inhibit MrgprX2 receptors). In embodiments, the MrgprX2 inhibitor compound is a MrgprX2 antagonist compound. In some embodiments, the compound is a compound of formula (la).

[0046] Provided are compounds of formula (la):Atty Dkt No.: EVOM-008WOR1(la)wherein:R1and R2are each independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl, or R1and R2together with the N to which they are attached form a heterocycloalkyl ring, substituted heterocycloalkyl ring, heterospirocycloalkyl ring, substituted heterospirocycloalkyl ring, heterobicycloalkyl ring or substituted heterobicycloalkyl ring;G1, G2, G3and G4are each independently selected from N, S, 0, C-H, C-L1-M1and N-L1-M1;each L1is independently selected from a bond, 0, C(=0), C(=O)NH, CHOH and CH2; and each M1is independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

[0047] As described above, R1and R2are each independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl, or R1and R2together with the N to which they are attached form a heterocycloalkyl ring, substituted heterocycloalkyl ring, heterospirocycloalkyl ring, substituted heterospirocycloalkyl ring, heterobicycloalkyl ring or a substituted heterobicycloalkyl ring.

[0048] In some cases, R1is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R1is selected from H, alkyl and substituted alkyl. In some cases, R1is selected from H and alkyl. In some cases, R1is selected from substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R1is selected from cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substitutedAtty Dkt No.: EVOM-008WOspirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R1is selected from substituted alkyl, substituted cycloalkyl, substituted spirocycloalkyl and substituted bicycloalkyl. In some cases, R1is selected from substituted cycloalkyl, substituted spirocycloalkyl and substituted bicycloalkyl.

[0049] In some cases, R1is H.

[0050] In some cases, R1is alkyl, such as Ci-io alkyl, Ci-6 alkyl, C1-5 alkyl, C1-4 alkyl, or C1-3 alkyl. In some cases, R1is methyl. In some cases, R1is ethyl.

[0051] In some cases, R1is substituted alkyl, such as substituted C1-10 alkyl, substituted C1-6 alkyl, substituted C1-5 alkyl, substituted C1-4 alkyl, or substituted C1-3 alkyl. In some cases, R1is substituted methyl. In some cases, R1is substituted ethyl.

[0052] In some cases, R1is cycloalkyl, such as C3-8 cycloalkyl, C3-7 cycloalkyl, C3-6 cycloalkyl, or C3-5 cycloalkyl. In some cases, R1is C4-7 cycloalkyl. In some cases, R1is C3 cycloalkyl. In some cases, R1is C4 cycloalkyl. In some cases, R1is C5 cycloalkyl. In some cases, R1is Ce cycloalkyl. In some cases, R1is C7cycloalkyl. In some cases, R1is Cs cycloalkyl.

[0053] In some cases, R1is substituted cycloalkyl, such as substituted C3-8 cycloalkyl, substituted C3-7 cycloalkyl, substituted C3-6 cycloalkyl, or substituted C3-5 cycloalkyl. In some cases, R1is substituted C4-7 cycloalkyl. In some cases, R1is substituted C3 cycloalkyl. In some cases, R1is substituted C4 cycloalkyl. In some cases, R1is substituted C5 cycloalkyl. In some cases, R1is substituted Ce cycloalkyl. In some cases, R1is substituted C7 cycloalkyl. In some cases, R1is substituted Cs cycloalkyl.

[0054] In some cases, R1is spirocycloalkyl, such as C5-20 spirocycloalkyl, C5-12 spirocycloalkyl, C5-10 spirocycloalkyl, C5-8 spirocycloalkyl, Ce-12 spirocycloalkyl, Ce-io spirocycloalkyl, Ce-s spirocycloalkyl, C7-12 spirocycloalkyl or C7-10 spirocycloalkyl. In some cases, R1is spirocyclopentane (e.g., spiro[2.2]pentane). In some cases, R1is spirocyclohexane (e.g., spiro[2.3]hexane). In some cases, R1is spirocycloheptane (e.g., spiro[3.3]heptane, spiro[2.4]heptane). In some cases, R1is spirocyclooctane (e.g., spiro[3.4]octane, spiro[2.5]octane). In some cases, R1is spirocyclononane (e.g., spiro[2.6]nonane, spiro[3.5]nonane, spiro[4.4]nonane). In some cases, R1is spirocyclodecane (e.g., spiro[2.7]decane, spiro[3.6]decane, spiro[4.5]decane).Atty Dkt No.: EVOM-008WO

[0055] In some cases, R1is substituted spirocycloalkyl, such as substituted C5-20 spirocycloalkyl, substituted C5-12 spirocycloalkyl, substituted C5-10 spirocycloalkyl, substituted C5-8 spirocycloalkyl, substituted C6-12 spirocycloalkyl, substituted Ce-io spirocycloalkyl, substituted Ce-8 spirocycloalkyl, substituted C7-12 spirocycloalkyl or substituted C7-10 spirocycloalkyl. In some cases, R1is substituted spirocyclopentane (e.g., substituted spiro[2.2]pentane). In some cases, R1is substituted spirocyclohexane (e.g., substituted spiro[2.3]hexane). In some cases, R1is substituted spirocycloheptane (e.g., substituted spiro[3.3]heptane, substituted spiro[2.4]heptane). In some cases, R1is substituted spirocyclooctane (e.g., substituted spiro[3.4]octane, substituted spiro[2.5]octane). In some cases, R1is substituted spirocyclononane (e.g., substituted spiro[2.6]nonane, substituted spiro[3.5]nonane, substituted spiro[4.4]nonane). In some cases, R1is substituted spirocyclodecane (e.g., substituted spiro[2.7]decane, substituted spiro[3.6]decane, substituted spiro[4.5]decane).

[0056] In some cases, R1is bicycloalkyl, such as C4-20 bicycloalkyl, C4-12 bicycloalkyl, C4-10 bicycloalkyl, C5-12 bicycloalkyl, C5-10 bicycloalkyl, C5-8 bicycloalkyl, C6-12 bicycloalkyl, Ce-io bicycloalkyl, C7-12 bicycloalkyl, C7-10 bicycloalkyl, C7.8 bicycloalkyl. In some cases, R1is fused bicycloalkyl, such as C4-20 fused bicycloalkyl, C4-12 fused bicycloalkyl, C4-10 fused bicycloalkyl, C5-12 fused bicycloalkyl, C5-10 fused bicycloalkyl, C5-8 fused bicycloalkyl, Ce-12 fused bicycloalkyl, Ce-io fused bicycloalkyl, C7-12 fused bicycloalkyl, C7-10 fused bicycloalkyl, or C7-8 fused bicycloalkyl. In some cases, R1is bridged bicycloalkyl, such as C4-20 bridged bicycloalkyl, C4-12 bridged bicycloalkyl, C4-10 bridged bicycloalkyl, C5-12 bridged bicycloalkyl, C5-10 bridged bicycloalkyl, C5-8 bridged bicycloalkyl, C6-12 bridged bicycloalkyl, Ce-io bridged bicycloalkyl, C7-12 bridged bicycloalkyl, C7-10 bridged bicycloalkyl, or C7-8 bridged bicycloalkyl. In some cases, R1is bicyclobutane (e.g., bicyclo[1.1.0]butane). In some cases, R1is bicyclopentane (e.g., bicyclo[l.l.l]pentane, bicyclo[2.1.0]pentane). In some cases, R1is bicyclohexane (e.g., bicyclo[2.1.1]hexane, bicyclo[3.1.0]hexane). In some cases, R1is bicycloheptane (e.g., bicyclo[4.1.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane). In some cases, R1is bicyclooctane (e.g., bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, bicyclo[4.2.0]octane). In some cases, R1is bicyclononane (e.g., bicyclo[3.3.1]nonane, bicyclo[4.3.0]nonane, bicyclo[5.2.0]nonane). In someAtty Dkt No.: EVOM-008WOcases, R1is bicyclodecane (e.g., bicyclo[4.4.0]decane, bicyclo[6.2.0]decane, bicyclo[7.1.0]decane, bicyclo[5.3.0]decane, bicyclo[4.3.1]decane, bicyclo[3.3.2]decane, bicyclo[4.2.2]decane).

[0057] In some cases, R1is substituted bicycloalkyl, such as substituted C4-20 bicycloalkyl, substituted C4-12 bicycloalkyl, substituted C4-10 bicycloalkyl, substituted C5-12 bicycloalkyl, substituted C5-10 bicycloalkyl, substituted C5-8 bicycloalkyl, substituted Ce 12 bicycloalkyl, substituted Ce-io bicycloalkyl, substituted C7.12 bicycloalkyl, substituted C7-10 bicycloalkyl, substituted C7 -8 bicycloalkyl. In some cases, R1is substituted fused bicycloalkyl, such as substituted C4-20 fused bicycloalkyl, substituted C4-12 fused bicycloalkyl, substituted C4-10 fused bicycloalkyl, substituted C5-12 fused bicycloalkyl, substituted C5-10 fused bicycloalkyl, substituted C5-8 fused bicycloalkyl, substituted C6-12 fused bicycloalkyl, substituted Ce-io fused bicycloalkyl, substituted C7-12 fused bicycloalkyl, substituted C7-10 fused bicycloalkyl, or substituted C7-8 fused bicycloalkyl. In some cases, R1is substituted bridged bicycloalkyl, such as substituted C4-20 bridged bicycloalkyl, substituted C4-12 bridged bicycloalkyl, substituted C4-10 bridged bicycloalkyl, substituted C5-12 bridged bicycloalkyl, substituted C5-10 bridged bicycloalkyl, substituted C5-8 bridged bicycloalkyl, substituted C6-12 bridged bicycloalkyl, substituted Ce-io bridged bicycloalkyl, substituted C7-12 bridged bicycloalkyl, substituted C7-10 bridged bicycloalkyl, or substituted C7-8 bridged bicycloalkyl. In some cases, R1is substituted bicyclobutane (e.g., substituted bicyclo[1.1.0]butane). In some cases, R1is substituted bicyclopentane (e.g., substituted bicyclo[l.l.l]pentane, substituted bicyclo[2.1.0]pentane). In some cases, R1is substituted bicyclohexane (e.g., substituted bicyclo[2.1.1]hexane, substituted bicyclo[3.1.0]hexane). In some cases, R1is substituted bicycloheptane (e.g., substituted bicyclo[4.1.0]heptane, substituted bicyclo[2.2.1]heptane, substituted bicyclo[3.1.1]heptane). In some cases, R1is substituted bicyclooctane (e.g., bicyclo[2.2.2]octane, substituted bicyclo[3.2.1]octane, substituted bicyclo[4.2.0]octane). In some cases, R1is substituted bicyclononane (e.g., substituted bicyclo[3.3.1]nonane, substituted bicyclo[4.3.0]nonane, substituted bicyclo[5.2.0]nonane). In some cases, R1is substituted bicyclodecane (e.g., substituted bicyclo[4.4.0]decane, substituted bicyclo[6.2.0]decane, substituted bicyclo[7.1.0]decane, substituted bicyclo[5.3.0]decane, substituted bicyclo[4.3.1]decane, substituted bicyclo[3.3.2]decane, substituted bicyclo[4.2.2]decane).Atty Dkt No.: EVOM-008WO

[0058] In some cases, R2is selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R2is selected from H, alkyl and substituted alkyl. In some cases, R2is selected from H and alkyl. In some cases, R2is selected from substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R2is selected from cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl. In some cases, R2is selected from substituted alkyl, substituted cycloalkyl, substituted spirocycloalkyl and substituted bicycloalkyl. In some cases, R2is selected from substituted cycloalkyl, substituted spirocycloalkyl and substituted bicycloalkyl.

[0059] In some cases, R2is H.

[0060] In some cases, R2is alkyl, such as Ci-io alkyl, Ci-6 alkyl, C1-5 alkyl, C1-4 alkyl, or C1-3 alkyl. In some cases, R2is methyl. In some cases, R2is ethyl.

[0061] In some cases, R2is substituted alkyl, such as substituted C1-10 alkyl, substituted C1-6 alkyl, substituted C1-5 alkyl, substituted C1-4 alkyl, or substituted C1-3 alkyl. In some cases, R2is substituted methyl. In some cases, R2is substituted ethyl.

[0062] In some cases, R2is cycloalkyl, such as C3-8 cycloalkyl, C3-7 cycloalkyl, C3.6 cycloalkyl, or C3-5 cycloalkyl. In some cases, R2is C4-7 cycloalkyl. In some cases, R2is C3 cycloalkyl. In some cases, R2is C4 cycloalkyl. In some cases, R2is C5 cycloalkyl. In some cases, R2is Ce cycloalkyl. In some cases, R2is C7cycloalkyl. In some cases, R2is Cs cycloalkyl.

[0063] In some cases, R2is substituted cycloalkyl, such as substituted C3-8 cycloalkyl, substituted C3-7 cycloalkyl, substituted C3-6 cycloalkyl, or substituted C3-5 cycloalkyl. In some cases, R2is substituted C4-7 cycloalkyl. In some cases, R2is substituted C3 cycloalkyl. In some cases, R2is substituted C4 cycloalkyl. In some cases, R2is substituted C5 cycloalkyl. In some cases, R2is substituted Ce cycloalkyl. In some cases, R2is substituted C7 cycloalkyl. In some cases, R2is substituted Cs cycloalkyl.

[0064] In some cases, R2is spirocycloalkyl, such as C5-20 spirocycloalkyl, C5-12 spirocycloalkyl, C5-10 spirocycloalkyl, C5-8 spirocycloalkyl, C6-12 spirocycloalkyl, Ce-io spirocycloalkyl, Ce-s spirocycloalkyl, C7-12 spirocycloalkyl or C7-10 spirocycloalkyl. In some cases, R2is spirocyclopentaneAtty Dkt No.: EVOM-008WO(e.g., spiro[2.2]pentane). In some cases, R2is spirocyclohexane (e.g., spiro[2.3]hexane). In some cases, R2is spirocycloheptane (e.g., spiro[3.3]heptane, spiro[2.4]heptane). In some cases, R2is spirocyclooctane (e.g., spiro[3.4]octane, spiro[2.5]octane). In some cases, R2is spirocyclononane (e.g., spiro[2.6]nonane, spiro[3.5]nonane, spiro[4.4]nonane). In some cases, R2is spirocyclodecane (e.g., spiro[2.7]decane, spiro[3.6]decane, spiro[4.5]decane).

[0065] In some cases, R2is substituted spirocycloalkyl, such as substituted C5-20 spirocycloalkyl, substituted C512 spirocycloalkyl, substituted C5-10 spirocycloalkyl, substituted Cs s spirocycloalkyl, substituted C6-12 spirocycloalkyl, substituted Ce-io spirocycloalkyl, substituted Ce-s spirocycloalkyl, substituted C7-12 spirocycloalkyl or substituted C7-10 spirocycloalkyl. In some cases, R2is substituted spirocyclopentane (e.g., substituted spiro[2.2]pentane). In some cases, R2is substituted spirocyclohexane (e.g., substituted spiro[2.3]hexane). In some cases, R2is substituted spirocycloheptane (e.g., substituted spiro[3.3]heptane, substituted spiro[2.4]heptane). In some cases, R2is substituted spirocyclooctane (e.g., substituted spiro[3.4]octane, substituted spiro[2.5]octane). In some cases, R2is substituted spirocyclononane (e.g., substituted spiro[2.6]nonane, substituted spiro[3.5]nonane, substituted spiro[4.4]nonane). In some cases, R2is substituted spirocyclodecane (e.g., substituted spiro[2.7]decane, substituted spiro[3.6]decane, substituted spiro[4.5]decane).

[0066] In some cases, R2is bicycloalkyl, such as C4-20 bicycloalkyl, C4-12 bicycloalkyl, C4-10 bicycloalkyl, C5-12 bicycloalkyl, C5-10 bicycloalkyl, C5-8 bicycloalkyl, C6-12 bicycloalkyl, Ce-io bicycloalkyl, C7-12 bicycloalkyl, C7-10 bicycloalkyl, C7-8 bicycloalkyl. In some cases, R2is fused bicycloalkyl, such as C4-20 fused bicycloalkyl, C4-12 fused bicycloalkyl, C4-10 fused bicycloalkyl, C5-12 fused bicycloalkyl, C5-10 fused bicycloalkyl, C5-8 fused bicycloalkyl, Ce-12 fused bicycloalkyl, Ce-io fused bicycloalkyl, C7-12 fused bicycloalkyl, C7-10 fused bicycloalkyl, or C7-8 fused bicycloalkyl. In some cases, R2is bridged bicycloalkyl, such as C4-20 bridged bicycloalkyl, C4-12 bridged bicycloalkyl, C4-10 bridged bicycloalkyl, C5-12 bridged bicycloalkyl, C5-10 bridged bicycloalkyl, C5-8 bridged bicycloalkyl, C6-12 bridged bicycloalkyl, Ce-io bridged bicycloalkyl, C7-12 bridged bicycloalkyl, C7-10 bridged bicycloalkyl, or C7-8 bridged bicycloalkyl. In some cases, R2is bicyclobutane (e.g., bicyclo[1.1.0]butane). In some cases, R2is bicyclopentane (e.g., bicyclo[l.l.l]pentane, bicyclo[2.1.0]pentane). In some cases, R2is bicyclohexane (e.g., bicyclo[2.1.1]hexane,Atty Dkt No.: EVOM-008WObicyclo[3.1.0]hexane). In some cases, R2is bicycloheptane (e.g., bicyclo[4.1.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane). In some cases, R2is bicyclooctane (e.g., bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, bicyclo[4.2.0]octane). In some cases, R2is bicyclononane (e.g., bicyclo[3.3.1]nonane, bicyclo[4.3.0]nonane, bicyclo[5.2.0]nonane). In some cases, R2is bicyclodecane (e.g., bicyclo[4.4.0]decane, bicyclo[6.2.0]decane, bicyclo[7.1.0]decane, bicyclo[5.3.0]decane, bicyclo[4.3.1]decane, bicyclo[3.3.2]decane, bicyclo[4.2.2]decane).

[0067] In some cases, R2is substituted bicycloalkyl, such as substituted C4-20 bicycloalkyl, substituted C4-12 bicycloalkyl, substituted C4-10 bicycloalkyl, substituted C5-12 bicycloalkyl, substituted C5-10 bicycloalkyl, substituted C5-8 bicycloalkyl, substituted C6-12 bicycloalkyl, substituted Ce-io bicycloalkyl, substituted C7-12 bicycloalkyl, substituted C7-10 bicycloalkyl, substituted C7-8 bicycloalkyl. In some cases, R2is substituted fused bicycloalkyl, such as substituted C4-20 fused bicycloalkyl, substituted C4-12 fused bicycloalkyl, substituted C4-10 fused bicycloalkyl, substituted C5.12 fused bicycloalkyl, substituted C5-10 fused bicycloalkyl, substituted C5-8 fused bicycloalkyl, substituted C6-12 fused bicycloalkyl, substituted Ce-io fused bicycloalkyl, substituted C7-12 fused bicycloalkyl, substituted C7-10 fused bicycloalkyl, or substituted C7-8 fused bicycloalkyl. In some cases, R2is substituted bridged bicycloalkyl, such as substituted C4-20 bridged bicycloalkyl, substituted C4-12 bridged bicycloalkyl, substituted C4-10 bridged bicycloalkyl, substituted C5-12 bridged bicycloalkyl, substituted C5-10 bridged bicycloalkyl, substituted C5-8 bridged bicycloalkyl, substituted C6-12 bridged bicycloalkyl, substituted Ce-io bridged bicycloalkyl, substituted C7-12 bridged bicycloalkyl, substituted C7-10 bridged bicycloalkyl, or substituted C7-8 bridged bicycloalkyl. In some cases, R2is substituted bicyclobutane (e.g., substituted bicyclo[1.1.0]butane). In some cases, R2is substituted bicyclopentane (e.g., substituted bicyclo[l.l.l]pentane, substituted bicyclo[2.1.0]pentane). In some cases, R2is substituted bicyclohexane (e.g., substituted bicyclo[2.1.1]hexane, substituted bicyclo[3.1.0]hexane). In some cases, R2is substituted bicycloheptane (e.g., substituted bicyclo[4.1.0]heptane, substituted bicyclo[2.2.1]heptane, substituted bicyclo[3.1.1]heptane). In some cases, R2is substituted bicyclooctane (e.g., bicyclo[2.2.2]octane, substituted bicyclo[3.2.1]octane, substituted bicyclo[4.2.0]octane). In some cases, R2is substituted bicyclononane (e.g., substituted bicyclo[3.3.1]nonane, substituted bicyclo[4.3.0]nonane, substituted bicyclo[5.2.0]nonane). InAtty Dkt No.: EVOM-008WOsome cases, R2is substituted bicyclodecane (e.g., substituted bicyclo[4.4.0]decane, substituted bicyclo[6.2.0]decane, substituted bicyclo[7.1.0]decane, substituted bicyclo[5.3.0]decane, substituted bicyclo[4.3.1]decane, substituted bicyclo[3.3.2]decane, substituted bicyclo[4.2.2]decane).

[0068] In some cases, R1and R2together with the N to which they are attached form a heterocycloalkyl ring, substituted heterocycloalkyl ring, heterospirocycloalkyl ring, substituted heterospirocycloalkyl ring, heterobicycloalkyl ring or substituted heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted heterocycloalkyl ring, substituted heterospirocycloalkyl ring or substituted heterobicycloalkyl ring.

[0069] In some cases, R1and R2together with the N to which they are attached form a heterocycloalkyl ring, such as a 3-8 membered heterocycloalkyl ring, a 3-7 membered heterocycloalkyl ring, a 3-6 membered heterocycloalkyl ring, a 3-5 membered heterocycloalkyl ring, a 4-8 membered heterocycloalkyl ring, a 4-7 membered heterocycloalkyl ring or a 4-6 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 4-7 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 3 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 4 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 5 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 6 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 7 membered heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 8 membered heterocycloalkyl ring.

[0070] In some cases, R1and R2together with the N to which they are attached form a substituted heterocycloalkyl ring, such as a 3-8 membered substituted heterocycloalkyl ring, a 3-7 membered substituted heterocycloalkyl ring, a 3-6 membered substituted heterocycloalkyl ring, a 3-5 membered substituted heterocycloalkyl ring, a 4-8 membered substituted heterocycloalkyl ring, a 4-7 membered substituted heterocycloalkyl ring or a 4-6 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attachedAtty Dkt No.: EVOM-008WOform a 4-7 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 3 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 4 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 5 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 6 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 7 membered substituted heterocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a 8 membered substituted heterocycloalkyl ring.

[0071] In some cases, R1and R2together with the N to which they are attached form a heterospirocycloalkyl ring, such as a 5-20 membered heterospirocycloalkyl ring, a 5-12 membered heterospirocycloalkyl ring, a 5-10 membered heterospirocycloalkyl ring, a 5-8 membered heterospirocycloalkyl ring, a 6-12 membered heterospirocycloalkyl ring, a 6-10 membered heterospirocycloalkyl ring, a 6-8 membered heterospirocycloalkyl ring, a 7-12 membered heterospirocycloalkyl ring or a 7-10 heterospirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form an azaspirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form an oxaspirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a thiaspirocycloalkyl ring.

[0072] In some cases, R1and R2together with the N to which they are attached form a substituted heterospirocycloalkyl ring, such as a 5-20 membered substituted heterospirocycloalkyl ring, a 5-12 membered substituted heterospirocycloalkyl ring, a 5-10 membered substituted heterospirocycloalkyl ring, a 5-8 membered substituted heterospirocycloalkyl ring, a 6-12 membered substituted heterospirocycloalkyl ring, a 6-10 membered substituted heterospirocycloalkyl ring, a 6-8 membered substituted heterospirocycloalkyl ring, a 7-12 membered substituted heterospirocycloalkyl ring or a 7-10 substituted heterospirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted azaspirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted oxaspirocycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted thiaspirocycloalkyl ring.Atty Dkt No.: EVOM-008WO

[0073] In some cases, R1and R2together with the N to which they are attached form a heterobicycloalkyl ring, such as a 4-20 membered heterobicycloalkyl ring, a 4-12 membered heterobicycloalkyl ring, a 4-10 membered heterobicycloalkyl ring, a 5-12 membered heterobicycloalkyl ring, a 5-10 membered heterobicycloalkyl ring, a 5-8 membered heterobicycloalkyl ring, a 6-12 membered heterobicycloalkyl ring, a 6-10 membered heterobicycloalkyl ring, a 7-12 membered heterobicycloalkyl ring, a 7-10 membered heterobicycloalkyl ring, or a 7-8 membered heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a fused heterobicycloalkyl ring, such as a 4-20 membered fused heterobicycloalkyl ring, a 4-12 membered fused heterobicycloalkyl ring, a 4- 10 membered fused heterobicycloalkyl ring, a 5-12 membered fused heterobicycloalkyl ring, a 5-10 membered fused heterobicycloalkyl ring, a 5-8 membered fused heterobicycloalkyl ring, a 6-12 membered fused heterobicycloalkyl ring, a 6-10 membered fused heterobicycloalkyl ring, a 7-12 membered fused heterobicycloalkyl ring, a 7-10 membered fused heterobicycloalkyl ring, or a 7-8 membered fused heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a bridged heterobicycloalkyl ring, such as a 4-20 membered bridged heterobicycloalkyl ring, a 4-12 membered bridged heterobicycloalkyl ring, a 4-10 membered bridged heterobicycloalkyl ring, a 5-12 membered bridged heterobicycloalkyl ring, a 5-10 membered bridged heterobicycloalkyl ring, a 5-8 membered bridged heterobicycloalkyl ring, a 6-12 membered bridged heterobicycloalkyl ring, a 6-10 membered bridged heterobicycloalkyl ring, a 7-12 membered bridged heterobicycloalkyl ring, a 7-10 membered bridged heterobicycloalkyl ring, ora 7-8 membered bridged heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form an azabicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form an oxabicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a thiabicycloalkyl ring.

[0074] In some cases, R1and R2together with the N to which they are attached form a substituted heterobicycloalkyl ring, such as a 4-20 membered substituted heterobicycloalkyl ring, a 4-12 membered substituted heterobicycloalkyl ring, a 4-10 membered substituted heterobicycloalkyl ring, a 5-12 membered substituted heterobicycloalkyl ring, a 5-10 membered substituted heterobicycloalkyl ring, a 5-8 membered substituted heterobicycloalkyl ring, a 6-12Atty Dkt No.: EVOM-008WOmembered substituted heterobicycloalkyl ring, a 6-10 membered substituted heterobicycloalkyl ring, a 7-12 membered substituted heterobicycloalkyl ring, a 7-10 membered substituted heterobicycloalkyl ring, or a 7-8 membered substituted heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a fused substituted heterobicycloalkyl ring, such as a 4-20 membered fused substituted heterobicycloalkyl ring, a 4-12 membered fused substituted heterobicycloalkyl ring, a 4-10 membered fused substituted heterobicycloalkyl ring, a 5-12 membered fused substituted heterobicycloalkyl ring, a 5-10 membered fused substituted heterobicycloalkyl ring, a 5-8 membered fused substituted heterobicycloalkyl ring, a 6-12 membered fused substituted heterobicycloalkyl ring, a 6-10 membered fused substituted heterobicycloalkyl ring, a 7-12 membered fused substituted heterobicycloalkyl ring, a 7-10 membered fused substituted heterobicycloalkyl ring, or a 7-8 membered fused substituted heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a bridged substituted heterobicycloalkyl ring, such as a 4-20 membered bridged substituted heterobicycloalkyl ring, a 4-12 membered bridged substituted heterobicycloalkyl ring, a 4-10 membered bridged substituted heterobicycloalkyl ring, a 5-12 membered bridged substituted heterobicycloalkyl ring, a 5-10 membered bridged substituted heterobicycloalkyl ring, a 5-8 membered bridged substituted heterobicycloalkyl ring, a 6-12 membered bridged substituted heterobicycloalkyl ring, a 6-10 membered bridged substituted heterobicycloalkyl ring, a 7-12 membered bridged substituted heterobicycloalkyl ring, a 7-10 membered bridged substituted heterobicycloalkyl ring, or a 7-8 membered bridged substituted heterobicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted azabicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted oxabicycloalkyl ring. In some cases, R1and R2together with the N to which they are attached form a substituted thiabicycloalkyl ring.

[0075] As described above, G1, G2, G3, G4and G5are each independently selected from N, C-H and C- -M1. In some cases, G1is N. In some cases, G1is C-H. In some cases, G1is C- -M1. In some cases, G2is N. In some cases, G2is C-H. In some cases, G2is C- -M1. In some cases, G3is N. In some cases, G3is C-H. In some cases, G3is C-L1-!^1. In some cases, G4is N. In some cases, G4is C-Atty Dkt No.: EVOM-008WOH. In some cases, G4is C-l M1. In some cases, G5is N. In some cases, G5is C-H. In some cases, G5is C-L1-M1.

[0076] As described above, G1, G2, G3and G4are each independently selected from N, S, 0, C-H, C-L -M1and N-L1-M1. In some cases, G1is N. In some cases, G1is S. In some cases, G1is 0. In some cases, G1is C-H. In some cases, G1is C-L1-!^1. In some cases, G1is N-L1-M1. In some cases, G2is N. In some cases, G2is S. In some cases, G2is O. In some cases, G2is C-H. In some cases, G2is C-L1-M1. In some cases, G2is N-L1-M1. In some cases, G3is N. In some cases, G3is S. In some cases, G3is O. In some cases, G3is C-H. In some cases, G3is C-L1-M1. In some cases, G3is N-L1-M1. In some cases, G4is N. In some cases, G4is S. In some cases, G4is 0. In some cases, G4is C-H. In some cases, G4is C-L1-M1. In some cases, G4is N-l^-M1.

[0077] In some embodiments, at least one of G1, G2, G3and G4is N. In some embodiments, one of G1, G2, G3and G4is N. In some embodiments, two of G1, G2, G3and G4is N. In some embodiments, at least one of G1, G2, G3and G4is S. In some embodiments, one of G1, G2, G3and G4is S. In some embodiments, at least one of G1, G2, G3and G4is C-l^-M1. In some embodiments, one of G1, G2, G3and G4is C-l^-M1. In some embodiments, at least one of G1, G2, G3and G4is N-L1-M1. In some embodiments, one of G1, G2, G3and G4is N- -M1. In some embodiments, at least one of G1, G2, G3and G4is C-H. In some embodiments, one of G1, G2, G3and G4is C-H.

[0078] In some embodiments, G1is N, G2is C-H, G3is C- -M1and G4is S. In some embodiments, G1is N, G2is N, G3is C-L1-M1and G4is S. In some embodiments, G1is C-H, G2is C-H, G3is N-L1-M1and G4is N.

[0079] As described above, each L1is independently selected from a bond, 0, C(=O), C(=O)NH, CHOH and CH2. In some cases, L1is a bond. In some cases, L1is 0. In some cases, L1is C(=O). In some cases, L1is C(=O)NH. In some cases, L1is CHOH. In some cases, L1is CH2.

[0080] As described above, each M1is independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl. In some cases, M1is selected from aryl and heteroaryl or substituted versions thereof. In some cases, M1is selected from aryl and heteroaryl or substituted versions thereof. In some cases, M1is halogen (e.g., F, Cl, Br, I). In some cases, M1is hydroxy. In some cases, M1is cyano. In some cases, M1is alkyl orAtty Dkt No.: EVOM-008WOsubstituted alkyl, such as Ci-io alkyl, Ci-6 alkyl or Ci-6 substituted alkyl, C1-5 alkyl or C1.5 substituted alkyl, or C1-4 alkyl or C1-4 substituted alkyl, or C1-3 alkyl or C1-3 substituted alkyl. In some cases, M1is cycloalkyl or substituted cycloalkyl, such as C3-8 cycloalkyl or C3-8 substituted cycloalkyl, such as a C3-7 cycloalkyl or C3-7 substituted cycloalkyl, such as a C3.6 cycloalkyl or C3-6 substituted cycloalkyl, or a C35 cycloalkyl or C3 -5 substituted cycloalkyl. In some cases, M1is heterocycloalkyl or substituted heterocycloalkyl, such as C3-8 heterocycloalkyl or C3.8 substituted heterocycloalkyl, such as a C3-7 heterocycloalkyl or C3-7 substituted heterocycloalkyl, such as a C3-6 heterocycloalkyl or C3-6 substituted heterocycloalkyl, ora C3-5 heterocycloalkyl or C3-5 substituted heterocycloalkyl. In some cases, M1is aryl or substituted aryl, such as C5-8 aryl or C5-8 substituted aryl, such as a C5 aryl or C5 substituted aryl, or a Ce aryl or Ce substituted aryl. In some cases, M1is heteroaryl or substituted heteroaryl, such as C5-8 heteroaryl or C5-8 substituted heteroaryl, such as a C5 heteroaryl or C5 substituted heteroaryl, or a Ce heteroaryl or Ce substituted heteroaryl.

[0081] In some cases, M1is phenyl ora substituted version thereof. In some cases, M1is pyridyl or a substituted version thereof. In some cases, M1is benzothiazole or a substituted versionthereof. In some cases,M1is or a substituted version thereof. In some cases, M1is thiophene or a substituted version thereof. In some cases, M1is pyrazine or a substituted version thereof. In some cases, M1is pyridazine or a substituted version thereof. In some cases, M1is pyrimidine or a substituted version thereof. In some cases, M1is thiazole or a substituted version -Sthereof. In some cases, M1is or a substituted version thereof. In some cases, M1isthereof. In some cases, M1is triazole or a substituted version thereof. In some cases, M1isor a substituted version thereof. In some cases, M1is pyrrolidine or a substitutedAtty Dkt No.: EVOM-008WOversion thereof. In some cases, M1isor a substituted version thereof. In some cases, M1is imidazole or a substituted version thereof. In some cases, M1is cyclopropyl or a substituted version thereof.

[0082] In some embodiments, the compound is a compound of formula (lb).

[0083] Provided are compounds of formula (lb):(lb)wherein:R1is selected from H and alkyl;W1is selected from cycloalkyl, spirocycloalkyl and bicycloalkyl.p is 0 or an integer from 1 to 10; andeach R3is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, halogen, alkoxy, hydroxy, cyano and oxo.

[0084] As described above, R1is selected from H and alkyl. In some cases, R1is H. In some cases, R1is alkyl, such as Ci-io alkyl, Ci-6 alkyl, C1-5 alkyl, C1-4 alkyl, or C1-3 alkyl. In some cases, R1is methyl. In some cases, R1is ethyl.

[0085] As described above, W1is selected from cycloalkyl, spirocycloalkyl and bicycloalkyl. In some cases, W1is cycloalkyl. In some cases, W1is spirocycloalkyl. In some cases, W1is bicycloalkyl.

[0086] In some cases, W1is cycloalkyl. In some cases, W1is cycloalkyl, such as C3-8 cycloalkyl, C3-7 cycloalkyl, C3-6 cycloalkyl, C3-5 cycloalkyl, C4-8 cycloalkyl, C4-7 cycloalkyl or C4-6 cycloalkyl. In some cases, W1is C4-7 cycloalkyl. In some cases, W1is C3 cycloalkyl. In some cases, W1is C4 cycloalkyl. In some cases, W1is Cs cycloalkyl. In some cases, W1is Ce cycloalkyl. In some cases, W1is C7cycloalkyl. In some cases, W1is Cs cycloalkyl.

[0087] In some cases, W1is spirocycloalkyl, such as C5-20 spirocycloalkyl, C5-12 spirocycloalkyl, C5-10 spirocycloalkyl, C5-8 spirocycloalkyl, C6-12 spirocycloalkyl, Ce-io spirocycloalkyl, CG-8Atty Dkt No.: EVOM-008WOspirocycloalkyl, C7-12 spirocycloalkyl or C7-10 spirocycloalkyl. In some cases, W1is spirocyclopentane (e.g., spiro[2.2]pentane). In some cases, W1is spirocyclohexane (e.g., spiro[2.3]hexane). In some cases, W1is spirocycloheptane (e.g., spiro[3.3]heptane, spiro[2.4]heptane). In some cases, W1is spirocyclooctane (e.g., spiro[3.4]octane, spiro[2.5]octane). In some cases, W1is spirocyclononane (e.g., spiro[2.6]nonane, spiro[3.5]nonane, spiro[4.4]nonane). In some cases, W1is spirocyclodecane (e.g., spiro[2.7]decane, spiro[3.6]decane, spiro[4.5]decane).

[0088] In some cases, W1is bicycloalkyl, such as C4-20 bicycloalkyl, C4-12 bicycloalkyl, C4-10 bicycloalkyl, C5-12 bicycloalkyl, C5-10 bicycloalkyl, C5-8 bicycloalkyl, C6-12 bicycloalkyl, Ce-io bicycloalkyl, C7-12 bicycloalkyl, C7-10 bicycloalkyl, C7-8 bicycloalkyl. In some cases, W1is fused bicycloalkyl, such as C4-20 fused bicycloalkyl, C4-12 fused bicycloalkyl, C4-10 fused bicycloalkyl, C5-12 fused bicycloalkyl, C5-10 fused bicycloalkyl, C5-8 fused bicycloalkyl, C6-12 fused bicycloalkyl, Ce-io fused bicycloalkyl, C7-12 fused bicycloalkyl, C7-10 fused bicycloalkyl, or C7-8 fused bicycloalkyl. In some cases, W1is bridged bicycloalkyl, such as C4-20 bridged bicycloalkyl, C4-12 bridged bicycloalkyl, C4-10 bridged bicycloalkyl, C5-12 bridged bicycloalkyl, C5-10 bridged bicycloalkyl, C5-8 bridged bicycloalkyl, C6-12 bridged bicycloalkyl, Ce-io bridged bicycloalkyl, C7-12 bridged bicycloalkyl, C7-10 bridged bicycloalkyl or C7-8 bridged bicycloalkyl. In some cases, W1is bicyclobutane (e.g., bicyclo[1.1.0]butane). In some cases, W1is bicyclopentane (e.g., bicyclo[l.l.l]pentane, bicyclo[2.1.0]pentane). In some cases, W1is bicyclohexane (e.g., bicyclo[2.1.1]hexane, bicyclo[3.1.0]hexane). In some cases, W1is bicycloheptane (e.g., bicyclo[4.1.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane). In some cases, W1is bicyclooctane (e.g., bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, bicyclo[4.2.0]octane). In some cases, W1is bicyclononane (e.g., bicyclo[3.3.1]nonane, bicyclo[4.3.0]nonane, bicyclo[5.2.0]nonane). In some cases, W1is bicyclodecane (e.g., bicyclo[4.4.0]decane, bicyclo[6.2.0]decane, bicyclo[7.1.0]decane, bicyclo[5.3.0]decane, bicyclo[4.3.1]decane, bicyclo[3.3.2]decane, bicyclo[4.2.2]decane).

[0089] As described above, p is 0 or an integer from 1 to 10. In some cases, p is 0. In some cases, p is an integer from 1 to 10. In some cases, p is an integer from 1 to 5. In some cases, p is an integer from 2 to 4. In some cases, p is an integer from 1 to 3. In some cases, p is 1. In someAtty Dkt No.: EVOM-008WOcases, p is 2. In some cases, p is 3. In some cases, p is 4. In some cases, p is 5. In some cases, p is 6. In some cases, p is 7. In some cases, p is 8. In some cases, p is 9. In some cases, p is 10.

[0090] As described above, each R3is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, halogen, alkoxy, hydroxy, cyano and oxo. In some cases, R3is H. In some cases, R3is alkyl or substituted alkyl, such as Ci-io alkyl, Ci-6 alkyl or Ci-6 substituted alkyl, Ci-5 alkyl or C1-5 substituted alkyl, or C1-4 alkyl or C1-4 substituted alkyl, or C1-3 alkyl or C1-3 substituted alkyl. In some cases, R3is methyl. In some cases, R3is ethyl. In some cases, R3is haloalkyl, such as C1-6 haloalkyl, C1-5 haloalkyl, C1-4 haloalkyl, or C1-3 haloalkyl. In some cases, R3is halomethyl. In some cases, R3is haloethyl. In some cases, R3is triha loa I ky I, such as trihalomethyl or trihaloethyl. In some cases, R3is CF3. In some cases, R3is CCI3. In some cases, R3is CBrs. In some cases, R3is cycloalkyl or substituted cycloalkyl, such as C3-8 cycloalkyl or C3-8 substituted cycloalkyl, such as a C3-7 cycloalkyl or C3-7 substituted cycloalkyl, such as a C3-6 cycloalkyl or C3-6 substituted cycloalkyl, or a C3-5 cycloalkyl or C3-5 substituted cycloalkyl. In some cases, R3is cyclopropyl. In some cases, R3is halogen, such as F, Cl, Br or I. In some cases, R3is F. In some cases, R3is alkoxy. In some cases, R3is methoxy. In some cases, R3is ethoxy. In some cases, R3is hydroxy. In some cases, R3is cyano. In some cases, R3is oxo.

[0091] In embodiments where p is 2, a first R3group may be haloalkyl (e.g., triha loal kyl, such as CF3) and a second R3group may be hydroxy. In other embodiments where p is 2, a first R3group may be alkyl (e.g., methyl) and a second R3group may be hydroxy.

[0092] In some embodiments of formula (lb), R1, G1, G2, G3and G4are as defined above.

[0093] In some embodiments, the compound is a compound of formula (II).

[0094] Provided are compounds of formula (II):f " N N'n | H3R1wherein:m is 0 or 1; andAtty Dkt No.: EVOM-008WOn is 1 or 2.

[0095] As described above, m is 0 or 1 and n is 1 or 2. In some cases, m is 0. In some cases, m is 1. In some cases, n is 1. In some cases, n is 2. In some cases, m is 1 and n is 1. In some cases, m is 0 and n is 1. In some cases, m is 1 and n is 2.

[0096] In some embodiments of formula (II), R1, R3, G1, G2, G3and G4are as defined above.

[0097] In some embodiments, the compound is a compound of formula (III).

[0098] Provided are compounds of formula (III):

[0099] In some embodiments of formula (III), m, n, R1, R3, G1, G2, G3and G4are as defined above.

[0100] In some embodiments of formula (III), each R3is independently selected from haloalkyl and hydroxy. In some cases, a first R3group may be haloalkyl (e.g., trihaloa Ikyl, such as CF3) and a second R3group may be hydroxy. In some cases, a first R3group may be alkyl (e.g., methyl) and a second R3group may be hydroxy.

[0101] In some embodiments, the compound is a compound of formula (IV).

[0102] Provided are compounds of formula (IV):(IV).

[0103] In some embodiments of formula (IV), m, n, R1, G1, G2, G3and G4are as defined above.

[0104] In some embodiments, the compound is a compound of formula (V).

[0105] Provided are compounds of formula (V):Atty Dkt No.: EVOM-008WO(V).

[0106] In some embodiments of formula (V), R1, G1, G2, G3and G4are as defined above.

[0107] In some embodiments, the compound is a compound of formula (VI).

[0108] Provided are compounds of formula (VI):(VI)wherein:Q1, Q2, Q3, Q4and Q5are each independently selected from N, C-H and C-RQ; and each RQis independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

[0109] As described above, Q1, Q2, Q3, Q4and Q5are each independently selected from N, C-H and C-RQ. In some cases, Q1is N. In some cases, Q1is C-H. In some cases, Q1is C-RQ. In some cases, Q2is N. In some cases, Q2is C-H. In some cases, Q2is C-RQ. In some cases, Q3is N. In some cases, Q3is C-H. In some cases, Q3is C-RQ. In some cases, Q4is N. In some cases, Q4is C-H. In some cases, Q4is C-RQ. In some cases, Q5is N. In some cases, Q5is C-H. In some cases, Q5is C-RQ.

[0110] In some cases, at least one of Q1, Q2, Q3, Q4and Q5is C-RQ. In some cases, one to three of Q1, Q2, Q3, Q4and Q5is C-RQ. In some cases, one or two of Q1, Q2, Q3, Q4and Q5is C-RQ. In some cases, one of Q1, Q2, Q3, Q4and Q5is C-RQ. In some cases, two of Q1, Q2, Q3, Q4and Q5is C-RQ. In some cases, three of Q1, Q2, Q3, Q4and Q5is C-RQ.Atty Dkt No.: EVOM-008WO

[0111] As described above, each RQis independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl. In some embodiments, each RQis independently selected from halogen, haloalkyl and alkyl. In some cases, RQis halogen (e.g., F, Cl, Br, I). In some cases, RQis hydroxy. In some cases, RQis cyano. In some cases, RQis alkyl or substituted alkyl, such as Ci-6 alkyl or Ci-6 substituted alkyl, C1-5 alkyl or C1-5 substituted alkyl, or C1-4 alkyl or C1-4 substituted alkyl, or C1-3 alkyl or C1-3 substituted alkyl. In some cases, RQis cycloalkyl or substituted cycloalkyl, such as C3-8 cycloalkyl orCs-8 substituted cycloalkyl, such as a C3-7 cycloalkyl or C3-7 substituted cycloalkyl, such as a C3-6 cycloalkyl or C3-6 substituted cycloalkyl, or a C3-5 cycloalkyl or C3-5 substituted cycloalkyl. In some cases, RQis heterocycloalkyl or substituted heterocycloalkyl, such as C3-8 heterocycloalkyl or C3-8 substituted heterocycloalkyl, such as a C3-7 heterocycloalkyl or C3-7 substituted heterocycloalkyl, such as a C3-6 heterocycloalkyl or C3-6 substituted heterocycloalkyl, ora C3-5 heterocycloalkyl or C3-5 substituted heterocycloalkyl. In some cases, RQis aryl or substituted aryl, such as C5-8 aryl or C5-8 substituted aryl, such as a C5 aryl or C5 substituted aryl, or a C6aryl or Ce substituted aryl. In some cases, RQis heteroaryl or substituted heteroaryl, such as C5-8 heteroaryl or C5-8 substituted heteroaryl, such as a C5 heteroaryl or C5 substituted heteroaryl, or a Ce heteroaryl or Ce substituted heteroaryl.

[0112] In some embodiments, one or two of Q1, Q2, Q3, Q4and Q5is C-RQ, wherein each RQis selected from halogen (e.g., F, Cl, Br, I). In some embodiments, one of Q1, Q2, Q3, Q4and Q5is C-RQ, wherein each RQis selected from halogen (e.g., F, Cl, Br, I). In some embodiments, two of Q1, Q2, Q3, Q4and Q5is C-RQ, wherein each RQis selected from halogen (e.g., F, Cl, Br, I).

[0113] In some embodiments of formula (VI), R1, G1, G2, G4and L1are as defined above.

[0114] In some embodiments, the compound is a compound of formula (VII).

[0115] Provided are compounds of formula (VII):(VII)Atty Dkt No.: EVOM-008WOwherein:W2is selected from heterocycloalkyl, heterospirocycloalkyl and heterobicycloalkyl.

[0116] As described above, W2is selected from heterocycloalkyl, heterospirocycloalkyl and heterobicycloalkyl. In some cases, W2is heterocycloalkyl. In some cases, W2is heterocycloalkyl, such as 3-8 membered heterocycloalkyl, 3-7 membered heterocycloalkyl, 3-6 membered heterocycloalkyl, 3-5 membered heterocycloalkyl, 4-8 membered heterocycloalkyl, 4-7 membered heterocycloalkyl or 4-6 membered heterocycloalkyl. In some cases, W2is 4-7 membered heterocycloalkyl. In some cases, W2is 3 membered heterocycloalkyl. In some cases, W2is 4 membered heterocycloalkyl. In some cases, W2is 5 membered heterocycloalkyl. In some cases, W2is 6 membered heterocycloalkyl. In some cases, W2is 7 membered heterocycloalkyl. In some cases, W2is 8 membered heterocycloalkyl.

[0117] In some ases, W2is heter iirocycloalkyl, such as 5-20 membered heterospirocycloalkyl, 5-12 membered heterospirocycloalkyl, 5-10 membered heterospirocycloalkyl, 5-8 membered heterospirocycloalkyl, 6-12 membered heterospirocycloalkyl, 6-10 membered heterospirocycloalkyl, 6-8 membered heterospirocycloalkyl, 7-12 memberedterospirocycloalkyl or 7-10 membered heterospirocycloalkyl. In some cases, W2azaspirocycloalkyl. In s ome cases, W2is oxaspirocycloalkyl. In some cases, W2is thiaspirocycloalkyl.

[0118] In some cases, W2is heterobicycloalkyl, such as 4-20 membered heterobicycloalkyl, 4- 12 membered heterobicycloalkyl, 4-10 membered heterobicycloalkyl, 5-12 membered heterobicycloalkyl, 5-10 membered heterobicycloalkyl, 5-8 membered heterobicycloalkyl, 6-12 membered heterobicycloalkyl, 6-10 membered heterobicycloalkyl, 7-12 membered heterobicycloalkyl, 7-10 membered heterobicycloalkyl, 7-8 membered heterobicycloalkyl. In some cases, W2is fused heterobicycloalkyl, such as 4-20 membered fused heterobicycloalkyl, 4-12 membered fused heterobicycloalkyl, 4-10 membered fused heterobicycloalkyl, 5-12 membered fused heterobicycloalkyl, 5-10 membered fused heterobicycloalkyl, 5-8 membered fused heterobicycloalkyl, 6-12 membered fused heterobicycloalkyl, 6-10 membered fused heterobicycloalkyl, 7-12 membered fused heterobicycloalkyl, 7-10 membered fused heterobicycloalkyl, or 7-8 membered fused heterobicycloalkyl. In some cases, W2is bridgedAtty Dkt No.: EVOM-OQ8WOheterobicycloalkyl, such as 4-20 membered bridged heterobicycloalkyl, 4-12 membered bridged heterobicycloalkyl, 4-10 membered bridged heterobicycloalkyl, 5-12 membered bridged heterobicycloalkyl, 5-10 membered bridged heterobicycloalkyl, 5-8 membered bridged heterobicycloalkyl, 6-12 membered bridged heterobicycloalkyl, 6-10 membered bridged heterobicycloalkyl, 7-12 membered bridged heterobicycloalkyl, 7-10 membered bridged heterobicycloalkyl or 7-8 membered bridged heterobicycloalkyl. In some cases, W2is azabicycloalkyl. In some cases, W2is oxabicycloalkyl. In some cases, W2is thiabicycloalkyl.

[0119] In some embodiments of formula (VII), p, R3, G1, G2, G3and G4are as defined above.

[0120] In some embodiments, the compound has a structure selected from:FAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-OQ8WOstereoisomer, tautomer, or pharmaceutically acceptable salt thereof.Atty Dkt No.: EVOM-008WOCOMPOSITIONS

[0122] Also provided are compositions comprising any of the compounds described above, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In some embodiments, the composition comprises a compound according to formula (la), formula (lb), formula (II), formula (III), formula (IV), formula (V) or formula (VI), including all sub-generic formulae if any, as described above. In some cases, the composition includes a racemic mixture of stereoisomers. In some embodiments, the composition is enriched in a particular stereoisomer, e.g., the composition is enriched in a first enantiomer relative to a second enantiomer. The term "enantiomeric excess" is used herein to quantify the relative amount of the first enantiomer compared to the second enantiomer, wherein enantiomeric excess is the absolute difference between the mole fraction of each enantiomer. For instance, if 70% of a compound is a first enantiomer and 30% of the compound is the second enantiomer, then the enantiomeric excess is 40% (i.e., 70% minus 40%). In some cases, the composition has an enantiomeric excess of the first enantiomer of 1% or more, such as 10% or more, 20% or more, 30% or more, or 40% or more.

[0123] In some embodiments, the compound is a prodrug of any of the compounds described thereof. By prodrug it is meant a compound that is biologically inactive until it is metabolized in the body.

[0124] In certain embodiments, the disclosed compounds and prodrugs thereof are useful for the treatment of a disease or disorder. Accordingly, pharmaceutical compositions comprising at least one disclosed compound (or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof) or prodrug are also described herein. For example, the present disclosure provides pharmaceutical compositions that include a therapeutically effective amount of a compound or prodrug of the present disclosure (or a pharmaceutically acceptable salt or solvate or hydrate or stereoisomer thereof) and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient is a dermatologically or orally acceptable excipient.

[0125] A pharmaceutical composition that includes a subject compound may be administered to a patient alone, or in combination with other supplementary active agents. For example, one or more compounds or prodrugs according to the present disclosure can be administered to a patient with or without supplementary active agents. The pharmaceutical compositions may beAtty Dkt No.: EVOM-008WOmanufactured using any of a variety of processes, including, but not limited to, conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing, and the like. The pharmaceutical composition can take any of a variety of forms including, but not limited to, a sterile solution, suspension, emulsion, spray dried dispersion, lyophilisate, tablet, microtablets, pill, pellet, capsule, powder, syrup, elixir or any other dosage form suitable for administration. Routes of administration useful in the disclosed methods include, but are not limited to, oral and parenteral routes, such as intravenous (iv), intraperitoneal (ip), rectal, topical, ophthalmic, nasal, otic, intrathecal, and transdermal.

[0126] A compound of the present disclosure may be administered to a subject using any convenient means capable of resulting in the desired reduction in disease condition or symptom. Thus, a compound can be incorporated into a variety of formulations for therapeutic administration. More particularly, a compound can be formulated into pharmaceutical compositions by combination with appropriate pharmaceutically acceptable excipients, carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, creams, gels, foams, solutions, suppositories, injections, inhalants, aerosols, and the like.

[0127] Formulations for pharmaceutical compositions are described in, for example, Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 19th Edition, 1995, which describes examples of formulations (and components thereof) suitable for pharmaceutical delivery of the disclosed compounds. Pharmaceutical compositions that include at least one of the compounds can be formulated for use in human or veterinary medicine. Particular formulations of a disclosed pharmaceutical composition may depend, for example, on the mode of administration and / or on the location of the subject to be treated. In some embodiments, formulations include a pharmaceutically acceptable excipient in addition to at least one active ingredient, such as a compound of the present disclosure. In other embodiments, other medicinal or pharmaceutical agents, for example, with similar, related or complementary effects on the disease or condition being treated can also be included as active ingredients in a pharmaceutical composition.Atty Dkt No.: EVOM-008WO

[0128] Pharmaceutically acceptable carriers useful for the disclosed methods and compositions may depend on the particular mode of administration being employed. In addition to biologically neutral carriers, pharmaceutical compositions to be administered can optionally contain non-toxic auxiliary substances (e.g., excipients), such as wetting or emulsifying agents, preservatives, and pH buffering agents, and the like. The disclosed pharmaceutical compositions may be formulated as a pharmaceutically acceptable salt of a disclosed compound.

[0129] In certain embodiments, the pharmaceutical compositions described herein include a dermatologically acceptable excipient. Dermatologically acceptable excipients may be one or more solvents that solubilize and / or stabilize the active ingredient (e.g., MrgprX2 antagonist) contained therein. Dermatologically acceptable excipients may also include skin penetration enhancers, preservatives, viscosity enhancers, pH adjusters, film forming agents and the like. Non-limiting examples of the suitable excipients include water, PEG 200, PEG 400, ethanol, glycerol, Transcutol P (diethylene glycol monoethyl ether), propylene glycol, l,3-dimethyl-2-imidazolidinone (DMI), sodium metabisulfite, butylated hydroxytoluene (BHT), benzyl alcohol, sodium benzoate, isopropyl myristate, diisopropyl adipate, crodamol OHS (ethylhexyl hydroxystearate), mineral oil, Betadex, TWEEN 20, Brij S20 (polyoxyethylene (20) stearyl ether).

[0130] In some embodiments, the composition is a topical composition. By "topical composition" it is meant a composition (e.g., pharmaceutical composition comprising a dermatologically acceptable excipient) that is applied directly to the skin. Topical preparations include, but are not limited to, ointments, creams, lotions, sprays and the like. Compositions in the form of a spray (e.g., a spray that includes the MrgprX2 antagonist compound) may dry in a cosmetically acceptable way without the greasy appearance that a lotion or ointment would have when applied to the skin.

[0131] In some cases, the topical composition includes one or more skin penetration enhancers. The skin (e.g., stratum corneum) provides a physical barrier to the harmful effects of the external environment. In doing so, it may also interfere with the absorption or transdermal delivery of topical therapeutic drugs. Thus, a suitable dermatologically acceptable excipient may include one or more penetration enhancers (or permeation enhancers), which areAtty Dkt No.: EVOM-008WOsubstances that promote the diffusion of the therapeutic drugs (e.g., the MrgprX2 antagonist compounds described herein) through the skin barrier. They typically act to reduce the impedance or resistance of the skin to allow improved permeation of the therapeutic drugs. In particular, substances which would perturb the normal structure of the stratum corneum are capable of disrupting the intercellular lipid organization, thus reducing its effectiveness as a barrier. These substances could include any lipid material which would partition into the stratum corneum lipids causing a direct effect or any material which would affect the proteins and cause an indirect perturbation of the lipid structure. Furthermore, solvents, such as ethanol, can remove lipids from the stratum corneum, thus destroying its lipid organization and disrupting its barrier function.

[0132] Examples of penetration enhancers or barrier function disrupters include, but are not limited to, alcohol-based enhancers, such as alkanols with one to sixteen carbons, benzyl alcohol, butylene glycol, diethylene glycol, glycofurol, glycerides, glycerin, glycerol, phenethyl alcohol, polypropylene glycol, polyvinyl alcohol, and phenol; amide-based enhancers, such as N-butyl-N-dodecylacetamide, crotamiton, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl formamide, and urea; amino acids, such as L-a-amino acids and water soluble proteins; azone and azone-like compounds, such as azacycloalkanes; essential oils, such as almond oil, amyl butyrate, apricot kernel oil, avocado oil, camphor, castor oil, 1-carvone, coconut oil, corn oil, cotton seed oil, eugenol, menthol, oil of anise, oil of clove, orange oil, peanut oil, peppermint oil, rose oil, safflower oil, sesame oil, shark liver oil (squalene), soybean oil, sunflower oil, and walnut oil; vitamins and herbs, such as aloe, allantoin, black walnut extract, chamomile extract, panthenol, papain, tocopherol, and vitamin A palmitate; waxes, such as candelilla wax, carnuba wax, ceresin wax, beeswax, lanolin wax, jojoba oil, petrolatum; mixes, such as primary esters of fractionated vegetable oil fatty acids with glycerine or propylene glycol, and interesterified medium chain triglyceride oils; fatty acids and fatty acid esters, such as amyl caproate, butyl acetate, caprylic acid, cetyl ester, diethyl sebacate, dioctyl malate, elaidic acid ethyl caprylate, ethyl glycol palmitostearate, glyceryl beheate, glucose glutamate, isobutyl acetate, laureth-4, lauric acid, malic acid, methyl caprate, mineral oil, myristic acid, oleic acid, palmitic acid, PEG fatty esters, polyoxylene sorbitan monooleate, polypropyleneAtty Dkt No.: EVOM-008WOglycols, propylene glycols, saccharose disterate, salicylic acid, sodium citrate, stearic acid, soaps, and caproic-, caprylic-, capric-, and lauric-triglycerides; macrocylics, such as butylated hydroxyanisole, cyclopentadecanolide, cyclodextrins; phospholipid and phosphate enhancers, such as dialkylphosphates, ditetradecyl phosphate, lecithin, 2-pyrrolidone derivatives, such as alkyl pyrrolidone-5-carboxylate esters, pyroglutamic acid esters, N-methyl pyrrolidone, biodegradable soft penetration enhancers, such as dioxane derivatives and dioxolane derivatives; sulphoxide enhancers, such as dimethyl sulphoxide and decylmethyl sulphoxide; acid enhancers, such as alginic acid, sorbic acid, and succinic acid; cyclic amines; imidazolinones; imidazoles; ketones, such as acetone, dimethicone, methyl ethyl ketone, and pentanedione; lanolin derivatives, such as lanolin alcohol, PEG 16 lanolin, and acetylated lanolin; oxazolines; oxazolindinones; proline esters; pyrroles, urethanes; and surfactants, such as nonoxynols, polysorbates, polyoxylene alcohols, polyoxylene fatty acid esters, sodium lauryl sulfate, and sorbitan monostearate.

[0133] Topical compositions described herein may include one or more carriers. In some cases, the one or more carriers have a vapor pressure greater than or equal to 23.8 mm Hg at 25 °C. Preferred concentration range of a single carrier or the total of a combination of carriers can be from about 0.1 wt.% to about 10 wt. %, about 10 wt. % to about 50 wt.%, or about 50 wt. % to about 95 wt. % of the dermatological composition. Non-limiting examples of the carrier include water (e.g., deionized water) and lower alcohols, including ethanol, 2-propanol and n-propanol.

[0134] Topical compositions described herein may include one or more hydrophilic cocarriers, which are miscible with water and / or lower chain alcohols. In some cases, the one or more hydrophilic co-carriers have a vapor pressure less than water at 25°C (~ 23.8 mm Hg). By using a carrier with a vapor pressure greater than or equal to the vapor pressure of the hydrophilic co-carrier, the active ingredient (e.g., a MrgprX2 antagonist of the present disclosure) can be concentrated on the skin. Hydrophilic co-carriers include, but are not limited to glycols, such as propylene glycol. The propylene glycol may be from the class of polyethylene glycols, specifically polyethylene glycols ranging in molecular weight from 200 to 20000. In some cases, the hydrophilic co-carrier is a glycol ether. In some cases, the hydrophilic coAtty Dkt No.: EVOM-008WOcarrier is diethylene glycol monoethyl ether (transcutol). As used herein, "diethylene glycol monoethyl ether" (" DGME") or "transcutol" refers to 2-(2-ethoxyethoxy)ethanol {CAS NO 001893} or ethyoxydiglycol. In some cases, the hydrophilic co-carrier is l,3-dimethyl-2-imidazolidinone (DMI).

[0135] The topical compositions described herein may include one or more "humectant(s)" used to provide a moistening effect. Preferably the humectant remains stable in the composition. Any suitable concentration of a single humectant or a combination of humectants can be employed, provided that the resulting concentration provides the desired moistening effect. Typically, the suitable amount of humectant will depend upon the specific humectant or humectants employed. In some cases, the concentration range of a single humectant or the total of a combination of humectants can be from about 0.1 wt.% to about 70 wt.%, about 5.0 wt.% to about 30 wt.%, or about 10 wt.% to about 25 wt.% of the composition. Non-limiting examples of humectants include glycerin, polyhydric alcohols and silicone oils. In some cases, the humectant is glycerin, propylene glycol and / or cyclomethicone.

[0136] The topical compositions described herein may include one or more chelating agents. As used herein, the term "chelating agent" or "chelator" refers to agents capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions. The chelating agents for use herein are preferably formulated at concentrations ranging from about 0.001 wt.% to about 10 wt.% (e.g., about 0.05 wt.% to about 5.0 wt.%) of the dermatological composition. Non-limiting examples of chelating agents include EDTA, disodium edeate, dipotassium edeate, cyclodextrin, trisodium edetate, tetrasodium edetate, citric acid, sodium citrate, gluconic acid and potassium gluconate. In some cases, the chelating agent is EDTA, disodium edeate, dipotassium edate, trisodium edetate or potassium gluconate.

[0137] In certain embodiments, the pharmaceutical composition includes a viscosity enhancing agent (e.g., gelling agent) or an emulsifier. Gelling agents are used to increase the viscosity of the final composition. Emulsifiers are substances that stabilize an emulsion. The viscosity enhancing agent can also act as an emulsifying agent. Typically, the concentration and combination of viscosity enhancing agents will depend on the physical stability of the finishedAtty Dkt No.: EVOM-008WOproduct. Preferred concentration range of a viscosity enhancing agent can be from about 0.01 wt.% to about 20 wt.%, about 0.1 wt.% to about 10 wt.%, or about 0.5 wt. % to about 5 wt.% of the composition. Non-limiting examples of viscosity enhancing agents include classes of celluloses, acrylate polymers and acrylate crosspolymers, such as, hydroxypropyl cellulose, hydroxymethyl cellulose, Pluronic PF127 polymer, carbomer 980, carbomer 1342 and carbomer 940, more preferably hydroxypropyl cellulose, Pluronic PF127 carbomer 980 and carbomer 1342, more specifically hydroxypropyl cellulose (Klucel® EF, GF and / or HF), Pluronic PF127, carbomer 980 and / or carbomer 1342 (Pemulen® TR-1, TR-2 and / or Carbopol® ETD 2020). Nonlimiting examples of emulsifiers include polysorbates, laureth-4, and potassium cetyl sulfate.

[0138] In certain embodiments, the pharmaceutical compositions described herein include an orally acceptable excipient. Orally acceptable excipients include, but are not limited to, lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.

[0139] In some embodiments, the composition is an oral composition. Oral compositions may be liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powders, pills, tablets, or capsules). Oral compositions may include appropriate additives to make tablets, powders, granules or capsules. In some instances, an oral composition is provided that is designed and configured to achieve delayed release of the compound (i.e., compound described herein) in the small intestine of the subject.

[0140] The compositions (e.g., topical or oral compositions) described herein may contain one or more anti-oxidants, radical scavengers, and / or stabilizing agents, at a concentration range from about 0.001 wt.% to about 0.1 wt.% or about 0.1 wt.% to about 5 wt.% of the composition. Non-limiting examples of anti-oxidants, radical scavengers, and / or stabilizing agents include butylatedhydroxytoluene, butylatedhydroxyanisole, ascorbyl palmitate, citric acid, vitamin E, vitamin E acetate, vitamin E-TPGS, ascorbic acid, tocophersolan and propylAtty Dkt No.: EVOM-008WOgallate. In some cases, the anti-oxidant is ascorbyl palmitate, vitamin E acetate, vitamin E-TPGS, vitamin E or butylatedhydroxy toluene.

[0141] The compositions (e.g., topical or oral compositions) described herein may also contain preservatives that exhibit anti-bacterial and / or anti-fungal properties. Preservatives can be present in a gelled composition (e.g., a gelled topical composition) of the invention to minimize bacterial and / or fungal over its shelf-life. Concentration ranges of preservatives in a composition of the invention can be from about 0.001 wt.% to about 0.01 wt.%, or about 0.01 wt.% to about 0.5 wt.% of the composition. Non-limiting examples of preservatives include diazolidinyl urea, methylparaben, propylparaben, tetrasodium EDTA, and ethylparaben. In some cases, the preservative may be a combination of methylparaben and propylparaben.

[0142] The compositions (e.g., topical compositions) described herein may include one or more compatible cosmetically acceptable adjuvants commonly used, such as colorants, fragrances, emollients, and the like, as well as botanicals, such as aloe, chamomile, witch hazel and the like.

[0143] The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosagesforhuman and animal subjects, each unit containinga predetermined quantity of a compound calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, excipient, carrier or vehicle. The specifications for a compound depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the subject.

[0144] Certain embodiments of the pharmaceutical compositions that include a subject compound may be formulated in unit dosage form suitable for individual administration of precise dosages. The amount of active ingredient administered may depend on the subject being treated, the severity of the affliction, and the manner of administration, and is known to those skilled in the art. In certain instances, the formulation to be administered contains a quantity of the compound disclosed herein in an amount effective to achieve the desired effect in the subject being treated.

[0145] In some cases, the composition is formulated such that the compound is stable in the composition over a prolonged period of time. In some cases, the compound is stable in theAtty Dkt No.: EVOM-008WOcomposition over a period of up to about 3 years, up to 1 year, or up to about 6 months, which is typical in the manufacturing, packaging, shipping and / or storage of dermatologically acceptable compositions. A compound of the present disclosure can be in solution, partially in solution with an undissolved portion or completely undissolved suspension.

[0146] A compound of the present disclosure can be present in a composition of the invention in a concentration range from about 0.001 wt.% to about 80 wt.%, from about 0.001 wt.% to about 50 wt.%, from about 0.001 wt.% to about 25 wt.%, or from about 0.001 wt.% to about 6 wt.% of the composition. In some cases, a compound of the present disclosure can be present in a concentration range of from about 0.001 wt.% to about 10 wt.%, from about 0.1 wt.% to about 10 wt.%, from about 0.05 wt.% to about 5 wt.% or from about 1.0 wt.% to about 5.0 wt.% of the composition.

[0147] In embodiments, where two or more compounds are administered, each therapeutic compound can independently be in any dosage form, such as those described herein, and can also be administered in various ways, as described herein. For example, the compounds may be formulated together, in a single dosage unit (that is, combined together in one form such as capsule, tablet, powder, or liquid, etc.) as a combination product. Alternatively, when not formulated together in a single dosage unit, an individual compound may be administered at the same time as another therapeutic compound or sequentially, in any order thereof.

[0148] A disclosed compound can be administered alone, as the sole active pharmaceutical agent, or in combination with one or more additional compounds or prodrugs of the present disclosure or in conjunction with other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are administered simultaneously or at different times, or the therapeutic agents can be administered together as a single composition combining two or more therapeutic agents. Thus, the pharmaceutical compositions disclosed herein containing a compound of the present disclosure optionally include other therapeutic agents. Accordingly, certain embodiments are directed to such pharmaceutical compositions, where the composition further includes a therapeutically effective amount of an agent selected as is known to those of skill in the art.Atty Dkt No.: EVOM-008WOMETHODS OF TREATMENT

[0149] Provided are methods of treating a subject for a condition by administering a MrgprX2 inhibitor compound as described herein. In some cases, the subject has been diagnosed with a MrgprX2 related condition.

[0150] In some embodiments, the method is a method of treating a subject for an inflammatory disorder, the method comprising administering to a subject in need thereof a pharmaceutical composition as described herein. In some embodiments, the invention provides a method for treating an inflammatory disorder, the method comprising administering to a mammal in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist. In an exemplary embodiment, the subject is not otherwise in need of treatment with the MRGPRX2 antagonist. In some embodiments, the inflammatory disorder activates MrgprX2 or is consequent to activation of MrgprX2.

[0151] In some embodiments, the inflammatory disorder is an inflammatory disorder of the skin. In some embodiments, the inflammatory disorder is an anaphylactic reaction, an anaphylactoid reaction, chronic urticaria, systemic itch, rosacea, atopic dermatitis, allergic contact dermatitis, ulcerative colitis and allergic asthma.

[0152] I n some embodiments, the inflammatory disorder is inflammatory bowel disease. In an exemplary embodiment, the mammal is in need of treatment of inflammatory bowel disease, but not in need of treatment for an inflammatory disorder selected from the group consisting of ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions.

[0153] In some embodiments, the method is a method of treating a condition associated with a peripheral sensory neuron, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist.Atty Dkt No.: EVOM-008WO

[0154] By "treatment" is meant that at least an amelioration of the symptoms associated with the condition afflicting the host is achieved, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the condition being treated. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g., prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the condition, or at least the symptoms that characterize the condition. Thus treatment includes: (i) prevention, that is, reducing the risk of development of clinical symptoms, including causing the clinical symptoms not to develop, e.g., preventing disease progression to a harmful state; (ii) inhibition, that is, arresting the development or further development of clinical symptoms, e.g., mitigating or completely inhibiting an active disease; and / or (iii) relief, that is, causing the regression of clinical symptoms.

[0155] Subjects to be treated according to the methods of the disclosure may vary. The terms "subject," "individual" and "patient," are used interchangeably herein, and generally refer to a mammal, including, but not limited to, murines (e.g., rats, mice), non-human primates, humans, canines, felines, ungulates (e.g., equines, bovines, ovines, porcines, caprines), lagomorphs, etc. In some cases, the subject is a human. In some cases, the subject is a non-human primate. In some cases, the subject is a rodent, e.g., a rat or a mouse. In some cases, the subject is a lagomorph, e.g., a rabbit. Where the subject is a human, the subject may be a human of any age including, e.g., a juvenile human (i.e., a human less than 18 years old) or an adult human (i.e., a human 18 years or older).

[0156] The compounds find use for treating a disease or disorder in a subject. The route of administration may be selected according to a variety of factors including, but not limited to, the condition to be treated, the formulation and / or device used, the subject to be treated, and the like. Routes of administration useful in the disclosed methods include, but are not limited to, oral and parenteral routes, such as intravenous (iv), intraperitoneal (ip), rectal, topical, ophthalmic, nasal, otic, intrathecal, and transdermal.

[0157] In some embodiments, the inflammatory disorder is an anaphylactic reaction. An "anaphylactic reaction" or "anaphylactic shock" is an extreme, often life-threatening allergicAtty Dkt No.: EVOM-008WOreaction to an antigen to which the body has become hypersensitive. Anaphylactic reactions are immediate systemic reactions caused by IgE-mediated immune release of potent mediators from sue mast cells and peripheral blood basophils. Anaphylaxis may be measured using skin prick tests and / or blood tests (e.g., blood tests that measure tryptase, histamine and / or IgE antibodies).

[0158] In some embodiments, the inflammatory disorder is an anaphylactoid reaction. An "anaphylactoid reaction" is similar to an anaphylactic reaction in that it is often a life-threatening allergic reaction to an antigen. However, unlike anaphylactic reactions, anaphylactoid reactions are non-lgE-mediated triggering events. Anaphylactoid reactions may be measured using skin prick tests and / or blood tests (e.g., blood tests that measure tryptase, histamine and / or IgE antibodies).

[0159] In some embodiments, the inflammatory disorder is chronic urticaria. " Chronic urticaria" or "chronic hives" is a skin rash that lasts for more than 6 weeks. In some cases, the chronic urticaria may go away and then reappear. Symptoms can include itchy, raised, red, or skin-colored welts on the skin's surface. In some cases, the chronic urticaria may be chronic inducible urticaria, i.e., chronic urticaria with a known trigger. Chronic urticaria may be triggered by a variety of causes including, but not limited to, certain foods, medications, stress, temperature, sunlight, exercise, vibrations or pressure on the skin. In some cases, the chronic urticaria may be chronic spontaneous urticaria, i.e., chronic urticaria that develops without a known trigger. Urticaria may be assessed using patient reported outcomes (e.g., Urticaria Activity Score (UAS7), Urticaria Control Test (UCT)), skin prick tests and / or blood tests.

[0160] In some embodiments, the inflammatory disorder is systemic itch. " Systemic itch" or "systemic pruritus" is a generalized itching sensation that may occur all over the body. In some cases, systemic itch may be caused by an underlying disease including, but not limited to, liver disease, kidney disease, anemia, diabetes, thyroid conditions or cancer. Systemic itch may be assessed using patient reported outcomes (see, e.g., Pereira, M. P., et al. Itch 2019, l:e29) and / or blood tests.

[0161] In some embodiments, the inflammatory disorder is rosacea. " Rosacea" is a chronic inflammatory condition that primarily affects the face. Symptoms of rosacea include redness,Atty Dkt No.: EVOM-008WOpus-filled bumps, swelling, dilated blood vessels, or combinations thereof. Rosacea may be assessed using a skin examination (e.g., a skin examination by a clinician). Rosacea after treatment may present as decreased redness, decreased affected area and / or decreased bumps.

[0162] In some embodiments, the inflammatory disorder is atopic dermatitis. " Atopic dermatitis" or "eczema" refers to a skin condition involving chronic inflammation, and symptoms of atopic dermatitis include a red, itchy rash. Atopic dermatitis may be present on the skin of any part of the body, but is common on the hands, feet, upper chest, and in the bends of elbows or knees. Additional symptoms of atopic dermatitis may include small raised bumps or thickened, scaly skin. In some cases, the atopic dermatitis is Asian atopic dermatitis. In some cases, the atopic dermatitis is European atopic dermatitis. Asian atopic dermatitis and European atopic dermatitis have differing phenotypes, with Asian atopic dermatitis having higher TH17 activation and a strong TH2 component (see, e.g., Noda, et al., J Allergy Clin Immunol. 2015. 136:1254-1264). Atopic dermatitis may be assessed using a scoring system (e.g., Eczema Area and Severity Index (EASI), Scoring Atomic Dermatitis (SCORAD)).

[0163] In some embodiments, the inflammatory disorder is allergic contact dermatitis. " Allergic contact dermatitis" is an itchy rash that is caused by direct contact of an allergen with the skin. Allergens include, but are not limited to, solvents, rubber, bleach, detergents (e.g., soaps), hair products, airborne substances, plants and other chemicals (e.g., fertilizers and pesticides). Symptoms of allergic contact dermatitis include, but are not limited to, redness, itchy rash, blisters, swelling, scaly skin and dry skin. Allergic contact dermatitis may be assessed using a patch test.

[0164] In some embodiments, the inflammatory disorder is ulcerative colitis. " Ulcerative colitis" is a chronic inflammatory bowel disease resulting in inflammation and / or ulcers in the colon and rectum. Symptoms of ulcerative colitis include, but are not limited to, abdominal pain and bloody diarrhea. In some cases, symptoms may also include fever and / or weight loss. Ulcerative colitis may be assessed using one or more of: endoscopy (e.g., colonoscopy or sigmoidoscopy), biopsy, blood tests (e.g., blood tests for inflammatory markers ) and imaging (e.g., barium enema, computed tomography (CT) scan, magnetic resonance imaging (MRI)).Atty Dkt No.: EVOM-008WO

[0165] In some embodiments, the inflammatory disorder is allergic asthma. " Allergic asthma" is a type of asthma triggered by allergens in which a person's airways become inflamed, narrow and swell, and produce extra mucus, which makes it difficult to breathe. Allergens may include airborne allergens. Allergens include, but are not limited to, certain foods, spores, pollen, dust and pet dander. Allergic asthma may be assessed using one or more of: lung function tests (e.g., spirometry), skin prick tests, blood tests (e.g., blood tests to measure IgE levels related to particular antigens) and bronchoprovocation testing (e.g., methacholine testing).

[0166] As reviewed above, the invention provides a method for treating a condition associated with a peripheral sensory neuron, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist. In another aspect, the invention provides a method for treating a condition associated with a peripheral sensory neuron, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist, wherein the peripheral sensory neuron is a(n) trigeminal ganglion neuron, enteric neuron, nodose ganglion neuron, or dorsal root ganglion neuron. In another aspect, the invention provides a method for treating a condition associated with a peripheral sensory neuron, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist, wherein the peripheral sensory neuron is a Navi.8+ neuron. In another aspect, the invention provides a method for treating a condition associated with a peripheral sensory neuron, the method comprising administering to a subject in need of treatment thereof a therapeutically effective amount of a MRGPRX2 antagonist, wherein the peripheral sensory neuron is a Scnl0a+ neuron. In an exemplary embodiment, the subject is not otherwise in need of treatment with the MRGPRX2 antagonist.

[0167] In an exemplary embodiment, the peripheral sensory neuron is a trigeminal ganglion neuron. In an exemplary embodiment, the condition is headache. In an exemplary embodiment, the condition is secondary headache. In an exemplary embodiment, the condition is primary headache. In an exemplary embodiment, the condition is primary headache, and the primary headache is migraine, cluster headache, tension-type headache (TTH), trigeminal autonomic cephalalgia (TACs), primary cough headache, primary exercise headache, primary headacheAtty Dkt No.: EVOM-008WOassociated with sexual activity, primary thunderclap headache, cold-stimulus headache, externalpressure headache, primary stabbing headache, nummular headache, hypnic headache, new daily persistent headache, or a combination thereof. In an exemplary embodiment, the condition is migraine. In an exemplary embodiment, the condition is cluster headache. In an exemplary embodiment, for a condition described in this paragraph, the peripheral sensory neuron is a trigeminal ganglion neuron.

[0168]

[0001] In an exemplary embodiment, the subject is in need of treatment of a condition associated with a trigeminal ganglion neuron, but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions. In an exemplary embodiment, the subject is in need of treatment of a primary headache (e.g. migraine), but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions.

[0169] In an exemplary embodiment, the peripheral sensory neuron is an enteric neuron. In an exemplary embodiment, the peripheral sensory neuron is a myenteric plexus enteric neuron. In an exemplary embodiment, the peripheral sensory neuron is an Auerbach's plexus enteric neuron. In an exemplary embodiment, the peripheral sensory neuron is a submucosal plexus enteric neuron. In an exemplary embodiment, the peripheral sensory neuron is a Meissner's plexus enteric neuron.Atty Dkt No.: EVOM-008WO

[0170] In an exemplary embodiment, the subject is in need of treatment of a condition associated with an enteric neuron, but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions.

[0171] In an exemplary embodiment, the peripheral sensory neuron is a nodose neuron. In an exemplary embodiment, the condition is asthma, chronic cough, or a combination thereof. In an exemplary embodiment, for a condition described in this paragraph, the peripheral sensory neuron is a nodose neuron.

[0172] In an exemplary embodiment, the subject is in need of treatment of a condition associated with a nodose ganglion neuron, but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions. In an exemplary embodiment, the subject is in need of treatment of chronic cough, but not in need of treatment for asthma.

[0173] In an exemplary embodiment, the peripheral sensory neuron is a dorsal root ganglion neuron. In an exemplary embodiment, the condition is interstitial cystitis, irritable bowel syndrome, or a combination thereof. In an exemplary embodiment, for a condition described in this paragraph, the peripheral sensory neuron is a dorsal root ganglion neuron.

[0174] In an exemplary embodiment, the subject is in need of treatment of a condition associated with a dorsal root ganglion neuron, but not in need of treatment for an inflammatoryAtty Dkt No.: EVOM-008WOdisorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions. In an exemplary embodiment, the subject is in need of treatment of interstitial cystitis, but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions. In an exemplary embodiment, the subject is in need of treatment of irritable bowel syndrome, but not in need of treatment for an inflammatory disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, atopic dermatitis (e.g., Asian atopic dermatitis, European atopic dermatitis), urticaria (e.g. chronic urticaria, e.g. chronic spontaneous urticaria or chronic inducible urticaria), pseudo-allergic reactions triggered by small molecules for example anaphylactoid reaction (e.g. anaphylactoid drug reaction), anaphylactic reaction (e.g. anaphylactic shock), rosacea, asthma (e.g. allergic asthma), systemic itch such as cholestatic or uremic itch, chronic itch triggered by systemic diseases, and drug-adverse reactions. In an exemplary embodiment, the subject is in need of treatment of interstitial cystitis, but not in need of treatment for irritable bowel syndrome. In an exemplary embodiment, the subject is in need of treatment of irritable bowel syndrome, but not in need of treatment for interstitial cystitis.

[0175] An effective amount of a subject compound may depend, at least, on the particular method of use, the subject being treated, the severity of the affliction, and the manner of administration of the therapeutic composition. A "therapeutically effective amount" of aAtty Dkt No.: EVOM-008WOcomposition is a quantity of a specified compound sufficient to achieve a desired effect in a subject (e.g., patient) being treated. Forexample, this may be the amount of a subject compound necessary to prevent, inhibit, reduce or relieve a disease or disorder in a subject. Ideally, a therapeutically effective amount of a compound is an amount sufficient to prevent, inhibit, reduce or relieve a disease or disorder in a subject without causing a substantial cytotoxic effect on host cells in the subject.

[0176] Therapeutically effective doses of a subject compound or pharmaceutical composition can be determined by one of skill in the art. For example, in some instances, a therapeutically effective dose of a compound or pharmaceutical composition is administered with a goal of achieving local (e.g., tissue) concentrations that are at least as high as the IC50 of an applicable compound disclosed herein.

[0177] The specific dose level and frequency of dosage for any particular subject may be varied and may depend upon a variety of factors, including the activity of the subject compound, the metabolic stability and length of action of that compound, the age, body weight, general health, sex and diet of the subject, mode and time of administration, rate of excretion, drug combination, and severity of the condition of the host undergoing therapy.

[0178] In some embodiments, multiple doses of a compound are administered. The frequency of administration of a compound can vary depending on any of a variety of factors, e.g., severity of the symptoms, condition of the subject, etc. Forexample, in some embodiments, a compound is administered once per month, twice per month, three times per month, every other week, once per week (qwk), twice per week, three times per week, four times per week, five times per week, six times per week, every other day, daily (qd / od), twice a day (bds / bid), or three times a day (tds / tid), etc.EXPERIMENTAL EXAMPLES

[0179] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts,Atty Dkt No.: EVOM-008WOtemperature, etc.) but some experimental errors and deviations should be accounted for. As will be understood, by those of skill in the art of organic synthesis and medicinal chemistry the specific conditions set forth below are exemplary and can be varied or adapted to other reagents and products in routine fashion. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); nt, nucleotide(s); and the like.General Synthetic MethodsStandard abbreviations:LCMS: Liquid chromatography mass spectrometryMS: Mass spectrometryNMR: Nuclear magnetic resonanceHPLC: High-performance liquid chromatographySFC: Supercritical fluid chromatographyESI: Electrospray ionizations or sec: Second(s)min: Minute(s)h or hr: Hour(s)TEA: Trifluoroacetic acidDMAP: 4-dimethylaminopyridineEtOAc: Ethyl AcetateNaHCO3: Sodium bicarbonateNa2SO4: Sodium sulfateSiO2: Silica gelDMSO -d6- Deuterated dimethylsulfoxideCDCI3: Deuterated chloroformDMF: / V, / V-DimethylformamideAtty Dkt No.: EVOM-008WOTHF: Tetra hydrofuranDIPEA: / V, / V-diisopropylethylamineMeOH: MethanolEtOH: EthanolNEta: TriethylamineN2: NitrogenAr: ArgonCeCh: Cerium chlorideACN: AcetonitrileDPPA: Diphenylphosphoryl azideMTBE: Methyl tert-butyl etherPTSA: p-toluene sulfonic acidDCM: Dichloromethane

[0180] The following examples are intended to illustrate the invention and are not to be construed as being limitation thereon. Reaction temperatures are indicated in degrees centigrade. All evaporations are performed under reduced pressure using rotary evaporator. The structure of the intermediates and the final products are confirmed by standard analytical methods such as spectroscopic analyses: liquid chromatography mass spectrometry (LCMS), nuclear magnetic resonance (NMR), etc., and purity confirmed by high-performance liquid chromatography (HPLC) and / or chiral supercritical fluid chromatography (SFC) as indicated. All starting materials, regents, building blocks, catalysts, and solvents used in this invention are either commercially available or can be synthesized using standard organic synthesis procedures. Reactions are carried out in inert atmosphere using either nitrogen or argon unless stated otherwise.

[0181] Many general references providing commonly known chemical synthetic schemes and conditions useful for synthesizing the disclosed compounds are available (see, e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, FifthAtty Dkt No.: EVOM-OQ8WOEdition, Wiley-lnterscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978).

[0182] Compounds as described herein can be purified by any purification protocol known in the art, including chromatography, such as HPLC, preparative thin layer chromatography, flash column chromatography and ion exchange chromatography. Any suitable stationary phase can be used, including normal and reversed phases as well as ionic resins. In certain embodiments, the disclosed compounds are purified via silica gel and / or alumina chromatography. See, e.g., Introduction to Modern Liquid Chromatography, 2nd Edition, ed. L. R. Snyder and J. J. Kirkland, John Wiley and Sons, 1979; and Thin Layer Chromatography, ed E. Stahl, Springer-Verlag, New York, 1969.

[0183] During any of the processes for preparation of the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups as described in standard works, such as J. F. W. McOmie, " Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, " Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999, in " The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in " Methoden der organischen Chemie", Houben-Weyl, 4thedition, Vol. 15 / 1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, " Aminosauren, Peptide, Proteine", Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or in Jochen Lehmann, " Chemie der Kohlenhydrate: Monosaccharide and Derivate", Georg Thieme Verlag, Stuttgart 1974. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

[0184] The subject compounds can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods. A variety of examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described in the schemes below.Atty Dkt No.: EVOM-008WOAnalytical Methods: LCMS

[0185] Method 1: Shimadzu LC-20AB & MS 2020 System equipped with a Merck, Chromolith Flash RP-18e 25-3mm, at 50 °C, using H2O with 0.04% TFA as the mobile phase A, and MeCN with 0.02% TFA as the mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0. OOmin and 5-95% B at 0.00-0.70 min, hold on 95% B for 0.40 min, and then 95-5%B in O. Olmin, hold on 5% B for 0.39min, the flow rate was 1.5 ml / min. UV detection at 220 &254 nm.

[0186] Method 2: LC / MS is a system equipped with PDA and Shimadzu 2020 mass spectrometer, which use the following conditions: The column used for chromatography was a HALO,90A, C18 5um 3.0x30mm. MS mode was positive electrospray ionization. Mobile phase: 0.04% TFA in water (solvent A) and 0.02% TFA in acetonitrile (solvent B), using the elution gradient 5%-95% (solvent B) over 0.8 minutes and holding at 95% for 0.15 minutes, then drop back to 5% in O. Olmin and keep for 0.09min at a flow rate of 2.0 mL / min. UV detection at 220 & 254 nm.

[0187] Method 3: LC / MS is a system equipped with PDA and Shimadzu 2020 mass spectrometer, which use the following conditions: The column used for chromatography was a Merck, Chromolith Flash RP-18e 25-3mm. MS mode was positive electrospray ionization. Mobile phase: 0.04% TFA in water (solvent A) and 0.02% TFA in acetonitrile (solvent B), using the elution gradient 5%-95% (solvent B) over 0.7 minutes and holding at 95% for 0.4 minutes, then drop back to 5% in O. Olmin and keep for 0.39min at a flow rate of 1.5 mL / min. UV detection at 220&254 nm.

[0188] Method 4: Shimadzu LC-20ADXR & MS 2020 System equipped with a Kinetex® 5um EVO C18100A 2.1x30mm (PN:00A-4633-AN) at 50 °C, using H20+0.04 %(v / v) TFA as the mobile phase A, and ACN+0.02 %(v / v) TFA as the mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0. OOmin and 5-95% B at 0.00-0.80 min, hold on 95% B for 0.15 min, and then 95-5%B in O. Olmin, hold on 5% B for 0.09 min, the flow rate was 2 mL / min. UV detection at 220&254 nm.

[0189] Method 5: System equipped with PDA and Shimadzu 2020 mass spectrometer, using the following conditions: The column used for chromatography was a XtimateTM C18, 3pm, 3x30mm. MS mode was positive electrospray ionization. Mobile phase: 0.04% TFA in waterAtty Dkt No.: EVOM-008WO(solvent A) and 0.02% TFA in acetonitrile (solvent B), using the elution gradient 0%-30% (solvent B) over 6 minutes and holding at 30% for 0.5 minutes, then drop back to 0% in 0.01 min and keep for 0.49min at a flow rate of 0.8 mL / min. UV detection at 220&254 nm.

[0190] Method 6: Waters Acquity LCMS instrument equipped with XBridge C18, 5um, 3x100mm column. Solvent A: Water with 0.1% NH4OH. SolventB: ACN. Flow rate: 1.5 mL / min. Initial cond: 90%A, 10%B. 0.5min: 90%A, 10%B. 3.0min: 5%A, 95%B. 4.0min: 5%A, 95%B. 4.1min: 90%A, 10%B. S. Omin: 90%A, 10%B.Analytical Methods: NMR

[0191] Proton NMR (1H NMR) experiment is conducted in commonly used deuterated solvents and are reported as chemical shift (6) values in part-per-million relative to a reference standard.

[0192] In some instances, intermediates and compounds described in the examples comprise one or more stereocenters and more than one enantiomer / diastereomer was produced. In some embodiments, these enantiomers / diastereomers were separated and isolated; in some embodiments, the stereochemistry was resolved and confirmed by appropriate analytical techniques (2D NMR experiments), while in some instances the stereochemistry was not resolved and was assigned arbitrarily. Accordingly, any compound with arbitrarily assigned stereochemistry or produced from an intermediate with arbitrarily assigned stereochemistry may be depicted herein as a certain stereoisomer, but it is understood that such compound may be the other stereoisomer (enantiomer or diastereomer).Example 1: Synthesis of (lR,3R)-3-{3-[5-(o-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l(trifluoromethyl)cyclopentanol

[0193] Below is a general procedure described for synthesis of (lR,3R)-3-{3-[5-(o-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l(trifluoromethyl)cyclopentanol (Compound 1) in Scheme 1 (Method A).Scheme 1Atty Dkt No.: EVOM-008WO1) pyridine(1.20 eq), F— eq) 4-nitrophenyl chloroformate H2N S / = / MeCN, 70 °C, 1 h 2) DIPEA (1.70 eq). HCI H2N S THF, 20 °C, 16 hlnt-1 R = CF3for 1H2N

[0194] 5-(2-fluorophenoxy)thiazol-2-amine: To a solution of 5-fluorothiazol-2-amine hydrochloride (100 mg, 892 pmol) and 2-fluorophenol (275 mg, 1.78 mmol) in ACN (2 mL) was added CS2CO3 (726 mg, 2.23 mmol). The mixture was stirred at 70 °C for lhr. The reaction was poured into aq. Na2COs (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with brine (50 mL) and concentrated under reduced pressure to give a residue 5-(2-fluorophenoxy)thiazol-2-amine (58 mg, 275 pmol) as a yellow solid, LCMS (ESI): C9H7FN2OS: m / z = 210.03, found 211.0 [M+H]+; tR = 0.325 min (Method 2). The residue was used for next step without further purification.FF<lW

[0195] Synthesis of (lR,3R)-3-{3-[5-(o-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}- l(trifluoromethyl)cyclopentanol: To a mixture of 4-nitrophenyl chloroformate (66.7 mg, 331 pmol) and 5-(2-fluorophenoxy)thiazol-2-amine (58 mg, 275 pmol) inTHF (2 mL) in a 100 mLthree- necked flask was added pyridine (36 pL, 441 pmol) at 25°C and the mixture was stirred for 0.5 hr. To the above mixture was added a solution of (lR,3R)-3-(methylamino)-l- (trifluoromethyl)cyclopentan-l-ol (55.6 mg, 303 pmol) and DIPEA (53.5 mg, 413 pmol). The mixture was stirred at 25°C for 12 hrs and monitored by LCMS. The reaction mixture was poured into aq. NazCOs (50 mL) and extracted with EtOAc (50 mL x2.) The combined organic extracts were washed with brine (50 mL) and concentrated under reduced pressure to give a crudeAtty Dkt No.: EVOM-008WOresidue, which was purified by column chromatography (SiO2, hexanes: EtOAc=100 / l to 3 / 1) to afford (lR,3R)-3-{3-[5-(o-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l(trifluoromethyl)cyclopentanol as a white solid (80 mg, 190 pmol).

[0196] XH NMR (400 MHz, DMSO-d6) 5 = 10.85 - 10.64 (m, 1H), 7.43 - 7.34 (m, 1H), 7.27 - 7.17 (m, 3H), 7.15 (s, 1H), 6.00 (s, 1H), 5.03 - 4.79 (m, 1H), 2.83 (s, 3H), 2.08 - 2.01 (m, 1H), 2.00 - 1.81 (m, 3H), 1.71 (br d, J = 7.2 Hz, 2H); LCMS (ESI): C17H17F4N3O3S: m / z = 419.09, found [M+H]+: 420.0, tR = 0.575 min (Method 2).Example 2: Synthesis of (lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5-pyrazolyl]-l-methylureido}-l-(trifluoromethyl)cyclopentanol

[0197] Below is the general procedure described for synthesis of (lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5-pyrazolyl]-l-methylureido}-l-(trifluoromethyl)cyclopentanol (Compound 72) in Scheme 2 (Method B).Scheme 2

[0198] 3-(3-fluorophenyl)-l-methyl-lH-pyrazol-5-amine: To a solution of 3-bromo-l-methyl-lH-pyrazol-5-amine (135 mg, 766.98 pmol, 1 eq) and 3-fluorophenyl boronic acid (139.51 mg, 997.08 pmol, 1.3 eq) in dioxane (2 mL) and H2O (0.5 ml) was added CS2CO3 (499.8 mg, 1.53 mmol, 2 eq) and Pd(dppf)Cl2 (56.12 mg, 76.70 pmol, 10 mol%). The mixture was stirred at 110 °C for 3 hr. The reaction mixture was diluted with EtOAc (lOOmL) and washed with H2O (100 mL x 2). The combined organic extracts were dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, hexanes: EtOAc=100 / l to 1 / 1) to afford 3-(3-fluorophenyl)-l-methyl-lH-pyrazol-5-amine (110Atty Dkt No.: EVOM-008WOmg, 563.79 pmol) as a light yellow solid. LCMS (ESI): C10H10FN3: m / z = 191, found 192.2 [M+H]+; tR = 0.325 min (Method 2).

[0199] Synthesis of (lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5-pyrazolyl]-l-methylureido}-l-(trifluoromethyl)cyclopentanol: To a mixture of pyridine (33.10 mg, 418.40 pmol, 33.77 pL, 1.6 eq) and 3-(3-fluorophenyl)-l-methyl-lH-pyrazol-5-amine (50 mg, 261.50 pmol, 1 eq) in THF (2 mL) in a 100 mL three-necked flask was added DIPEA (50.69 mg, 392.25 pmol, 68.32 pL, 1.5 eq). After stirring the mixture at 25°C for 0.5 hr was added a solution of lR,3R)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol (52.69 mg, 287.65 pmol, 1.1 eq) and 4-nitrophenyl chloroformate (63.25 mg, 313.80 pmol, 1.2 eq). The reaction mixture was stirred at 25°C for 12 hr (monitored by LCMS). The reaction was poured into aq. Na2COs (50 mL) and was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL x 1) and concentrated under reduced pressure to obtain a crude residue. The residue was purified by column chromatography (SiOz, hexanes: EtOAc=100 / l to 1 / 1) to afford (lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5-pyrazolyl]-l-methylureido}-l-(trifluoromethyl)cyclopentanol as a white solid (38 mg, 94.91 pmol).XH NMR (400 MHz, DMSO-d6) 6 = 8.54 (s, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.59 (br d, J = 9.6 Hz, 1H), 7.53 - 7.45 (m, 1H), 7.16 (dt, J = 2.4, 8.8 Hz, 1H), 6.60 (s, 1H), 6.07 (s, 1H), 5.06 - 4.91 (m, 1H), 3.70 (s, 3H), 2.91 (s, 3H), 2.19 - 2.09 (m, 1H), 2.06 - 1.99 (m, 1H), 1.98 - 1.88 (m, 2H), 1.87 - 1.69 (m, 2H); LCMS (ESI): m / z = 400.15, found 401.2 [M+H]+; tR = 0506 min (Method 2)Example 3: Synthesis of (lR,3R)-3-[l-methyl-3-(5-phenyl-l,3-thiazol-2-yl)ureido]-l-(trifluoromethyl)cyclopentanol

[0200] Below is the general procedure described for synthesis of (lR,3R)-3-[l-methyl-3-(5-phenyl-l,3-thiazol-2-yl)ureido]-l-(trifluoromethyl)cyclopentanol (Compound 87) in Scheme 3 (Method C).Scheme 3Atty Dkt No.: EVOM-008WO1. 4-nitrophenyl chloroformate, Pyridine, THF, 20 °C, 1 5 hr2. DIPEA, THF, 20 °C, 16 hrsFI

[0201] To a solution of 5-phenylthiazol-2-amine (20 mg, 94.03 pmol) in THF (2 mL) was added pyridine (11.4 pL, 141 pmol) at 25°C and the mixture was stirred at 25°C for 1.5 hr. To the above mixture was added a solution of (lR,3R)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol (17.22 mg, 94.03 pmol, 1 eq) and DIPEA (24.57 pL, 141.04 pmol). The mixture was stirred at 25°C for 16 hr and monitored by LCMS. The reaction mixture was poured into aq. NazCCh (10 mL) and extracted with EtOAc (10 mL x2). The combined organic extracts were washed with brine (10 mL) and concentrated under reduced pressure to give a crude residue, which was purified by prep-HPLC (column: Xtimate C18 100x30mmx3um;mobile phase: [H2O (0.075% TFA)-ACN]; gradient:28%-58% B over 8.0 min) to afford (lR,3R)-3-[l-methyl-3-(5-phenyl-l,3-thiazol-2-yl)ureido]-l-(trifluoromethyl)cyclopentanol (11 mg, 27.5%) as a white solid. 1H NMR (400 MHz, DMSO-d6) 67.73 - 7.79 (m, 1 H), 7.55 (br d, J = 7.8 Hz, 2 H), 7.35 - 7.42 (m, 2 H), 7.23 - 7.29 (m, 1 H), 5.85 - 6.24 (m, 1 H), 5.00 (br s, 1 H), 2.86 (s, 3 H), 2.04 - 2.10 (m, 1 H), 1.94 - 2.01 (m, 1 H), 1.84 - 1.91 (m, 2 H), 1.71 (br d, J = 5.2 Hz, 2 H); LCMS (ESI): C17H18F3N3O2S: m / z = 385.11, found 386.2 [M+H]+; tR = 0.553 min (Method 2)Example 4: Synthesis of 5-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]-3-methylureido}-l,3-thiazol-5-yloxy)-2-fluorobenzonitrile

[0202] Below is the general procedure described for synthesis of 5-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]-3-methylureido}-l,3-thiazol-5-yloxy)-2-fluorobenzonitrile (Compound 108) in Scheme 4 (Method D).Scheme 41. 4-nitrophenyl chloroformate, Pyridine, THF, 20 °C, 2 hr 2. DIPEA, 20 °C, 16 hrAtty Dkt No.: EVOM-008WO

[0203] To a solution of 5-((2-aminothiazol-5-yl)oxy)-2-fluorobenzonitrile (15.0 mg, 63.7 nmol) THF (1 mL) at 20 °C was added (4-nitrophenyl) carbonochloridate (15.4 mg, 76.5 pmol), followed by the addition of pyridine (83 pL, 102 pmol). The reaction mixture was stirred at 20 °C for 2 hr. To the reaction mixture was added (lR,3R)-l-cyclopropyl-3-(methylamino)cyclopentan-l-ol (10.9 mg, 70.1 pmol) and DIPEA (16.5 pL, 95.6 pmol), and the mixture was stirred at 20 °C for 16 hr (LCMS). The reaction was quenched by addition of EtOAc (10 mL) and sat. Na2COs (5 mL). The organic layer was separated and washed with sat. Na? CO3 (10 mLx4). The organic extract was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue, which was purified by prep-TLC (hexanes: EtOAc = 1:1, Rf = 0.38) to afford 5-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]-3-methylureido}-l,3-thiazol-5-yloxy)-2-fluorobenzonitrile (7.00 mg, 26.3% yield) as a yellow solid.XH NMR (400 MHz, DMSO-d6) 67.74-7.72 (m, 1H), 7.54-7.51 (m, 2H), 7.17 (s, 1H), 4.98 (br, 1H), 4.06 (s, 1H), 2.80 (s, 3H), 1.95-1.90 (m, 1H), 1.59-1.49 (m, 5H), 1.34-1.29 (m, 1H), 0.94-0.93 (m, 1H), 0.30-0.24 (m, 4H); LCMS (ESI) C20H21FN4O3S: (m / z) = 416.47; found 417.3 [M+H]+, tR= 0.652 min (Method 1).Example 5: Synthesis of (lS,3S)*-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol and (lS,3R)*-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol (*Stereochemistry arbitrarily assigned)

[0204] Below is the general procedure described for synthesis of (lS,3S)*-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol and (lS,3R)*-3-{3-[5-(3, 5-dif luorophenoxy)-l, 3-th iazol-2-yl]-l-methylureido}-l-spiro[3.3] heptanol (Compounds 148 and 149) in Scheme 5 (Method E).Scheme 5

[0205] To a solution of 5-(3,5-difluorophenoxy)thiazol-2-amine (48.0 mg, 210 pmol) in THF (1 mL) was added (4-nitrophenyl) chloroformate (50.9 mg, 252 pmol), followed by the addition of a solution of pyridine (20.4 pL, 252 pmol) in THF (0.5 mL). The reaction mixture was stirred at 20 °CAtty Dkt No.: EVOM-008WOfor 1.5 hr. To the mixture was added a solution of 3-(methylamino)spiro[3.3]heptan-l-ol (29.7 mg, 210 pmol) and DIPEA (62.3 pL, 357 pmol) in THF (0.5 mL). The reaction mixture was stirred at 20 °C for 16 hr. The reaction mixture was diluted with EtOAc (10 mL) and washed with aq. Na2CC>3 (5 mL x 3) and H2O (5 mLx 2). The organic layer was separated, dried (anhydrous Na2SO4), and concentrated under reduced pressure. The residue thus obtained was purified by prep-TLC (hexanes: EtOAc =1:1, R / =0.29, UV) to afford 3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol (70.0 mg, 84.17% yield) as a white solid. This was further purified by prep-HPLC (column: Xtimate C18100 x 30 mm x 3 um; mobile phase: [H2O (0.1% TFA)-ACN]; gradient: 28%-58% B over 10.0 min) to afford (lS,3S)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol (4.5 mg, 6.3% yield) as a white solid; LCMS-ESI (m / z) calculated C18H19F2N3O3S: 395.1; found 396.3 [M+H]+, tR = 0.572 min (Method 2),1HNMR: (400 MHz, DMSO-d6): 6 10.96 - 10.52 (m, 1H), 7.23 (s, 1H), 7.09 - 6.99 (m, 1H), 6.94 - 6.85 (m, 2H), 4.60 - 4.46 (m, 1H), 4.03 (dd, J = 6.0, 7.1 Hz, 1H), 2.87 (s, 3H), 2.35 - 2.30 (m, 1H), 2.25 (br d, J = 6.4 Hz, 1H), 1.96 (ddd, J =4.8, 9.8, 12.9 Hz, 1H), 1.81 - 1.67 (m, 5H); and (15,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol (15 mg, 21.1% yield) as a white solid; LCMS-ESI (m / z) calculated Ci8Hi9F2N3O3S: 395.11; found 396.3 [M+H]+, tR = 0.589 min (Method 2),TH NMR (400 MHz, DMSO-d6): 611.03 - 10.36 (m, 1H), 7.24 (s, 1H), 7.09 - 6.99 (m, 1H), 6.90 (dd, J = 2.0, 8.5 Hz, 2H), 3.98 (br t, J = 8.8 Hz, 1H), 3.68 (t, J = 7.6 Hz, 1H), 2.90 (s, 3H), 2.32 - 2.26 (m, 1H), 2.23 - 2.14 (m, 2H), 1.88 - 1.78 (m, 2H), 1.77 - 1.65 (m, 2H), 1.64 - 1.55 (m, 1H).Example 6: Synthesis of (lS,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol

[0206] Below is the general procedure described for synthesis of (lS,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro[3.3]heptanol (Compound 158) in Scheme 6 (Method F).Scheme 6Atty Dkt No.: EVOM-008WO

[0207] To a solution of 5-(3-fluorophenoxy)thiazol-2-amine (880 mg, 4.19 mmol) in dryTHF (21 mL) was added pyridine (400 pL, 5.02 mmol, 1.2 equiv.) and the mixture was cooled to 0 °C. Phenyl chloroformate (1.05 mL, 8.37 mmol, 2.0 equiv.) was added dropwise over 5 minutes and the mixture was stirred at 0 °C for 30 min. The pyridinium chloride precipitate was filtered and the solvent of the filtrate was removed in vacuo at 40 °C on a rotary evaporator to give a brown solid, which was recrystallized as follows: EtOAc (~10 mL) was added to the solid and it was heated using a heat gun (estimated maximum temperature: 77 °C). Extra portions of EtOAc were added as needed, and heating was continued until all solids were dissolved. The solution was left to cool to room temperature without stirring over 2 hr. After reaching room temperature, it was cooled to 4 °C for 15 h. The resulting crystals of phenyl (5-(3-fluorophenoxy)thiazol-2-yl)carbamate were isolated by filtration (crop 1). The solvent of the supernatant was removed in vacuo to give a brown solid which was recrystallized as described above to give a 2ndcrop of phenyl (5-(3-fluorophenoxy)thiazol-2-yl)carbamate as a colorless crystalline solid. Crystalline solids were combined yielding phenyl (5-(3-fluorophenoxy)thiazol-2-yl)carbamate (1.35 g, 97%) as a colorless crystalline solid, which was used in the following step without additional purification.

[0208] (15,3R)-3-(methylamino)spiro[3.3]heptan-l-ol (16.9 mg, 0.12 mmol) was weighed out into a 1 mL screw cap Matrix tube and then treated with 800 uL of a solution containing phenyl (5-(3-fluorophenoxy)thiazol-2-yl)carbamate (19.8 mg, 0.06 mmol) and DIPEA (32 uL). The Matrix tube was capped and sonicated to ensure a homogeneous solution then left to stand at room temperature for 16 hr. The reaction mixture was then injected onto a preparative C18 Xterra HPLC column (19 mm x 100 mm). The isolated fraction containing the desired product was isolated by gradient elution using 5-95% acetonitrile in water (containing 0.05 % formic acid) at 30 mL / min flow rate. The fraction was dried by Genevac centrifugal evaporation at < 409C to (lS,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l-methylureido}-l-spiro [3.3] heptanol (16.9 mg, 74.7 % yield) as an off-white solid. LCMS-ESI (m / z) calculated C18H19F2N3O3S: 377.0; foundAtty Dkt No.: EVOM-008WO377.9 [M+H]+, tR = 2.61 min (Method 6),1H NMR (500 MHz, DMSO-d6): δ 10.69 (s, 1H), 7.36 (td, J = 8.5, 6.7 Hz, 1H), 7.13 (s, 1H), 6.98 - 6.86 (m, 3H), 5.09 (d, J = 6.1 Hz, 1H), 3.91 (t, J = 9.1 Hz, 1H), 3.61 (q, J = 7.0 Hz, 1H), 2.83 (s, 3H), 2.48 (s, 5H), 2.22 (ddd, J = 11.0, 8.0, 6.8 Hz, 1H), 2.12 (tdd, J = 10.6, 6.1, 2.5 Hz, 2H), 1.80 - 1.58 (m, 4H), 1.53 (ddd, J = 13.5, 9.1, 4.6 Hz, 1H).Example 7: Synthesis of Intermediates

[0209] Synthesis of (lS,3S)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-olScheme 7 LAH CbzCI, Et3N, DMAP DMP O (S) THF, 0-70 °C, 16 hrs THF, 20 °C, 16 hrs DCM, 20 °C, 16 hrs ''NCbzTMSCFj, CsF 2M aq HCI THF, 0~20 °C, 22 hrs 0'20 °C, 16 hrsPd / C, H2(50 psi) MeOH, 20 °C, 2 hrs

[0210] (3S)-3-(methylamino)cyclopentan-l-ol: A cold (0 °C) solution of tert-butyl (S)-(3-oxocyclopentyl)carbamate (5.00 g, 25.0 mmol) in THF (100 mL) in a 250 mL three-neck flask was degassed and purged with N2(3 x). To this solution under ^atmosphere was added a solution of LAH (2.5 M in THF, 35 mL ) at 0 °C. The reaction mixture was slowly warmed to 70 °C and stirred at that temperature for 16 hr (monitored by TLC). The reaction mixture was then cooled to 0 °C, and quenched by slow, sequential addition of H2O (5 mL), 15% aq. NaOH (5 mL) and H2O (15 mL). To the mixture was then added Na2SO4and the mixture was stirred for 30 mins, filtered, and theAtty Dkt No.: EVOM-008WOfilter cake was washed with THF (100 mL). The combined filtrate was concentrated to afford (3S)-3-(methylamino)cyclopentan-l-ol (3.60 g) as a brown oilTHNMR (400 MHz, DMSO-de): 64.35 (br d, J = 3.6 Hz, 1H), 4.16 - 3.97 (m, 1H), 3.05 - 2.79 (m, 1H), 2.20 (d, J = 7.2 Hz, 3H), 1.90 - 1.75 (m, 2H), 1.67 - 1.60 (m, 1H), 1.56 - 1.39 (m, 2H), 1.36 - 1.16 (m, 3H).HO (S)zNCbz

[0211] Benzyl ((lS)-3-hydroxycyclopentyl)(methyl)carbamate: To a solution of (3S)-3-(methylamino)cyclopentan-l-ol (3.60 g, 31.2 mmol) in THF (80 mL) in a 250 mL three-neck flask at 20 °C was added TEA (6.96 g, 68.7 mmol) and DMAP (534 mg, 4.38 mmol). The reaction mixture degassed and purged with N2 for 3 times. To the reaction mixture was added benzyl carbonochloridate (5.33 g, 31.2 mmol) and the mixture was stirred at 20 °C for 16 hr (monitored with LCMS). The reaction mixture was quenched with H2O (100 mL). The aqueous layer was extracted with EtOAc (100 mL x 3). The combined organic extracts were washed with brine (100 mL), dried over anhydrous MgSC, filtered and concentrated. The residue was purified by flash silica gel chromatography (40 g Silica Flash Column, Eluent of 0~3% MeOH / DCM gradient @ 50 mL / min) to afford Benzyl ((lS)-3-hydroxycyclopentyl)(methyl)carbamate (4.72 g, 60.5% yield) as a light yellow oil. LCMS (ESI): C14H19NO3: m / z = 249.1, found 250.1 [M+H]+; tR = 0.85 min (Method 1);XHNMR (400 MHz, CDCI3): 6 7.41 - 7.29 (m, 5H), 5.14 (d, J = 3.2 Hz, 2H), 4.93 - 4.24 (m, 2H), 2.95 - 2.78 (m, 3H), 1. T1 - 2.15 (m, 1H), 2.27 - 1.92 (m, 1H), 1.90 - 1.62 (m, 4H), 1.59 - 1.54 (m, 1H).'NCbz

[0212] Benzyl (S)-methyl(3-oxocyclopentyl)carbamate: To a solution of Benzyl ((lS)-3-hydroxycyclopentyl)(methyl)carbamate (4.70 g, 18.8 mmol) in DCM (100 mL) under N2 atmosphere was added DMP (12.0 g, 28.3 mmol) at 20 °C. The mixture was stirred at 20 °C for 16 hr (monitored by LCMS). The reaction mixture was diluted with DCM (50 mL), washed with sat. Na2SC>3 (150 mL), sat. NaHCO3(150 mL) and brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gelAtty Dkt No.: EVOM-008WOchromatography (40 g Silica Flash Column, Eluent of 0~2% MeOH / DCM gradient @ 50 mL / min) to afford Benzyl (S)-methyl(3-oxocyclopentyl)carbamate (4.28 g, 91.8% yield) as a light yellow oil. LCMS (ESI): C14H17NO3: m / z = 247.1, found 248.1 [M+H]+; tR = 0.857 min (Method 1);XHNMR (400 MHz, DMSO-dg): 67.41 - 7.28 (m, 4H), 5.09 (s, 2H), 4.75 - 4.64 (m, 1H), 2.81 (s, 3H), 2.40 - 2.15 (m, 4H), 2.07 - 1.91 (m, 2H).

[0213] Benzyl methyl((lS)-3-(trifluoromethyl)-3-((trimethylsilyl)oxy)cyclopentyl)carbamate:To a solution of Benzyl (S)-methyl(3-oxocyclopentyl)carbamate (4.27 g, 17.3 mmol) in THF (100 mL) 0 °C was added CsF (262 mg, 1.72 mmol) under N2 atmosphere. To the reaction mixture was added a solution of trimethyl (trifluoromethyl) silane (6.14 g, 43.2 mmol) in THF (15 mL) at 0 °C. The reaction mixture was slowly warmed to 20 °C and stirred for 19 hr. The reaction mixture was further cooled to 0 °C and a second aliquot of CsF (262 mg, 1.72 mmol) was added at 0 °C followed by the addition of a solution of trimethyl (trifluoromethyl) silane (2.46 g, 17.27 mmol, 1 eq) in THF (6 mL) at 0°C. After warming to 20°C, the reaction mixture was stirred at 20 °C for 3 hrs (monitored by TLC and LCMS as complete). The crude title product (~ 6.73 g, ~100% yield) was obtained as a solution in THF (~120 mL) and was used without further purification in the next step.F

[0214] Benzyl ((lS)-3-hydroxy-3-(trifluoromethyl)cydopentyl)(methyl)carbamate: To the above solution of benzyl methyl((lS)-3-(trifluoromethyl)-3- ((trimethylsilyl)oxy)cyclopentyl)carbamate (~6.73 g, ~17.3 mmol) in THF (120 mL) in a 500 mL three-necked flask was added 2 M aq. HCI (86.4 mL) at 0 °C. The reaction mixture was allowed to warm to 25 °C and stirred at 25 °C for 16 hr (monitored by LCMS). The organic and aqueous layers separated. The aqueous layer was extracted with EtOAc (80 mL). The combined organic extracts were washed with brine (150 mL), dried using anhydrous Na2SO4, filtered andAtty Dkt No.: EVOM-008WOconcentrated under reduced pressure. The residue was purified by flash silica gel chromatography (40 g Silica Flash Column, Eluent of 0~2% MeOH / DCM gradient @ 50 mL / min) to afford a crude product (4.18 g). The crude product was further purified by flash silica gel chromatography (80 g Silica Flash Column, Eluent of 12~16% EtOAc / hexanes gradient @ 50 mL / min) to afford benzyl ((lS)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate (3.91 g, 70.1% purity, 50.0% yield) as a yellow oil. LCMS (ESI): C15H18F3NO3: m / z = 317.1, found 318.0 [M+H]+; tR = 0.592 min (Method 2).

[0215] Benzyl ((lS,3R)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate and Benzyl ((lS,3S)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate: Chiral resolution of the mixture of diastereomers benzyl ((lS)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate (1.00 g) were carried out by SFC (column: Daicel ChiralPak IG (250*30mm, lOum); mobile phase: [CCh-EtOH (0.1% NH3H2O)]; B%:20%, isocratic elution mode) to afford a peak eluting at 1.712 min. as benzyl ((lS,3R)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate (364 mg, 36.4% yield) as a colorless oil;1HNMR (400 MHz, DMSO-d6): 67.40 - 7.29 (m, 5H), 6.06 (s, 1H), 5.07 (s, 2H), 4.63 (br s, 1H), 2.80 (s, 3H), 2.19 (dd, JI = 14.4 Hz, J2= 10.4 Hz, 1H), 1.95 - 1.84 (m, 1H), 1.84 - 1.70 (m, 3H), 1.65 (br dd, JI = 14.4 Hz, J2= 7.6 Hz,lH), and a peak eluting at 1.842 min. as benzyl ((lS,3S)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate (514 mg, 51.4% yield) as an off-white solid,THNMR (400 MHz, DMSO-c / 6): 67.42 - 7.28 (m, 5H), 6.02 (br s, 1H), 5.09 (s, 2H), 4.81 - 4.67 (m, 1H), inn (s, 3H), 2.07 - 1.80 (m, 4H), 1.77 - 1.65 (m, 2H).

[0216] (lS,3S)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol: To a Hydrogenation bottle was taken 10% dry Pd / C (100 mg) at 20 °C under Ar atmosphere. To this was carefullyAtty Dkt No.: EVOM-008WOadded MeOH (10 mL) at 20 °C, followed by the careful addition of a solution of benzyl ((lS,3S)-3-hydroxy-3-(trifluoromethyl)cyclopentyl)(methyl)carbamate (510 mg, 1.51 mmol) in MeOH (10 mL) at 20 °C. The suspension was degassed under vacuum and purged with Ar (3 x). The suspension was further degassed under vacuum and purged with H2 (3 x). The mixture was stirred under H2 pressure (50 psi) at 20 °C for 16 hr. (complete by TLC). The reaction mixture was filtered through a pad of celite, washed with MeOH (10 mL x3) and the filtrate was concentrated under reduced pressure to afford compound (lS,3S)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol (290 mg, 98.5% yield) as a green oil.1H NMR (400 MHz, DMSO-d6): 5 6.22 - 5.40 (m, 1H), 3.47 - 3.42 (m, 2H), 3.25 - 3.18 (m, 1H), 2. 1 (s, 3H), 2.05 - 1.94 (m, 3H), 1.67 (br dd, = 11.2 Hz, J2= 5.6 Hz, 1H), 1.58 (dd, h = 13.2 Hz, J2= 8.4 Hz,lH), 1.46 (td, h = 9.2 Hz, J2= 6.0 Hz, 1H).

[0217] Synthesis of (lR,3R)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol:

[0218] Using the representative procedure to synthesize the (1S,3S) enantiomer, (lR,3R)-3-(methylamino)-l-(trifluoromethyl)cyclopentan-l-ol was obtained from (3S)-3-(methylamino)cyclopentan-l-ol as a white solid (285 mg, 97 % yield),1HNMR (400 MHz, DMSO-d6): 65.75 (s, 1H), 3.12 (m, 1H), 2.21 (s, 3H), 1.96 (m, 3H), 1.64 (m, 1H), 1.50 (dd, J= 13.26, 8.00 Hz, 1H), 1.39 (m, 1H).

[0219] Synthesis of (lS,3S)-l-methYl-3-(methylamino)cyclopentan-l-ol and (1S,3R)-1-methyl-3-(methylamino)cyclopentan-l-ol:AndScheme 8Atty Dkt No.: EVOM-008WOMeMgBr, CeCI3HOv / '> I=\ (S) 'NHBoc THF, 0~20°C 'NHBoc NHBocLAH LAH THF, 70°C THF, 70°CHO^ / . J And %-BOC

[0220] Tert-butyl ((lS,3S)-3-hydroxy-3-methylcyclopentyl)carbamate and tert-butyl ((lS,3R)-3-hydroxy-3-methylcyclopentyl)carbamate: To a 100 mL three-necked reaction flask was take CeCh (2.78 g, 11.3 mmol) and THF (30 mL) under N2 atmosphere. The mixture was stirred at 20°C for 1 hr. After cooling the reaction mixture to 0 °C, was added a solution of bromo(methyl)magnesium in THF (3 M; 7.5 mL, 22.5 mmol) at 0 °C. The mixture was stirred at 0 °C for 0.5 hr, then a solution of tert-butyl (S)-(3-oxocyclopentyl)carbamate (1.5 g, 7.53 mmol) in THF (15 mL) was added at 0 °C. The mixture was stirred at 0 °C for 2 hr (monitored by TLC). The reaction was quenched by the addition of 10% AcOH (15 mL), followed by H2O (15 mL). The mixture was extracted with EtOAc (30 mL x 5). The combined organic extracts were washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g Silica Flash Column, eluting with 20~33% EtOAc / hexanes gradient @ 40 mL / min) to afford tert-butyl ((lS,3S)-3-hydroxy-3-methylcyclopentyl)carbamate (240 mg, 14.8% yield) as a colorlessgum,1HNMR (400 MHz, CDCI3): 6 4.62 - 4.33 (m, 1H), 4.29 - 4.14 (m, 1H), 2.34 - 2.22 (m, 1H), 2.16 (br dd, J = 7.6, 13.6 Hz, 1H), 1.84 - 1.66 (m, 2H), 1.47 - 1.42 (m, 11H), 1.38 (s, 3H) and tert-butyl ((lS,3R)-3-hydroxy-3-methylcyclopentyl)carbamate (660 mg, 40.7% yield) as a colorless oil,XHNMR (400 MHz, CDCI3): 65.38 - 5.01 (m, 1H), 4.12 - 4.01 (m, 1H), 2.17 - 2.08 (m, 1H), 1.93 (dd, J = 8.4, 14.0 Hz, 1H), 1.86 - 1.76 (m, 2H), 1.67 (br d, J = 14.4 Hz, 1H), 1.61 - 1.57 (m, 1H), 1.46 (s, 1H), 1.44 (s, 9H), 1.37 (s, 3H).Atty Dkt No.: EVOM-008WO

[0221] (lR,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol: To a schlenk tube equipped with a N2 balloon at 20 °C was added THF (5 mL) followed by the addition of a solution of LAH in THF (2.5 M; 3.2 mL, 1.28 mmol) at 20°C. The mixture was cooled to 0°C and a solution of tert-butyl ((lR,3S)-3-hydroxy-3-methylcyclopentyl)carbamate (300 mg, 1.39 mmol, 1 eq) in THF (2 mL) in portions at 0°C. The reaction mixture was stirred at 20°C for 1 hr, then it was heated at 70°C for 1 hr (monitored by TLC). The reaction mixture was cooled to 0°C and was quenched by the sequential addition of H2O (0.3 mL), 15% aq. NaOH (0.3 mL) and H2O (1 mL). To the mixture was added Na2SO4 and THF (10 mL), and the mixture was stirred for 10 mins, filtered and the filter cake was washed with THF (5 mL x 4). The filtrate was concentrate to afford (lR,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol (160 mg, 88.8% yield) as a colorless oil.1HNMR (400 MHz, CDCI3): 6 3.22 (t, J = 5.6 Hz, 1H), 2.39 (s, 3H), 1.99 - 1.95 (m, 1H), 1.95 - 1.90 (m, 1H), 1.82 - 1.77 (m, 1H), 1.73 - 1.64 (m, 2H), 1.51 (dd, J = 5.2, 13.6 Hz, 1H), 1.44 (s, 2H), 1.33 (s, 3H).Jfs;^" NHI

[0222] (lS,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol: Following the procedure used for (lR,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol isomer, ((lS,3S)-3-hydroxy-3-methylcyclopentyl)carbamate was reacted with LAH to obtain (lS,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol (140 mg, 83.3% yield) as colorless oil.XH NMR (400 MHz, CDCI3) 8 3.36 - 3.26 (m, 1H), 2.40 (s, 3H), 3.19 - 2.08 (m, 1H), 2.08 - 2.02 (m, 1H), 1.88 - 1.80 (m, 1H), 1.73 - 1.64 (m, 2H), 1.49 - 1.44 (m, 1H), 1.44 (s, 1H), 1.41 (br t, J = 2.8 Hz, 1H), 1.39 (s, 3H), 1.37 (d, J = 8.4 Hz, 1H).Atty Dkt No.: EVOM-008WO

[0223] (lR,3R)-l-methyl-3-(methylamino)cyclopentan-l-ol: Following the procedure used for (lR,3S)-l-methyl-3-(nnethylamino)cyclopentan-l-ol isomer, ((lR,3R)-3-hydroxy-3-methylcyclopentyl)carbamate was reacted with LAH to obtain (lR,3R)-l-methyl-3-(methylamino)cyclopentan-l-ol (207 mg, 98.5% yield) as colorless oil,1H NMR (400 MHz, CDCI3) 5 3.36 - 3.26 (m, 1H), 2.39 (s, 3H), 2.08 - 2.02 (m, 1H), 1.88 - 1.80 (m, 1H), 1.88 - 1.79 (m, 1H), 1.72 - 1.65 (m, 3H), 1.49 - 1.45 (m, 1H), 1.44 (s, 1H), 1.43 - 1.40 (m, 1H), 1.39 (s, 3H), 1.37 (d, J = 8.0 Hz, 1H)..

[0224] (lS,3R)-l-methyl-3-(methylamino)cyclopentan-l-ol: Following the procedure used for (lR,3S)-l-methyl-3-(methylamino)cyclopentan-l-ol isomer, ((lS,3R)-3-hydroxy-3-methylcyclopentyl)carbamate was reacted with LAH to obtain (lS,3R)-l-methyl-3-(methylamino)cyclopentan-l-ol (153 mg, 84.9% yield) as colorless oil,XH NMR (400 MHz, CDCI3) 6 3.22 (t, J = 5.6 Hz, 1H), 2.39 (s, 3H), 1.99 - 1.90 (m, 3H), 1.80 (br d, J = 13.6 Hz, 1H), 1.72 - 1.63 (m, 2H), 1.51 (dd, J = 5.2, 13.6 Hz, 1H), 1.44 (s, 1H), 1.33 (s, 3H)..

[0225] Synthesis of (c / s)-3-(ethylamino)-l-(trifluoromethyl)cyclopentan-l-ol and [trans)-3- (ethylamino)-l-(trifluoromethyl)cydopentan-l-olFHScheme 9Atty Dkt No.: EVOM-008WOTBSONHCbz

[0226] Benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)carbamate: To a solution of benzyl (3-hydroxycyclopentyl)carbamate (1.00 g, 4.25 mmol) in DCM (10 mL) at 25 °C was added imidazole (716 mg, 10.5 mmol) and the mixture was cooled to 0 °C. To the mixture was added TBSCI (5.10 mmol, 628 pL) at 0 °C. The mixture was allowed to warm to 25 °C and stirred at 25 °C for 16 hr. A second aliquot of imidazole (289 mg, 4.25 mmol) was added at 25 °C and mixture was cooled to 0 °C. To the mixture was added TBSCI (2.55 mmol, 314 |_iL) at 0 °C and the mixture was warmed to 25 °C and stirred for 15 hr. (monitored by TLC). The reaction mixture was diluted with EtOAc (50 mL x 3). The combined organic extracts were washed with H2O (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (4 g Silica Flash Column, eluting with 0~5% EtOAc / hexanes @30 mL / min) to afford benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)carbamate (1.00 g, 65.9% yield, 98% purity) as a colorless oil. LCMS (ESI): Ci9H3iNO3Si: m / z = 349.2, found 350.1 [M+H]+; tR = 0.872 min (Method 2);XH NMR (400 MHz, DMSO-C / 6): 67.41 - 7.26 (m, 5H), 5.75 (s, 1H), 5.26 (s, 1H), 4.99 (s, 2H), 4.25 - 4.12 (m, 1H), 3.82 - 3.69 (m, 1H), 2.11 (td, = 13.2, J2= 6.8 Hz, 1H), 1.88 - 1.67 (m, 2H), 1.60 - 1.46 (m, 2H), 1.43 - 1.32 (m, 1H), 0.85 (s, 8H), 0.02 (s, 6H).CbzAtty Dkt No.: EVOM-008WO

[0227] Benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)(ethyl)carbamate: To a cold (0 °C) solution of benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)carbamate (1.00 g, 2.86 mmol) DMF (10 mL) under N2 atmosphere was added NaH (150 mg, 3.75 mmol, 60 % dispersion in mineral oil). The reaction mixture was slowly allowed to warm to 25 °C and stirred at 25 °C for 1 hr. The reaction was again cooled to 0°C and wad added iodoethane (580 mg, 3.72 mmol) at 0°C. The reaction mixture was slowly allowed to warm to 25 °C and stirred at 25 °C for 16 hr. The reaction was quenched by the addition of water (100 mL), and the mixture was extracted into EtOAc (100 mL x 3). The organic layers were combined, washed with water (100 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~3% EtOAc / hexanes @ 20 mL / min) to afford benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)(ethyl)carbamate (765 mg, 58.9% yield, 83.3% purity) as a colorless oil, LCMS (ESI): C2iH25NO3Si: m / z = 377.6, found 378.6 [M+H]+; tR = 0.945 min (Method 2).HO

[0228] Benzyl ethyl(3-hydroxycyclopentyl)carbamate: To a solution of benzyl (3-((tert-butyldimethylsilyl)oxy)cyclopentyl)(ethyl)carbamate (765 mg, 2.03 mmol) in THF (5 mL) was added TBAF (1 M, 8.10 mL) at 25°C. The reaction mixture was stirred at 25°C for 16 hr. Water (100 mL) was added, and the mixture was extracted into EtOAc (100 mL x 3). The organic layers were combined, washed with water (100 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®;12 g SepaFlash® Silica Flash Column, Eluent of 0~27% EtOAc / Petroleum ether gradient @ 30 mL / min) to afford benzyl ethyl(3-hydroxycyclopentyl)carbamate (0.40 g, 63.6% yield, 84.8% purity) as a colorless oil. LCMS (ESI): C15H21NO3: m / z = 263.1, found 264.1 [M+H]+; tR = 0.538 min (Method 2);XH NMR (400 MHz, DMSO-c / 6): 67.41 - 7.28 (m, 4H), 5.06 (s, 2H), 4.68 (d, J = 4.0 Hz, 1H), 4.31 (br t, J = 8.8 Hz, 1H), 4.08 - 3.98 (m, 1H), 3.22 (q, J = 7.6 Hz, 2H), 2.09 - 1.99 (m, 1H), 1.75 - 1.64 (m, 2H), 1.63 - 1.50 (m, 2H), 1.40 (ddd, 72=13.2 Hz, J2=8.6 Hz, J3= 4.4 Hz, 1H), 1.07 (t, J = 7.2 Hz, 3H).Atty Dkt No.: EVOM-008WOCbz

[0229] Benzyl ethyl(3-oxocyclopentyl)carbamate: To a solution of benzyl ethyl(3-hydroxycyclopentyl)carbamate (0.40 g, 1.52 mmol) in DCM (10 mL) was added DMP (966 mg, 2.28 mmol) at 20°C under N2 atmosphere. The reaction was stirred at 20 °C for 16 hr. The reaction mixture was diluted with DCM (50 mL), washed with sat. NazSOa (150 mL), sat. NaHCO3(150 mL) and brine (200 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~37% EtOAc / Petroleum ether gradient @ 20 mL / min) to afford benzyl ethyl(3-oxocyclopentyl)carbamate (390 mg, 97.7% yield, 99.4% purity) as a colorless oil, LCMS (ESI): C15H19NO3: m / z = 261.1, found 262.2 [M+H]+; tR = 0.57 min (Method 2);XH NMR (400 MHz, DMSO-d6): 6 7.41 - 7.28 (m, 5H), 5.08 (s, 2H), 4.55 -4.38 (m, 1H), 3.26 (br d, J = 7.2 Hz, 2H), 2.34 (br d, J = 9.2 Hz, 2H), 2.28 - 2.01 (m, 3H), 2.29 - 1.99 (m, 1H), 1.06 (t, J= 6.8 Hz, 3H).

[0230] (c / s)-Benzyl ethyl(-3-hydroxy-3-(trifluoromethyl)cyclopentyl)carbamate and (trans)-Benzyl ethyl(-3-hydroxy-3-(trifluoromethyl)cyclopentyl)carbamate: To a solution of benzyl ethyl(3-oxocyclopentyl)carbamate (320 mg, 1.22 mmol) in THF (5 mL) was added CsF (18.6 mg, 122 pmol) at 0 °C. A solution of trimethyl (trifluoromethyl) silane (522 mg, 3.67 mmol) in THF (5 mL) was added at 0 °C. The reaction mixture was allowed to warm to 20 °C and was stirred for 16 hr. (monitored by LCMS) to give a solution of benzyl N-ethyl-N-[3- (trifluoromethyl)-3-trimethylsilyloxy-cyclopentyl]carbamate (494 mg, crude) in THF (5 mL) as a brown liquid. To the solution was added a solution of HCI (2 M, 6.12 mL) at 0°C. The reaction mixture was allowed to warm to 25°C and stirred at 25°C for 0.5 hrs, (monitored by LCMS). The organic layer was separated and the aqueous layer was extracted with EtOAc (80 mL). The combined organic layers were washed with brine (150 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 12 gAtty Dkt No.: EVOM-008WOSepaFlash® Silica Flash Column, Eluent of 0~15~20% EtOAc / Petroleum ether gradient @ 20 mL / min) to afford (c / s)-benzyl ethyl(-3-hydroxy-3-(trifluoromethyl)cyclopentyl)carbamate (148 mg, 31.0% yield, 85% purity) as a yellow oil, LCMS (ESI): C16H20F3NO3: m / z = 331.1, found 332.0 [M+H]+; tR = 0.712 min (Method 2); and (trans)-benzyl ethyl(-3-hydroxy-3- (trifluoromethyl)cyclopentyl)carbamate (154 mg, 32.9% yield, 86.8% purity) as a white solid, LCMS (ESI): C16H20F3NO3: m / z = 331.1, found 332.0 [M+H]+; tR = 0.692 min (Method 2).

[0231] (c / s)-3-(ethylamino)-l-(trifluoromethyl)cyclopentan-l-ol: To a Hydrogenation bottle was taken 10% dry Pd / C(20 mg) at 20 °C under Ar atmosphere. To this was carefully added MeOH (5 mL) at 20 °C, followed by the careful addition of a solution of (c / s)-Benzyl ethyl(-3-hydroxy-3-(trifluoromethyl)cyclopentyl)carbamate (148 mg, 447 pmol) in MeOH (2 mL) at 20°C. The suspension was degassed under vacuum and purged with Ar (3 x). The suspension was further degassed under vacuum and purged with H2 (3 x). The mixture was stirred under H2 pressure (50 psi) at 20 °C for 16 hr. (complete by LCMS). The reaction mixture was filtered through a pad of celite, washed with MeOH (10 mLx3) and the filtrate was concentrated under reduced pressure to afford (c / s)-3-(ethylamino)-l-(trifluoromethyl)cyclopentan-l-ol (70 mg, 79.5% yield) as a colorless oil,XH NMR (400 MHz, DMSO-c / 6): 63.12 - 3.01 (m, 1H), 2.10 (dd, =13.6 Hz, J2= 8.0 Hz, 1H), 1.94 - 1.84 (m, 1H), 1.80 - 1.73 (m, 2H), 1.64 - 1.50 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H).

[0232] (tra / 7s)-3-(ethylamino)-l-(trifluoromethyl)cyclopentan-l-ol: Using the procedure described for the cis isomer, reaction of (c / s)-Benzyl ethyl(-3-hydroxy-3-(trifluoromethyl)cyclopentyl)carbamate (154 mg, 465pmol) afforded (trons)-3-(ethylamino)-l-(trifluoromethyl)cyclopentan-l-ol (60 mg, 65.5% yield) as a colourless oil, 1H NMR (400 MHz, DMSO-C / 6): 65.89 - 5.71 (m, 1H), 4.20 - 3.96 (m, 1H), 3.17 (s, 2H), 2.38 (dq, J1=7.2 Hz, J2= 1.2Hz,Atty Dkt No.: EVOM-008WO1H), 2.06 - 1.86 (m, 3H), 1.72 - 1.58 (m, 1H), 1.58 - 1.48 (m, 1H), 1.48 - 1.34 (m, 1H), 1.02 - 0.93 (m, 3H).

[0233] Synthesis of (lR,3R)-l-ethyl-3-(methylamino)cyclopentan-l-ol:Scheme 10 (i) EtMgBr, LaCI32LiCI, THF, 0°C, 2.5 h Pd / C, H2, (ii) SFC N Cbz THF, 20 °C, 16 h, 50 PsiHO

[0234] Benzyl ((lR,3R)-3-ethyl-3-hydroxycyclopentyl)(methyl)carbamate: To a 100 mL threenecked flask was taken LaCl3.2LiCI (0.6 M, 10.1 mL) under N2 atmosphere at 0 °C. To this was added EtMgBr (3.4 M, 3.60 mL) at 0 °C. The reaction was stirred at 0 °C for 0.5 h, followed by the addition of a solution of benzyl (R)-methyl(3-oxocyclopentyl)carbamate (1.0 g, 4.04 mmol) in THF (7 mL) at 0 °C. The reaction was stirred at 0 °C for 1.5 h (monitored byTLC DCM: MeOH = 20:1, Rf =0.3, PMA). After completion, to the reaction mixture was added 10% AcOH (7 mL) and H2O (50 mL). The aqueous layer was extracted with EtOAc (40 mL x 2) and the combined organic extracts were dried over Na2SO4, filtered, concentrated to obtain a residue. Purified by flash silica gel chromatography (12 g Silica Flash Column) eluting with 15-20% EtOAc / hexanes gradient afforded benzyl ((lR)-3-ethyl-3-hydroxycyclopentyl)(methyl)carbamate (514 mg, 90.3% purity, 41.3% yield) as a colorless oil. LCMS (ESI): C16H23NO3: m / z = 277.1, found 278.2 [M+H]+; tR = 0.55 min (Method 1).

[0235] This was further separated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10 um); mobile phase: [CCh-EtOH (0.1% NH3H2O) ]; B%:20%, isocratic elution mode) to afford benzyl ((lR,3R)-3-ethyl-3-hydroxycyclopentyl)(methyl)carbamate (283 mg, 96.0% purity, 53.2% yield) asAtty Dkt No.: EVOM-008WOa colorless oil,XH NMR (400 MHz, CDCI3): 67.43 - 7.29 (m, 5H), 5.15 (s, 2H), 4.95 - 4.79 (m, 1H), 2.83 (s, 3H), 2.18 - 2.06 (m, 1H), 1.88 - 1.80 (m, 1H), 1.77 (dd, J = 4.0, 6.0 Hz, 1H), 1.72 - 1.58 (m, 6H), 0.98 (t, J = 7.6 Hz, 3H).; (1R,3R) stereochemistry confirmed by 2D NMR, and ((lS,3S)-3-ethyl-3-hydroxycyclopentyl)(methyl)carbamate (98.0 mg, 17.7% yield) as a light yellow oil,1H NMR (400 MHz, CDCI3): 67.41 - 7.29 (m, 5H), 5.13 (s, 2H), 4.50 - 4.20 (m, 1H), 2.93 (s, 3H), 2.04 - 1.96 (m, 1H), 1.91 - 1.81 (m, 1H), 1.74 - 1.67 (m, 2H), 1.59 (q, J = 6.8 Hz, 5H), 1.47 (td, J = 6.4, 13.2 Hz, 1H), 0.97 (t, 7 = 7.6 Hz, 3H).HO

[0236] (lR,3R)-l-ethyl-3-(methylamino)cyclopentan-l-ol: To a hydrogenation bottle was added 10% Pd / C (100 mg, 93.9 pmol) at 20 °C under Ar, followed by the addition of THF (5 mL) at 20 °C. A solution of benzyl ((lR,3R)-3-ethyl-3-hydroxycyclopentyl)(methyl)carbamate (280 mg, 1.01 mmol) in THF (5 mL) was added and the suspension was degassed under vacuum and purged with Ar (3 x), followed by degassing under vacuum and purging with H2 (5 x). The mixture was stirred under H2 (50 psi) at 20°C for 16 hr. The reaction mixture was filtered through a pad of celite, washed with THF (10 mL x 4) and the combined filtrate was concentrated under reduced pressure to afford (lR,3R)-l-ethyl-3-(methylamino)cyclopentan-l-ol (136 mg, 94.0% yield) as a colorless oil.XH NMR (400 MHz, DMSO-c / 6): 6 3.93 (br s, 1H), 3.07 (quin, J = 6.8 Hz, 1H), 2.19 (s, 3H), 1.94 - 1.83 (m, 1H), 1.78 (dd, J = 6.8, 12.4 Hz, 1H), 1.63 - 1.53 (m, 1H), 1.45 (q, J = 7.6 Hz, 3H), 1.30 - 1.20 (m, 1H), 1.14 (dd, J = 7.6, 12.8 Hz, 1H), 0.84 (t, J = 7.6 Hz, 3H).

[0237] (lR,3R)-l-isopropyl-3-(methylamino)cyclopentan-l-ol was synthesized from (R)-methyl(3-oxocyclopentyl)carbamate and i-PrMgBr following the procedure described for synthesis of (lR,3R)-l-ethyl-3-(methylamino)cyclopentan-l-ol.Atty Dkt No.: EVOM-008WO

[0238] (lR,3R)-l-cyclopropyl-3-(methylamino)cyclopentan-l-ol was synthesized from (R)-methyl(3-oxocyclopentyl)carbamate and c-PrMgBr following the procedure described for synthesis of (lR,3R)-l-ethyl-3-(methylamino)cyclopentan-l-ol.

[0239] Synthesis of 5-(3,5-difluorobenzyl)isoxazol-3-amine:Scheme 11

[0240] 4-(3,5-difluorophenyl)-3-oxobutanenitrile: To a three-neck flask was taken THF (lOmL) and was cooled to -78° C. To this was added n-BuLi (2.5 M, 8.59 mL, 2.00 eq) dropwise keeping the temperature below -70° C, followed by the dropwise addition of MeCN (22.5 mmol, 1.19 mL, 2.10 eq) in THF (15mL). After stirring the mixture for 2 h at -60° C, methyl 2-(3,5-difluorophenyl)acetate (2.00 g, 10.7 mmol, 1.00 eq) was added to the resulting white colloidal mixture. The reaction mixture was stirred for 2 h at -60° C. To the mixture was added saturated ammonium chloride solution (NH4CI, 75 mL) at -780C. The mixture was slowly allowed to warm to room temperature. It was then diluted with EtOAc (100 mL). The organic layer was separated, dried with sodium sulfate (Na2SO4), filtered and concentrated under reduced pressure to afford a crude product. The residue was purified by column chromatography (S1O2, hexanes: EtOAc =Atty Dkt No.: EVOM-008WO1 / 0 to 1 / 1) to afford 4-(3,5-difluorophenyl)-3-oxobutanenitrile (0.5 g, 23.8% yield) as a off-white solid.XH NMR (400 MHz, CDCI3): 56.86 - 6.72 (m, 3H), 3.90 (s, 2H), 3.53 (s, 2H).

[0241] 5-(3,5-difluorobenzyl)isoxazol-3-amine: Step 1 -To a solution of 4-(3,5-difluorophenyl)-3-oxobutanenitrile (0.50 g, 2.56 mmol, 1.00 eq) and ethylene glycol (2.23 g, 35.8 mmol, 2 mL, 14.0 eq) in toluene (5 mL) was added PTSA (8.82 mg, 51.24pmol, 0.02 eq). The mixture was stirred at 140 °C for 16 hr. The reaction mixture was concentrated under reduced pressure. The residue was diluted with MTBE (20 mL) and 1 M aq. NaOH (5 mL). The organic layer was separated, dried (Na2SO4), filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, hexanes: EtOAc =1 / 0 to 1 / 1) to obtain 2-(2-(3,5-difluorobenzyl)-l,3-dioxolan-2-yl)acetonitrile (0.40 g, 65.2% yield) as a yellow oil. Step 2- To a solution of NaOH (161 mg, 4.04 mmol) and hydroxylamine hydrochloride (267 mg, 3.85 mmol) in MeOH (5 mL) at 0°C was added 2-(2-(3,5-difluorobenzyl)-l,3-dioxolan-2-yl)acetonitrile and the mixture was stirred for 15 min. The reaction mixture was heated to 70 °C and stirred for 16 hr. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure to obtain 2-(2-(3,5-difluorobenzyl)-l,3-dioxolan-2-yl)-N-hydroxyacetimidamide (crude) as a brown solid (523 mg). LC-MS (ESI): C12H14F2N2O3 m / z = 272.1 found 273.2 [M+H]+; tR= 0.325 min (Mehod 1). The crude material was used in the next step without further purification. Step 3-To a solution of 2-(2-(3,5-difluorobenzyl)-l,3-dioxolan-2-yl)-N-hydroxyacetimidamide (523 mg, 1.92 mmol) in EtOH (10 mL) and water (2 mL) at room temperature was added 1 M HCI (3 mL). The reaction mixture was heated to 90 °C for 16 hr. After cooling to room temperature, the pH of the mixture was adjusted to pH ~7 using aq. Na2COs. The aqueous layer was extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with brine (50 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The residue thus obtained was purified by flash silica gel chromatography (ISCO; 4 g SepaFlash Silica Flash Column), eluting with 0-15% EtOAc / hexanes gradient) to obtain 5-(3,5-difluorobenzyl)isoxazol-3-amine (170 mg, 36% yield) asAtty Dkt No.: EVOM-008WOa yellow solid. LC-MS (ESI): CI0H8F2N2O m / z = 210.1, found 211.1 [M+H]+; tR= 0.739 min (Mehod 1),XHNMR (400 MHz, DMSO-c / 6): 67.19 - 7.08 (m, 1H), 7.06 - 6.97 (m, 2H), 5.61 (s, 1H), 5.51 (s, 2H), 3.98 (s, 2H).

[0242] Synthesis of (3-aminoisoxazol-5-yl)(3,5-difluorophenyl)methanone:F

[0243] To a solution of 5-(3,5-difluorobenzyl)isoxazol-3-amine (84.0 mg, 399 pmol) in DCE (5 mL) in a round bottom flask under N2was added MnO2(347 mg, 4 mmol) at room temperature. The dark suspension was heated at 85 °C for 2 h. The reaction mixture was cooled to room temperature, and filtered through a short pad of celite. The filtrate was concentrated to obtain a residue, which was purified by silica gel chromatography eluting with hexanes / EtOAc (2:1) to afford 3-aminoisoxazol-5-yl)(3,5-difluorophenyl)methanone (70 mg, 54% yield) as an off-white solid. LC-MS (ESI): CI0H6F2N2O2m / z = 224.2, found 225.2 [M+H]+; tR= 0.549 min (Mehod 1),XHNMR (400 MHz, DMSO-c / 6): 67.69 - 7.63 (m, 3H), 6.64 (s, 1H), 6.00 (s, 2H).

[0244] Synthesis of (3-aminoisoxazol-5-yl)(3,5-difluorophenyl)methanol:

[0245] To a solution of 3-aminoisoxazol-5-yl)(3,5-difluorophenyl)methanone (26 mg, 115 pmol) in MeOH (1 mL) under N2at 0 °C was added NaBH4 (6.6 mg, 173 pmol). The reaction mixture was allowed to warm to room temperature and was stirred for 2 hr. at room temperature. The reaction was quenched by addition of water (10 mL), and the product was extracted with DCM (10 mL x 2). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure to obtain (3-aminoisoxazol-5-yl)(3,5-difluorophenyl)methanol (35 mg, crude) as a yellow oil, which was used without further purification. LC-MS (ESI): CIOH8F2N202m / z = 226.2, found 227.1 [M+H]+; tR= 0.362 min (Mehod 1),XHNMR (400 MHz, DMSO-c / 6): 67.25 - 7.06 (m, 3H), 6.51 (d, J = 5.2 Hz, 1H), 5.71 (d, J = 5.2 Hz, 1H), 5.67 (s, 1H), 5.55 (s, 2H).Atty Dkt No.: EVOM-008WO

[0246] Synthesis of 5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-amine:Scheme 12BocHN

[0247] tert-butyl (5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-yl)carbamate: To a solution of tert-butyl (5-bromo-l-methyl-lH-pyrazol-3-yl)carbamate (0.100 g, 362 pmol, 1.00 eq) in THF (10 mL) was added 4-ditert-butylphosphanyl-N, N-dimethyl-aniline:dichloropalladium (0.026 g, 36.2 pmol, 0.100 eq) and (3,5-difluorobenzyl)zinc(ll) bromide (0.5 M, 1.09 mL, 1.50 eq) under N2 at 25 °C. The mixture was stirred at 60 °C for 16 hr. The reaction mixture was diluted with EtOAc (10 mL) and water (15 mL). The aqueous layer was separated and extracted with EtOAc (10 mL x 2). The combined organic extracts were concentrated under reduced pressure to afford a residue, which was purified by column chromatography (SiO2, hexanes: EtOAc = 84 / 16) to afford tertbutyl (5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-yl)carbamate (0.085 g, 257 pmol, 52.0% yield) as a yellow solid. LC-MS (ESI): Ci6Hi9F2N3O2 m / z = 323.3, found 324.8 [M+H]+; tR = 0.205 min (Method 1).XHNMR (CDCI3, 400M Hz): 67.15 (s, 1H), 6.71 - 6.67 (m, 3H), 6.31 (s, 1H), 3.92 (s, 1H), 3.58 (s, 3H), 1.50 (s, 9H).Atty Dkt No.: EVOM-008WO

[0248] 5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-amine: A mixture of tert-butyl (5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-yl)carbamate (0.035 g, 108 pmol, 1.00 eq) in HCI / dioxane (1.5 mL) was stirred at 25 °C for 16 hr. The reaction was quenched by adding sat. Na2COs to adjust pH to ~8. The mixture was extracted with EtOAc (10 mL x 2), the organic layers were washed with brine (15 mL) and dried with anhydrous Na2SO4, filtered and concentrated to give 5-(3,5-difluorobenzyl)-l-methyl-lH-pyrazol-3-amine (0.025 g) as a light-yellow oil. LC-MS (ESI): C11H11F2N3 m / z = 223.2, found 224.1 [M+H]+; tR = 0.338 min (Method 1).XHNMR (CDCI3, 400M Hz): 67.11 - 7.06 (m, 1H), 6.93 - 6.91 (m, 2H), 5.19 (s, 1H), 4.44 (s, 2H), 3.90 (s, 2H), 3.42 (s, 3H).

[0249]

[0250] Synthesis of (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanol:F

[0251] tert-Butyl (5-((3,5-difluorophenyl)(hydroxy)methyl)-l-methyl-lH-pyrazol-3-yljcarbamate: To a solution of tert-butyl (5-bromo-l-methyl-lH-pyrazol-3-yl)carbamate (0.8 g,Atty Dkt No.: EVOM-008WO2.9 mmol) in THF (10 mL) was dropwise added n-BuLi (2.5 M, 2.32 mL) at -70 °C under N2 and stirred for 0.5 h. To the cold mixture was then added 3,5-difluorobenzaldehyde (0.494 g, 3.48 mmol). The mixture was stirred at -70 °C for 2 hr. The reaction was quenched by addition of sat. NH4CI aq. Solution (20 mL). After warming the mixture to room temperature, the product was extracted with EtOAc (15 mL x 2). The combined organic extracts were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, hexanes: EtOAc = 82 / 18 to 69 / 31 ) to afford compound tert-Butyl (5-((3,5-difluorophenyl)(hydroxy)methyl)-l-methyl-lH-pyrazol-3-yl)carbamate (0.412 g, 39.0% yield) as a white solid. LC-MS (ESI): C16H19F2O3N3 m / z = 339.1, found 340.1 [M+H]+; tR = 0.55 min (Method 1).F

[0252] (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanol: A solution of tert- Butyl (5-((3,5-difluorophenyl)(hydroxy)methyl)-l-methyl-lH-pyrazol-3-yl)carbamate (0.04 g, 117 pmol) in HCI / dioxane (0.4 mL) was stirred at 25 °C for 2 hr. LCMS: ES30373-468-IPCL1 showed R1 was consumed and desired mass formed. Diluted with water (5 mL) added 2M NaOH solution to adjust pH about 11, extracted the EtOAc (5 mL x 3), the organic layers were washed with brine (10 mL) and dried with anhydrous Na2SO4, filtered and concentrated to afford (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanol (0.054 g, crude) as a light-yellow oil. LC-MS (ESI): C11H12F2N3O m / z = 239.1, found 240.1 [M+H]+; tR = 0.301 min (Method 1).

[0253] Synthesis of (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanone:Scheme 14HQ1 DMP, DCM. 20 °C, 16 h2. HCI / dioxane, 16 h N —N H2N NBocHN^N

[0254] (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanone: Step 1- To a solution of tert-Butyl (5-((3,5-difluorophenyl)(hydroxy)methyl)-l-methyl-lH-pyrazol-3-Atty Dkt No.: EVOM-008WOyl)carbamate (240 mg, 707 pmol) in DCM (5 mL) was added DMP (450 mg, 1.06 mmol) at 20 °C. The reaction mixture was stirred at 20 °C for 16 hr. The reaction mixture was diluted with DCM (10 mL), washed with satd. NaHCO3(30 mL) and brine (30 mL), dried (anhydrous Na2SO4), filtered and concentrated under reduced pressure to obtain tert-Butyl (5-(3,5-difluorobenzoyl)-l-methyl-lH-pyrazol-3-yl)carbamate (230 mg, crude) as a white solid. LC-MS (ESI): C16H17F2O3N3 m / z = 337, found 338.1 [M+H]+; tR = 0.645 min (Method 1). Step 2 - tert-Butyl (5-(3,5-difluorobenzoyl)-l-methyl-lH-pyrazol-3-yl)carbamate (100 mg, 296.45 pmol) was stirred with 2 M HCI / dioxane (6 mL) at 20 °C for 16 hr. The mixture was concentrated under reduced pressure and then neutralized by addition of aq. NaHCO3to adjust the ph ~8.0. The product was extracted with EtOAc (30 mL x 2). The combined organic extracts were washed with brine (20 mL), dried (anhydrous Na2SO4), filtered and concentrated to afford (3-amino-l-methyl-lH-pyrazol-5-yl)(3,5-difluorophenyl)methanone (70 mg, 71.4% yield) as a yellow solid. LC-MS (ESI): C16H19F2N3O2 m / z = 237.1, found 238.2 [M+H]+; tR = 0.434 min (Method 1).XHNMR (CDCI3, 400M Hz): δ 7.41-7.39 (m, 2H), 7.08-7.04 (m, 1H), 5.98 (d, 1H), 4.03 (s, 3H), 3.71 (brs, 2H).

[0255] Synthesis of l-methyl-3-(methylamino)spiro[3.3]heptan-l-ol:DMP CeCl3, CH3MgBr Pd / C, H2(50 psi) DCM, 20 °C, 14 h THF, 0-20 °C, 3 h MeOH, 20 °C, 15 hAtty Dkt No.: EVOM-008WO

[0256] 3-(Methylamino)spiro[3.3]heptan-l-ol: To a mixture of tert-butyl (3-oxospiro[3.3]heptan-l-yl)carbamate (300 mg, 1.33 mmol) in THF (20 mL) under N2 at 0 °C was added 2.5 M LAH (2.1 mL). The reaction mixture was slowly heated to 65 °C and stirred at that temperature for 16 hr (monitored by TLC). The reaction mixture was then cooled to 0 °C and was quenched with sequential addition of H2O (0.2 mL), 15% aq. NaOH (0.2 mL) and H2O (0.6 mL). To the mixture was added Na2SO4 (~1 gm) and the mixture was stirred for 30 min. The slurry was filtered and the filtrate was concentrated under reduced pressure to afford 3-(methylamino)spiro[3.3]heptan-l-ol (181 mg, 96.2 % yield) as a light yellow oil.1HNMR (400 MHz, CDCI3): δ 3.77 (t, J = 6.8 Hz, 1H), 2.57 - 2.46 (m, 2H), 2.46 - 2.40 (m, 3H), 2.21 - 1.80 (m, 8H).

[0257] Benzyl (3-hydroxyspiro[3.3]heptan-l-yl)(methyl)carbamate: To a solution of 3-(methylamino)spiro[3.3]heptan-l-ol (205 mg, 1.45 mmol) in THF (5 mL) at 20 °C was added NEts (0.44 mL, 3.16 mmol) and DMAP (18 mg, 147 pmol). The mixture was degassed and purged with N2 (3x), followed by the addition of CbzCI (248 mg, 1.45 mmol). The reaction mixture was stirred at 20 °C for 16 hr (TLC). The reaction mixture was diluted with EtOAc (20 mL), washed with H2O (10 mL), and dried over anhydrous Na2SO4, concentrated under reduced pressure. The residue thus obtained was purified by flash silica gel chromatography (4 g Silica Flash Column) eluting with 0~3% MeOH / DCM gradient @ 20 mL / min) to afford benzyl (3-hydroxyspiro[3.3]heptan-l-yl)(methyl)carbamate (334 mg, 83.5% yield) as a colorless oil. LC-MS (ESI): C16H21NO3 m / z = 275.1, found 276.1 [M+H]+; tR = 0.546 min (Method 1).

[0258] Benzyl methyl(3-oxospiro[3.3]heptan-l-yl)carbamate: To a solution of benzyl (3-hydroxyspiro[3.3]heptan-l-yl)(methyl)carbamate (330 mg, 1.2 mmol) in DCM (6 mL) at 20 °C was added DMP (762 mg, 1.8 mmol). The mixture was stirred at 20°C for 14 h (LCMS). The reaction mixture was diluted with DCM (10 mL). The organic layer was washed with sat. Na2SO3 (15 mL),Atty Dkt No.: EVOM-008WOsat. NaHCO3(12 mL) and brine (12 mL). The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford benzyl methyl(3-oxospiro[3.3]heptan-l-yl)carbamate (287 mg, 87.6% yield) as a yellow oil.1HNMR (400 MHz, CDCI3): δ 7.42 - 7.31 (m, 5H), 5.19 (q, J = 12.0 Hz, 2H), 4.61 - 4.31 (m, 1H), 3.27 - 3.11 (m, 2H), 2.92 (br s, 3H), 2.41 - 2.10 (m, 3H), 2.07 - 1.91 (m, 2H), 1.89 - 1.69 (m, 1H).

[0259] Benzyl (3-hydroxy-3-methylspiro[3.3]heptan-l-yl)(methyl)carbamate: To a 25 mL three-necked flask was taken CeCh (189 mg, 768 pmol) in THF (2 mL) under N2 and the mixture was stirred at 20 °C for 0.5 h. To the mixture was added 3M CHsMgBr (512 pL, 1.54 mmol), and the mixture was stirred at 0 °C for 0.5 hr. A solution of benzyl methyl(3-oxospiro[3.3]heptan-l-yl)carbamate (140 mg, 512 pmol) in THF (1 mL) was added to the reaction mixture at 0 °C and the stirring was continued for 2 hr. The reaction was quenched by addition of 10% AcOH (1 mL), followed by H2O (1 mL). The product was extracted with EtOAc (5 mL x 3). The combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford a crude product (200 mg) as a yellow oil. The crude product was purified by prep-HPLC (column: Xtimate C18 100 x 30mm x 3um; mobile phase: [H2O (0.1% TFA) -ACN]; gradient:26%-56% B over 8.0 min) to afford benzyl (3-hydroxy-3-methylspiro[3.3]heptan-l-yl)(methyl)carbamate (38.0 mg, 19.0% yield) as a colorless oil. LC-MS (ESI): C17H23NO3 m / z = 289.3, found 290.2 [M+H]+; tR = 0.567 min (Method 1).THNMR (400 MHz, CDCI3): δ 7.42 - 7.30 (m, 5H), 5.18 (s, 2H), 3.88 (t, J = 9.2 Hz, 1H), 2.96 (s, 3H), 2.1 - 1.80 (m, 7H), 1.29 (br s, 3H).

[0260] l-Methyl-3-(methylamino)spiro[3.3]heptan-l-ol: To a hydrogenation bottle wastaken 10% Pd / C (50 mg, 47.0 pmol) under Ar, followed by the addition of a solution of benzyl (3-hydroxy-3-methylspiro[3.3]heptan-l-yl)(methyl)carbamate (35.0 mg, 121 pmol) in MeOH (5 mL). The suspension was degassed under vacuum and purged with Ar (3 x), followed by degassingAtty Dkt No.: EVOM-008WOunder vacuum and purging with H2 (3 x). The mixture was stirred under H2 (50 psi) at 20 °C for 15 hr. The reaction mixture was filtered through a pad of celite, washed with MeOH (10 mL x 3) and the filtrate was concentrated under reduced pressure to afford l-methyl-3- (methylamino)spiro[3.3]heptan-l-ol (20.0 mg, crude) as a colorless oil.1HNMR (400 MHz, CDCI3): 5 3.50 (s, 1H), 2.72 (t, J = 7.2 Hz, 1H), 2.47 (s, 3H), 2.26 - 2.20 (m, 1H), 2.18 - 2.08 (m, 2H), 2.06 -1.96 (m, 1H), 1.86 - 1.82 (m, 2H), 1.81 - 1.77 (m, 2H), 1.52 (dd, J = 7.2, 11.6 Hz, 1H), 1.23 (s, 3H).

[0261] Synthesis of 3-(methylamino)-l-(trifluoromethyl)spiro[3.3]heptan-l-ol:1) TMSCF3, CSF Pd / C, H2(50 psi) 2) 2M aq. HCI MeOH, 20 °C, 15 h

[0262] Benzyl (3-hydroxy-3-(trifluoromethyl)spiro[3.3]heptan-l-yl)(methyl)carbamate: To solution of benzyl methyl(3-oxospiro[3.3]heptan-l-yl)carbamate (140 mg, 512 pmol) in THF (3 mL) was added CsF (7.78 mg, 51.2 pmol) at 0 °C, followed by the addition of a solution of trimethyl (trifluoromethyl) silane (182 mg, 1.28 mmol) in THF (0.5 mL). The reaction mixture was allowed to warm to room temperature and was stirred for 16 hr. The reaction mixture was cooled to 0 °C and was quenched by addition of 2 M aq. HCI (2.6 mL) at 0 °C. The mixture was allowed to warm to room temperature and was stirred for 1 h. The mixture was diluted with EtOAc (10 mL). The aqueous layer separated and the product was extracted with EtOAc (5 mL x 2). The combined organic extracts were dried (anhydrous Na2SO4), filtered and concentrated to afford the product (250 mg, crude) as a yellow oil. The residue was purified by prep-HPLC (column: Xtimate C18 100 x 30mm x 3um; mobile phase: [H2O (0.1% TFA) -ACN]; gradient:31%-61% B over 10.0 min) to afford benzyl (3-hydroxy-3-(trifluoromethyl)spiro[3.3]heptan-l-yl)(methyl)carbamate (70.0 mg,Atty Dkt No.: EVOM-008WO28.0% yield) as a colorless oil.XHNMR (400 MHz, CDCI3): δ 7.42 - 7.30 (m, 5H), 5.24 - 5.10 (m, 2H), 4.34 - 3.80 (m, 1H), 3.03 (br s, 3H), 2.81 - 2.62 (m, 1H), 2.51 - 1.96 (m, 5H), 1.70 - 1.50 (m, 3H).

[0263] 3-(Methylamino)-l-(trifluoromethyl)spiro[3.3]heptan-l-ol: To a hydrogenation bottle was taken 10% Pd / C (78 mg, 73.5 pmol) under Ar, followed by the addition of a solution of benzyl (3-hydroxy-3-(trifluoromethyl)spiro[3.3]heptan-l-yl)(methyl)carbamate (65.0 mg, 189 pmol) in MeOH (5 mL). The suspension was degassed under vacuum and purged with Ar (3 x), followed by degassing under vacuum and purging with H2 (3 x). The mixture was stirred under H2 (50 psi) at 20 °C for 15 hr. The reaction mixture was filtered through a pad of celite, washed with MeOH (10 mL x 3) and the filtrate was concentrated under reduced pressure to afford 3-(methylamino)-l-(trifluoromethyl)spiro[3.3]heptan-l-ol (42 mg, crude) as an off-white solid.XHNMR (400 MHz, CDCI3): 6 2.94 (t, J = 7.2 Hz, 1H), 2.65 (dd, J = 7.6, 12.8 Hz, 1H), 2.47 (s, 3H), 2.39 - 2.32 (m, 1H), 2.26 - 2.17 (m, 2H), 2.10 - 2.03 (m, 1H), 2.00 - 1.91 (m, 2H), 1.90 - 1.84 (m, 2H), 1.60 - 1.53 (m, 1H).Example 8: Characterization of Exemplary CompoundsTable 1: Exemplary CompoundsCompoundStructure IUPAC#(lR,3R)-3-{3-[5-(o-fluorophenoxy)-l,3-thiazol-2- 1 yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanolp(lR,3R)-3-{3-[5-(2,4-difluorophenoxy)-l,3-thiazol-2- 2yl]-l- methylureido}-l-methylcyclopentanolAtty Dkt No.: EVOM-008WO£(lR,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2- yl]-l- methylureido}-l-methylcyclopentanol A, X<(lR,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2- o yl]-l- methylureido}-l- \ methylcyclopentanol(lR,3R)-3-{3-[5-(3-chloro-5-fluorophenoxy)-l,3- thiazol- 2-yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(2-chloro-4-fluorophenoxy)-l,3- H WY thiazol- 2-yl]-l-methylureido}-l- Y (trifluoromethyl)cyclopentanolN^~AZZ2-fluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- Y(trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrileo 3-fluoro-4-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-rriethylureido}- v 1,3- thiazol-5-yloxy)benzonitrileYY: YF(lR,3R)-3-{3-[5-(2,5-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanolYYAtty Dkt No.: EVOM-008WO(lR,3R)-3-{3-[5-(3,4-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanolw5-fluoro-2-(2-{3-[(lR,3R)-3-hyd roxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrile 77^d(lR,3R)-3-{3-[5-(2-fluoro-4-pyridyloxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanolZ> (lR,3R)-3-{3-[5-(6-fluoro-3-pyridyloxy)-l,3- V thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(5-fluoro-3-pyridyloxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanolv. Zct(lR,3R)-3-{3-[5-(o-chlorophenoxy)-l,3-thiazol- c> 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol5-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)nicotinonitrileAtty Dkt No.: EVOM-008WO(lR,3R)-3-{3-[5-(2,3-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanol5-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)-3-toluonitrile5-fluoro-3-(2-{3-[(lR,3R)-3-hyd roxy-3- Q (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrile2-fluoro-4-(2-{3-[(lR,3R)-3-hyd roxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrile e(lR,3R)-3-{3-[5-(p-chlorophenoxy)-l,3-thiazol- 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanolVr\ (lR,3R)-3-{3-[5-(m-chlorophenoxy)-l,3-thiazol- 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol M y '(lR,3R)-3-(l-methyl-3-{5-[p- (trifluoromethyl)phenoxy]- l,3-thiazol-2- yl}ureido)-l- (trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WO(lR,3R)-3-(l-methyl-3-{5-[m- (trifluoromethyl)phenoxy]- l,3-thiazol-2- yl}ureido)-l- (trifluoromethyl)cyclopentanolM(lR,3R)-3-{3-[5-(p-fluorophenoxy)-l,3-thiazol- 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{l-methyl-3-[5-(3-pyridyloxy)-l,3- thiazol-2- yl]ureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{l-methyl-3-[5-(5-methyl-3- pyridyloxy)-l,3- thiazol-2-yl]ureido}-l- (trifluoromethyl)cyclopentanolp-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrilem-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrile(lR,3R)-3-(3-{l-[(2,4-difluorophenyl)methyl]- 3- pyrazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WO:s (lR,3R)-3-(3-{l-[(3,5-difluorophenyl)methyl]- 3- pyrazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanol(lR,3S)-3-{3-[5-(2,4-difluorophenoxy)-l,3- th iazol-2-y 1]- l-ethylureido}-l- (trifluoromethyl)cyclopentanol / 'P (lS,3S)-3-{3-[5-(2,4-difluorophenoxy)-l,3- th iazol-2-y 1]- l-ethylureido}-l- (trifluoromethyl)cyclopentanolO (lS,3S)-3-{3-[5-(2,4-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(2,4-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- V (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanol(lS,3S)-3-{3-[5-(3,5-difluorophenoxy)-l,3- thiazol-2-yl]- l-methylureido}-l- (trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WOh / \\ / o (lR,3R)-3-(3-{5-[(2,4-difluorophenyl)methyl]- 1,3,4- thiadiazol-2-yl}-l-methylureido)-l- A (trifluoromethyl)cyclopentanol AZ.b (lR,3R)-3-{3-[5-(2,4-difluorophenoxy)-l,3,4- thiadiazol- 2-yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol(lS,3S)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol- o 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol(lS,3S)-3-(3-{5-[(2,4-difluorophenyl)methyl]- 1,3,4- thiadiazol-2-yl}-l-methylureido)-l- (trifluoromethyl)cyclopentanol(lS,3S)-3-[3-(5-fluoro-l,3-thiazol-2-yl)-l- ^ methylureido]- 1- (trifluoromethyl)cyclopentanol(lS,3S)-3-{3-[5-(2,4-difluorophenoxy)-l,3,4- thiadiazol- 2-yl]-l-methylureido}-l- A (trifluoromethyl)cyclopentanol4(lR,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol- 2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WO(lR,3R)-3-[3-(5-fluoro-l,3-thiazol-2-yl)-l- methylureido]- 1- J0(trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(3-fluoro-2-tolyloxy)-l,3- thiazol-2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-(l-methyl-3-{5-[o- (trifluoromethyl)phenoxy]- l,3-thiazol-2- yl}ureido)-l- (trifluoromethyl)cyclopentanol Jr(lR,3R)-3-{l-methyl-3-[5-(o-tolyloxy)-l,3- thiazol-2- yl]ureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(3-fluoro-5-tolyloxy)-l,3- thiazol-2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanolo-(2-{3-[(lR,3R)-3-hydroxy-3- r\(trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3- thiazol-5-yloxy)benzonitrile r(lR,3R)-3-[l-methyl-3-(5-phenoxy-l,3-thiazol- 2-yl)ureido]-l-(trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WOo (lR,3R)-3-{l-methyl-3-[5-(p-tolyloxy)-l,3- thiazol-2- yl]ureido}-l- (trifluoromethyl)cyclopentanolu(lR,3R)-3-{l-methyl-3-[5-(m-tolyloxy)-l,3- thiazol-2- yl]ureido}-l- (trifluoromethyl)cyclopentanolO"F(lR,3R)-3-{3-[5-(3-chloro-2-fluorophenoxy)- 4l,3-thiazol-2- yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(3,4-difluoro-2-tolyloxy)-l,3- thiazol-2- yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{l-methyl-3-[5-(2,4,6- trifluorophenoxy)-l,3- thiazol-2-yl]ureido}-l- (trifluoromethyl)cyclopentanolW (lR,3R)-3-{3-[5-(2-fluoro-4-tolyloxy)-l,3- thiazol-2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(5-fluoro-2-tolyloxy)-l,3- thiazol-2-yl]-l- methylureido}-l- (trifluoromethyl)cyclopentanolAtty Dkt No.: EVOM-008WO6-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- O.^IH1,3-thiazol- 5-yloxy)-2-toluonitrileQr^. (lR,3R)-3-{l-methyl-3-[5-(2,3,6- trifluorophenoxy)-l,3- thiazol-2-yl]ureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{l-methyl-3-[5-(2,4,5- 0 trifluorophenoxy)-l,3- thiazol-2-yl]ureido}-l- (trifluoromethyl)cyclopentanoltp(lR,3R)-3-{l-methyl-3-[5-(2,3,4- P trifluorophenoxy)-l,3- thiazol-2-yl]ureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(4-chloro-2-fluorophenoxy)- l,3-thiazol-2- yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(2,4-difluoro-3-tolyloxy)-l,3- thiazol-2- yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanolQ 3-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}- 1,3-thiazol- 5-yloxy)-2-toluonitrileAtty Dkt No.: EVOM-008WO / \ / >M / b(lR,3R)-l-cyclopropyl-3-{3-[5-(3,5-difluorophenoxy)- l,3-thiazol-2-yl]-l-methylureido}cyclopentanol A,V. / OiV ’7 o\ / p(lR,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-N-> V^ yl]-l-methylureido}-l-isopropylcyclopentanol O^H1 V / SX V. V.7 OH ”_ / F\‘ vzvo(lR,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2- or yl]-l-methylureido}-l-ethylcyclopentanol (X "-i / NH / M (lR,3R)-3-{3-[3-(3,5-difluorophenyl)-l-methyl-5- pyrazolyl]-l-methylureido}-l-methylcyclopentanol A %JW!A,LK„(lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5- pyrazolyl]-l-methylureido}-l-methylcyclopentanolAtty Dkt No.: EVOM-008WOr(lR,3R)-3-{3-[3-(3,5-difluorophenyl)-l-methyl-5- r ' pyrazolyl]-l-methylureido}-l- <\VH(trifluoromethyl)cyclopentanolF0(lR,3R)-3-{3-[3-(m-fluorophenyl)-l-methyl-5- i \\_AK. pyrazolyl]-l-methylureido}-l- (trifluoromethyl)cyclopentanolL>Af (lR,3R)-3-{3-[3-(2,4-difluorophenyl)-l-methyl-5- Vs pyrazolyl]-l-methylureido}-l-methylcyclopentanol CV-NHrA„-\ >LXb - (lR,3R)-3-{3-[3-(2,4-difluorophenyl)-l-methyl-5- SsxX pyrazolyl]-l-methylureido}-l- ‘VNH (trifluoromethyl)cyclopentanolA ~F\zFi 'OHOH4,6-difluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- x methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- AVs"“X“fyloxy)benzonitrileH _ 0° W °Atty Dkt No.: EVOM-008WO°Y^r\z 6-fluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- XQ / VHLXHVs N methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- °C? yloxy)benzonitrile \ ■O AX” b MFO.. N! \ 2,6-difluoro-4-(2-{3-[(lR,3R)-3-hydroxy-3- / yv u y,=<I II methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- z:yloxy)benzonitrileOH. Y 4-fluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- / y\A.Vs j methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- Q yloxy)benzonitrile'M lf2,3-difluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileE F2,3,4-trifluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- CrV V" V™ methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- " V^ yloxy)benzonitrile! F / --M" 2,4,6-trifluoro-3-(2-{3-[(lR,3R)-3-hydroxy-3- HO' Wl MHrNfx ^. SF~X )— \ methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- ‘ a Vo FNV yloxy)benzonitrileAtty Dkt No.: EVOM-008WO2,3,4-trifluoro-6-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- T 2S Q*. yloxy)benzonitrileA KA aAp <! F2,6-difluoro-3-(2-{3-[(lR,3R)-3-hydroxy-3- v / V r$--^ methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- IZ°i:yloxy)benzonitrileI f / xA^o r^\ 2,4-difluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- f F--Z >--.-~Nmethylcyclopentyl]-3-methylureido}-l,3-thiazol-5-1s yo“ yloxy)benzonitrile; \ 4,5-difluoro-3-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- tW yloxy)benzonitrile<>>xro >\ 2,5-difluoro-3-(2-{3-[(lR,3R)-3-hydroxy-3- \, / | <x / / .Hcr^ n^-A / \ methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileV_7(lR,3R)-3-[l-methyl-3-(5-phenyl-l,3-thiazol-2- < >~X1"'NH r^x / x yl)ureido]-l-(trifluoromethyl)cyclopentanol cr NAtty Dkt No.: EVOM-008WO(lR,3R)-3-{3-[5-(4-fluoro-2-methoxyphenyl)-l,3- thiazol-2-yl]-l-methylureido}-l- (trifluoromethyl)cyclopentanol Sy \ 1 \ / <> _p~° H r~~ \ (lR,3R)-3-{3-[5-(o-methoxyphenyl)-l,3-thiazol-2-yl]-l-XN^~" NH rA / \Fmethylureido}-l-(trifluoromethyl)cyclopentanol 0 NIF(lR,3R)-3-{3-[5-(5-fluoro-2-methoxyphenyl)-l,3- y thiazol-2-yl]-l-methylureido}-l- S °AyS (trifluoromethyl)cyclopentanolR (lR,3R)-3-(l-methyl-3-{5-[o-(trifluoromethyl)phenyl]- l,3-thiazol-2-yl}ureido)-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-{3-[5-(3-fluoro-2-methoxyphenyl)-l,3- thiazol-2-yl]-l-methylureido}-l- SANH fA yZF(trifluoromethyl)cyclopentanol oAy’^OHOH0 I 3-chloro-2-fluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- 0 methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- \yloxy)benzonitrile\ / ~CI / *IMAtty Dkt No.: EVOM-008WO4-chloro-2-(2-{3-[(lR,3R)-3-hydroxy-3- \\ 1 I (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- >-« 8O\ _ thiazol-5-yloxy)benzonitrile2-chloro-4-(2-{3-[(lR,3R)-3-hydroxy-3- j (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- thiazol-5-yloxy)benzonitrilet ~7~"\\X 5-chloro-3-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- thiazol-5-yloxy)benzonitrileT>Ai 3-chloro-2-fluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- ) I (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- thiazol-5-yloxy)benzonitrile4-chloro-5-fluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- thiazol-5-yloxy)benzonitrilewoy 4-chloro-5-fluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- i \ methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileAtty Dkt No.: EVOM-008WOpHXX3,4, S-trifluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- M ' methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileX— -v / -F¥4,5-difluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- 5AXmethylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrilebCXH 2,3-difluoro-6-(2-{3-[(lR,3R)-3-hydroxy-3- HZN methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileF:2-chloro-3-fluoro-6-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileVAM 2-chloro-3-fluoro-6-(2-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methyliireido}-l,3- thiazol-5-yloxy)benzonitrileyy'OHQy (lR,3R)-l-cyclopropyl-3-{3-[5-(m-fluorophenoxy)-l,3- thiazol-2-yl]-l-methylureido}cyclopentanol. NAQAtty Dkt No.: EVOM-008WO4-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]- 3-methylureido}-l,3-thiazol-5-yloxy)-2- fluorobenzonitrile\o(lR,3R)-l-cyclopropyl-3-{3-[5-(p-fluorophenoxy)-l,3- thiazol-2-yl]-l-methylureido}cyclopentanolNBI”AJ5-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]- 3-methylureido}-l,3-thiazol-5-yloxy)-2- fluorobenzonitrilev / -X 3-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]- J JV 3-methylureido}-l,3-thiazol-5-yloxy)-5- fluorobenzonitrileV< / 4-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]- 3-methylureido}-l,3-thiazol-5-yloxy)-2,6- difluorobenzonitrile5-(2-{3-[(lR,3R)-3-cyclopropyl-3-hydroxycyclopentyl]- 3-methylureido}-l,3-thiazol-5-yloxy)-2,3- difluorobenzonitrile(lR,3R)-l-cyclopropyl-3-{l-methyl-3-[5-(3,4,5- trifluorophenoxy)-l,3-thiazol-2- yl]ureido}cyclopentanolAtty Dkt No.: EVOM-008WOM(lR,3R)-l-cyclopropyl-3-{3-[5-(3,4-diflLiorophenoxy)- l,3-thiazol-2-yl]-l-methylureido}cyclopentanolM 3-fluoro-4-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrilep-(2-{3-[(lR,3R)-3-hydroxy-3-methylcyclopentyl]-3- methylureido}-l,3-thiazol-5-yloxy)benzonitrileF2-fluoro-4-(2-{3-[(lR,3R)-3-hydroxy-3- ri methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileA (lR,3R)-l-methyl-3-{l-methyl-3-[5-(2,3,6- trifluorophenoxy)-l,3-thiazol-2- yl]ureido}cyclopentanol"i-5-fluoro-3-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrileHr 5-fluoro-2-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- AQ yloxy)benzonitrileAtty Dkt No.: EVOM-008WO2-fluoro-5-(2-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l,3-thiazol-5- yloxy)benzonitrile(lR,3R)-l-methyl-3-(l-methyl-3-{5-[m- (trifluoromethyl)phenoxy]-l,3-thiazol-2- V yl}ureido)cyclopentanolm-(2-{3-[(lR,3R)-3-hydroxy-3-methylcyclopentyl]-3- j methylureido}-l,3-thiazol-5-yloxy)benzonitrile HO(lR,3R)-3-{3-[5-(p-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-l-methylcyclopentanolr 5>- (lR,3R)-l-methyl-3-{l-methyl-3-[5-(2,3,4- r-\trifluorophenoxy)-l,3-thiazol-2- M yl]ureido}cyclopentanol" t!iO-J O^’ (lR,3R)-3-{3-[5-(3,4-difluorophenoxy)-l,3-thiazol-2- Y L tf x<>-0yl]-l-methylureido}-l-methylcyclopentanol 0Yfis z7(lR,3R)-l-methyl-3-{l-methyl-3-[5-(2,4,6- trifluorophenoxy)-l,3-thiazol-2- yl]ureido}cyclopentanolM-Atty Dkt No.: EVOM-008WO(lR,3R)-l-methyl-3-{l-methyl-3-[5-(3,4,5- trifluorophenoxy)-l,3-thiazol-2- yl]ureido}cyclopentanol4 > A' - o(lR,3R)-l-methyl-3-{l-methyl-3-[5-(2,4,5- trifluorophenoxy)-l,3-thiazol-2- yl]ureido}cyclopentanolA-\H'-d(lR,3R)-3-{3-[5-(5-fluoro-3-pyridyloxy)-l,3-thiazol-2- yl]-l-methylureido}-l-methylcyclopentanol Ap(lR,3R)-3-{3-[5-(6-fluoro-3-pyridyloxy)-l,3-thiazol-2- yl]-l-methylureido}-l-methylcyclopentanolFod(lR,3R)-3-{3-[5-(2-fluoro-4-pyridyloxy)-l,3-thiazol-2- (X yl]-l-methylureido}-l-methylcyclopentanol dv\" t!iO -(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)methyl]-3- isoxazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)methyl]-3- isoxazolyl}-l-methylureido)-l-methylcyclopentanolAQ„HOAtty Dkt No.: EVOM-008WO / (lR,3R)-3-(3-{5-[(3,5-difluorophenyl)methyl]-l- methyl-3-pyrazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanol(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)methyl]-l- methyl-3-pyrazolyl}-l-methyliireido)-l- methylcyclopentanolQ(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)hydroxymethyl]- 7 l-methyl-3-pyrazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanol)(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)hydroxymethyl]- l-methyl-3-pyrazolyl}-l-methylureido)-l- methylcyclopentanol(3,5-difluorophenyl)(3-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}-5- isoxazolyl)methanone(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)hydroxymethyl]- 3-isoxazolyl}-l-methylureido)-l- (trifluoromethyl)cyclopentanolHT / ^(3,5-difluorophenyl)(3-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-5- isoxazolyl)methanoneQ „HOAtty Dkt No.: EVOM-008WO(lR,3R)-3-(3-{5-[(3,5-difluorophenyl)hydroxymethyl]- 3-isoxazolyl}-l-methylureido)-l-methylcyclopentanol ndF" C^(3,5-difluorophenyl)(3-{3-[(lR,3R)-3-hydroxy-3- (trifluoromethyl)cyclopentyl]-3-methylureido}-l- •N.x- methyl-5-pyrazolyl)methanoneW-''N— (3,5-difluorophenyl)(3-{3-[(lR,3R)-3-hydroxy-3- methylcyclopentyl]-3-methylureido}-l-methyl-5- C^ VAlHpyrazolyl)methanonendF1 l>3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-l-(trifluoromethyl)-l- fSIW 0bi--{ x VF;spiro[3.3]heptanolHHxSFrScr 3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-l-(trifluoromethyl)-l- spiro[3.3]heptanol$?FZ / OHF3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- t^SN=X methylureido}-l-methyl-l-spiro[3.3]heptanolN- / / 0 Z xy\H \- / \Z / 'OHFn? T 3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-l-methyl-l-spiro[3.3]heptanol '' J' oH V / y / OHAtty Dkt No.: EVOM-008WO(lS;3S)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2-yl]- l-methylureido}-l-spiro[3.3]heptanol Tli o\ I!r i i\ rxo- F r \O7—(lS,3R)-3-{3-[5-(3,5-difluorophenoxy)-l,3-thiazol-2- Ms yl]-l-methylureido}-l-spiro[3.3]heptanol M / ? ON\ xHN— \ V-OH / VF-" WrOa N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-(2R,3R)-3- hydroxy-2-methyl-l-azetidinecarboxamideSjTbOH_(3R,4S)-4-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}tetrahydro-2H-pyran-3-olz0HFN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-5-hydroxy-2- ”Os,ivOazabicyclo[2.2.1]heptane-2-carboxamide Mi iAtty Dkt No.: EVOM-008WO < A." Y 3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l-methyl-l-HrSY\ (2-oxa-7-spiro[3.5]nonyl)urea M" / VA- -<t>HY 7-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- / ■°»N methylureido}-5-aza-4-spiro[2.4]heptanone £qJ J. \ XAX Q -Y- ^3 X 6-({3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}methyl)-2X6-thia-2,2- Y-s o y7spiro[3.3]heptanedione W YH 1(6-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-2-spiro[3.3]heptyl)methanolAtty Dkt No.: EVOM-008WOK HN (2-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- \ methylureido}-2-spiro[3.3]heptyl)methanolwAG-^0(lS,3R)-3-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- methylureido}-l-spiro[3.3]heptanol V H \> UZ 2\8-. OH / 6-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-l- HN-V, N methylureido}-2-spiro[3.3]heptanol £ / bV / ! \0%. JiH N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-8-hydroxy-8- 1(trifluoromethyl)-2-aza-2- dispiro[3.1.3.1]decanecarboxamideX / HO >\F TAtty Dkt No.: EVOM-008WO--0'-,,-s py--N M uN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-7-hydroxy-7- (trifluoromethyl)-2-aza-2- / “T spiro[3.5]nonanecarboxamide " AE:F F X PH F VV N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-6-hydroxy-6- HN^"'>0 (trifluoromethyl)-2-aza-2- spiro[3.3]heptanecarboxamide tSO / -'^'FXz-XZ A- '?i / i z-- "u-XN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-6- u.” ax x(difluoromethyl)-6-hydroxy-2-aza-2- spiro[3.3] heptanecarboxamideFN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-2-hydroxy-2- (trifluoromethyl)-7-aza-7- X n / spiro[3.5]nonanecarboxamide! it s — i &FAA < " NAtty Dkt No.: EVOM-008WOV-n p h N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-2-hydroxy-2- (trifluoromethyl)-6-aza-6- l n ■. spiro[3.4]octanecarboxamide A)H COlp / "f / J-T)N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-4-fluoro-4- (hydroxymethyl)-8-oxa-2-aza-2- Y spiro[4.5]decanecarboxamide( '> V \'i>—'HN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-6-(l,l- difluoro-2-hydroxyethyl)-2-aza-2- spiro[3.3]heptanecarboxamide / <r6 N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-2-hydroxy-2- \NH (trifluoromethyl)-6-aza-6-: V'— \ spiro[3.5]nonanecarboxamide < / . \ 2s.HO" V\.P-tFAtty Dkt No.: EVOM-008WOOHN-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-8-fluoro-8- 169 Ax (hydroxymethyl)-6-aza-6- Aspiro[3.4]octanecarboxamide °“Vl 6n \ / H O. A?' — NAoHN N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-8-fluoro-8- 170 (hydroxymethyl)-2-oxa-6-aza-6- V spiro[3.4]octanecarboxamide yX N-[5-(m-fluorophenoxy)-l,3-thiazol-2-yl]-2,2-difluoro- 171 A ) H A 8-hydroxy-6-aza-6-spiro[3.5]nonanecarboxamide W r xV-N OohA)q- (lR,2R,4R)-5-{3-[5-(m-fluorophenoxy)-l,3-thiazol-2- 172 NA.yl]-l-methylureido}-2-(trifluoromethyl)-2-norbornanol AOHTable 2: Characterization for Exemplary CompoundsSyntheticAmountCompound #XH NMR LCMS Yield Appearance methodXH NMR (400 [M+H]+:1 A 45 mg 39% white solidMHz, DMSO-d6) 420.0,Atty Dkt No.: EVOM-008WO= 10.85 - 10.64 tR = 0.575(m, 1H), 7.43 - min.34 (m, 1H), 7.27 (Method 2)- 7.17 (m, 3H),.15 (s, 1H), 6.00(s, 1H), 5.03 -.79 (m, 1H), 2.83(s, 3H), 2.08 -.01 (m, 1H), 2.00- 1.81 (m, 3H),.71 (brd, J = 7.2Hz, 2H)XH NMR (400MHz, DMSO-d6)10.60 (brs, 1H),7.51 - 7.43 (m,1H), 7.31 (td, J =5.6, 9.2 Hz, 1H),384.37.18 - 7.02 (m,[M+H]+, tR = off-white 2H), 4.97 - 4.77 A 22.9 mg 13%0.534 min solid (m, 1H), 4.32 (s,(Method 4).H), 2.79 (s, 3H),1.95 - 1.84 (m,1H), 1.70 - 1.61(m, 2H), 1.61 -.48 (m, 3H), 1.25(s, 3H).XH NMR (400MHz, DMSO-d6)10.68 (brs, 1H),.22 (s, 1H), 7.06 Found 384.3- 6.99 (m, [M+H]+, tR = off-white 1H),6.87 (dd, J = A 20.5 mg 23%0.550 min solid 1.6, 8.4 Hz, 2H), (Method 4).4.99 - 4.78 (m,H), 4.33 (s, 1H),.80 (s, 3H), 1.97- 1.85 (m, 1H),Atty Dkt No.: EVOM-008WO1.71 - 1.49 (m,5H), 1.26 (s, 3H).XH NMR (400MHz, DMSO-d6)6 10.63 (br s, 1H),7.46 - 7.37 (m,1H), 7.17 (s, 1H), 366.37.03 - 6.87 (m, [M+H]+, tR = light yellow A 23 mg 27%3H), 4.88 (br s, 0.533 min solid 1H), 4.33 (s, 1H), (Method 4).2.80 (s, 3H), 1.96- 1.85 (m, 1H),1.72 - 1.49 (m,5H), 1.26 (s, 3H).XH NMR (400MHz, DMSO-d6)6 11.28 - 10.53(m, 1H), 7.27 -.18 (m, 2H), 7.07[M+H]+:- 6.97 (m, 2H),454.0,6.01 (s, 1H), 4.94 Light yellow A tR = 0.649 100 mg 36%(br s, 1H), 2.84 (s, solid min3H), 2.12 - 2.02(Method 2)(m, 1H), 2.01 - 1.90 (m, 1H), 1.90- 1.79 (m, 2H),1.77 - 1.62 (m,2H)XH NMR (400MHz, DMSO-d6)5 11.12 - 10.45(m, 1H), 7.60 (dd, [M+H]+:J = 2.8, 8.4 Hz, 454.0,Light yellow 1H), 7.30 - 7.20 A tR = 0.622 80.0 mg 36%solid (m, 2H), 7.14 (s, min1H), 6.00 (s, 1H), (Method 2)4.92 (br s, 1H),2.83 (s, 3H), 2.10- 2.01 (m, 1H),Atty Dkt No.: EVOM-008WO1.99 - 1.90 (m,1H), 1.89 - 1.79(m, 2H), 1.76 - 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.84 (br s, 1H),7.79 - 7.71 (m,1H), 7.57 - 7.50[M+H]+:(m, 2H), 7.20 (s,445.0,1H), 6.01 (s, 1H), Light yellow A tR = 0.565 75.0 mg 40%4.92 (br s, 1H), solid min2.83 (s, 3H), 2.11(Method 2)- 2.02 (m, 1H),2.00 - 1.91 (m,1H), 1.89 - 1.79(m, 2H), 1.76 - 1.63 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.89 (br s, 1H),8.05 (dd, J = 2.0,11.0 Hz, 1H), 7.69(dd, J = 1.2, 8.4 [M+H]+:Hz, 1H), 7.36 - 445.0,Light yellow 7.26 (m, 2H), 6.01 A tR = 0.561 180 mg 53%solid (s, 1H), 4.91 (br s, min1H), 2.89 - 2.79 (Method 2)(m, 3H), 2.08 - 1.93 (m, 2H), 1.90- 1.80 (m, 2H),1.76 - 1.63 (m,2H)XH NMR (400 [M+H]+:MHz, DMSO-d6) 438.0,6 10.80 (br s, 1H), Light yellow A tR = 165 mg 57%7.49 - 7.40 (m, solid 0.586min1H), 7.21 (s, 1H), (Method 2)7.15 - 7.07 (m,Atty Dkt No.: EVOM-008WO1H), 7.04 (br s,1H), 6.00 (s, 1H),4.91 (br s, 1H),2.83 (s, 3H), 2.07(br s, 1H), 2.00 -.90 (m, 1H), 1.89- 1.79 (m, 2H),1.71 (br d, J = 7.2Hz, 1H)2H NMR (400MHz, DMSO-d6)6 10.99 - 10.50(m, 1H), 7.46 (brd, J = 9.6 Hz, 1H),7.35 - 7.24 (m,1H), 7.18 (s, 1H), [M+H]+:6.95 (br s, 1H), 438.2,6.01 (s, 1H), 4.98 A tR = 0.650 15 mg 10% White solid - 4.80 (m, 1H), min2.87 - 2.82 (m, (Method 4)3H), 2.11 - 2.04(m, 1H), 1.98 -.91 (m, 1H), 1.90- 1.82 (m, 2H),1.76 - 1.68 (m,2H)XH NMR (400MHz, DMSO-d6)5 10.88 (br d, J =1.6 Hz, 1H), 7.94(br d, J = 8.0 Hz, [M+H]+:1H), 7.64 - 7.54 445.3,(m, 1H), 7.33 - A tR = 0.614 60 mg 26% White solid.21 (m, 2H), 6.01 min(s, 1H), 5.02 - (Method 4).82 (m, 1H), 2.85(br s, 3H), 2.13 -.03 (m, 1H), 2.01- 1.93 (m, 1H),Atty Dkt No.: EVOM-008WO1.90 - 1.82 (m,2H), 1.76 - 1.66(m, 2H)XH NMR (400MHz, DMSO-d6)5 11.25 - 10.72(m, 1H), 8.19 (d, J= 5.6 Hz, 1H),7.31 (s, 1H), 7.10(dd, J = 1.2, 5.6 [M+H]+:Hz, 1H), 6.90 (d, J 421.0,= 2.0 Hz, 1H), A tR = 0.510 71 mg 28% White solid 6.02 (s, 1H), 5.05 min- 4.85 (m, 1H), (Method 2)2.85 (s, 3H), 2.12- 2.03 (m, 1H),2.00 - 1.92 (m,1H), 1.91 - 1.82(m, 2H), 1.78 - 1.67 (m, 2H)XH NMR (400MHz, DMSO-d6)6 11.14 - 10.59(m, 1H), 8.12 (dd,J = 1.6, 2.8 Hz,1H), 7.80 (m, [M+H]+:1H), 7.27 - 7.15 420.9,(m, 2H), 6.01 (s, A tR = 0.514 67 mg 31% White solid 1H), 4.94 (br s, min1H), 2.87 - 2.82 (Method 1)(m, 3H), 2.11 - 2.02 (m, 1H), 1.95(m, 1H), 1.90 - 1.81 (m, 2H), 1.77- 1.66 (m, 2H)2H NMR (400[M+H]+:MHz, DMSO-d6) A 421.0, 55 mg 36% White solid 6 11.22 - 10.66tR = 0.494(m, 1H), 8.39 (dd,Atty Dkt No.: EVOM-008WOJ = 2.0, 9.6 Hz, min2H), 7.60 (m, 1H), (Method 1)7.27 (s, 1H), 6.02(s, 1H), 4.95 (br s,1H), 2.85 (s, 3H),2.12 - 2.02 (m,1H), 2.00 - 1.91(m, 1H), 1.90 - 1.81 (m, 2H), 1.76- 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.94 - 10.62(m, 1H), 7.61 -.51 (m, 1H), 7.42- 7.33 (m, 1H), [M+H]+:7.27 - 7.15 (m, 435.9,Light yellow 3H), 6.01 (s, 1H), A tR = 0.612 50.0 mg 22%solid 5.04 - 4.76 (m, min1H), 2.84 (s, 3H), (Method 2)2.08 - 2.02 (m,1H), 1.98 - 1.90(m, 1H), 1.90 - 1.79 (m, 2H), 1.78- 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)8 = 11.20 - 10.46(m, 1H), 8.94 -.72 (m, 2H), 8.14[M+H]+:(br s, 1H), 7.27 (s,428.0,1H), 6.01 (s, 1H),A tR = 0.485 50 mg 22% white solid 5.09 - 4.79 (m,min1H), 2.84 (s, 3H),(Method 2)2.11 - 2.07 (m,1H), 1.99 - 1.91(m, 2H), 1.90 - 1.81 (m, 2H), 1.77- 1.65 (m, 2H)Atty Dkt No.: EVOM-008WOXH NMR (400MHz, DMSO-d6)8 = 11.15 - 10.48(m, 1H), 7.28 -.17 (m, 3H), 7.09[M+H]+:- 6.98 (m, 1H),438.0,6.00 (s, 1H), 4.91A tR = 0.592 40 mg 20% white solid (br s, 1H), 2.83 (s,min3H), 2.11 - 2.03(Method 1)(m, 1H), 2.00 - 1.91 (m, 1H), 1.91- 1.81 (m, 2H),1.77 - 1.62 (m,2H)XH NMR (400MHz, DMSO-d6)8 = 11.07 - 10.46(m, 1H), 7.47 -.42 (m, 1H), 7.39(s, 1H), 7.28 (s,[M+H]+:1H), 7.20 (s, 1H),441.0,6.00 (s, 1H), 5.13A tR = 0.585 60 mg 30% white solid - 4.77 (m, 1H),min2.84 (s, 3H), 2.34(Method 2)(s, 3H), 2.12 - 2.01 (m, 1H), 2.00- 1.90 (m, 1H),1.89 - 1.79 (m,2H), 1.77 - 1.63(m, 2H)2H NMR (400MHz, DMSO-d6)8 = 11.33 - 10.37 [M+H]+:(m, 1H), 7.65 (br 445.1,d, J = 7.6 Hz, 1H), A tR = 0.983 55 mg 19% white solid 7.52 (s, 1H), 7.44 min(dd, J = 2.0, 10.0 (Method 1)Hz, 1H), 7.26 (s,1H), 6.01 (s, 1H),Atty Dkt No.: EVOM-008WO5.12 - 4.62 (m,1H), 2.85 (s, 3H),2.12 - 2.06 (m,1H), 2.02 - 1.91(m, 1H), 1.90 - 1.80 (m, 2H), 1.77- 1.60 (m, 2H)XH NMR (400MHz, DMSO-d6)5 = 11.10 - 10.62(m, 1H), 8.00 -.85 (m, 1H), 7.33(dd, J = 2.3, 10.8Hz, 1H), 7.29 - [M+H]+:.25 (m, 1H), 7.16 445.1,- 7.09 (m, 1H), A tR = 0.977 50 mg 21% white solid 6.00 (s, 1H), 4.92 min(br d, J = 2.4 Hz, (Method 1)1H), 2.84 (s, 3H),2.12 - 2.01 (m,1H), 2.00 - 1.88(m, 1H), 1.88 - 1.80 (m, 1H), 1.76- 1.63 (m, 2H)XH NMR (400MHz, DMSO-d6)5 10.79 (br s, 1 H)7.43 (d, J = 9.2Hz, 2 H) 7.14 (t, J[M+H]+:= 9.2 Hz, 3 H)436.16.00 (s, 1 H) 4.91A tR = 0.921 12.7 mg 66% white solid (br s, 1 H) 2.83 (s,min3 H) 2.01 - 2.11(Method 1)(m, 1 H) 1.90 - 2.00 (m, 1 H) 1.79- 1.89 (m, 2 H)1.64 - 1.76 (m, 2H)Atty Dkt No.: EVOM-008WOXH NMR (400MHz, DMSO-d6)10.78 (brs, 1 H)7.41 (t, J = 8.4 Hz,1 H) 7.19 (t, J =6.8 Hz, 3 H) 7.09 [M+H]+:(dd, J = 2.4, 8.4 436.1Hz, 1 H) 6.01 (s, 1 A tR = 0.923 11.5 mg 45% yellow solid H) 4.92 (s, 1 H) min2.83 (s, 3 H) 2.02 (Method 1)- 2.12 (m, 1 H)1.90 - 2.00 (m, 1H) 1.79 - 1.89 (m,2 H) 1.63 - 1.76(m, 2 H)XH NMR (400MHz, DMSO-d6)10.81 (brs, 1H),7.75 (d, J = 8.8Hz, 2H), 7.31 - [M+H]+:.20 (m, 3H), 6.00470.0,(s, 1H), 5.01 - Light yellow A tR = 0.645 40 mg 28%.82 (m, 1H), 2.84 solid min(s, 3H), 2.12 - (Method 2).00 (m, 1H), 2.00- 1.91 (m, 1H),1.90 - 1.80 (m,2H), 1.77 - 1.63(m, 2H)XH NMR (400MHz, DMSO-d6)10.91 (brs, 1H), [M+H]+:7.68 - 7.58 (m, 470.0,1H), 7.51 (brd, J Light yellow A tR = 0.646 50 mg 23%= 8.0 Hz, 1H), solid min7.46 - 7.37 (m, (Method 2)2H), 7.24 (s, 1H),6.00 (s, 1H), 4.94(br d, J = 3.6 Hz,Atty Dkt No.: EVOM-008WO1H), 2.84 (s, 3H),2.11 - 1.90 (m,2H), 1.90 - 1.80(m, 2H), 1.77 - 1.63 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.87 (br s, 1H),7.27 - 7.18 (m,2H), 7.18 - 7.07[M+H]+:(m, 3H), 6.00 (s,419.9,1H), 5.02 - 4.84 Light yellow A tR = 0.581 14 mg 18%(m, 1H), 2.83 (s, solid min3H), 2.11 - 2.01(Method 2)(m, 1H), 1.99 - 1.90 (m, 1H), 1.89- 1.78 (m, 2H),1.76 - 1.62 (m,2H)XH NMR (400MHz, DMSO-d6)6 11.20 - 10.48(m, 1H), 8.47 (d, J= 3.2 Hz, 1H),8.40 - 8.31 (m,1H), 7.57 - 7.51[M+H]+:(m, 1H), 7.43 (dd,403.0,J = 4.8, 8.4 Hz,A tR = 0.366 31 mg 12% White solid 1H), 7.20 (s, 1H),min6.01 (s, 1H), 5.07(Method 2)- 4.85 (m, 1H),2.84 (s, 3H), 2.11- 2.03 (m, 1H),1.95 (m, 1H), 1.91- 1.82 (m, 2H),1.76 - 1.67 (m,2H)XH NMR (400 A [M+H]+: 13 mg 7% White solidMHz, DMSO-d6) 417.0,Atty Dkt No.: EVOM-008WO5 11.12 - 10.56 tR = 0.376(m, 1H), 8.29 - min.16 (m, 2H), 7.36 (Method 2)(s, 1H), 7.19 (s,1H), 6.01 (s, 1H),5.08 - 4.82 (m,1H), 2.84 (s, 3H),.31 (s, 3H), 2.07(m, 1H), 2.00 -.91 (m, 1H), 1.91- 1.83 (m, 2H),1.79 - 1.67 (m,2H)XH NMR (400MHz, DMSO-d6)= 11.09 - 10.60(m, 1H), 7.97 -.79 (m, 2H), 7.32[M+H]+:-7.19 (m, 3H),427.0,.01 (s, 1H), 4.81A tR = 0.538 45 mg 29% White solid (s, 1H), 2.85 (s,min3H), 2.04 (brd, J(Method 2)= 8.8 Hz, 1H),2.00 - 1.92 (m,1H), 1.91 - 1.80(m, 2H), 1.77 - 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)= 10.97 - 10.73(m, 1H), 7.65 - [M+H]+:.55 (m, 3H), 7.49 427.1,-7.41 (m, 1H), A tR = 0.869 40 mg 20% White solid.22 (s, 1H), 6.01 min(s, 1H), 5.04 - (Method 1).83 (m, 1H), 2.84(s, 3H), 2.10 -.06 (m, 1H), 2.00- 1.91 (m, 1H),Atty Dkt No.: EVOM-008WO1.90 - 1.79 (m,2H), 1.77 - 1.63(m, 2H)XH NMR (400MHz, DMSO-d6)5 8.79 (s, 1H),7.65 (s, 1H), 7.31- 7.19 (m, 2H),7.08 (br t, J = 7.6[M+H]+:Hz, 1H), 6.37 - 419.3; tR = Off-white 6.28 (m, 1H), 5.96 A 35.6 mg 36%0.540 min solid (s, 1H), 5.21 (s,(Method 4)2H), 4.97 - 4.83(m, 1H), 2.75 (s,3H), 2.10 - 1.97(m, 1H), 1.92 - 1.76 (m, 3H), 1.76- 1.58 (m, 2H).:H NMR: (400MHz, DMSO-d6)6 8.81 (s, 1H),7.70 (d, J = 2.4Hz, 1H), 7.19- 7.13(m, 1H), 6.95- 6.80 (m, 2H),419.06.36 (d, J = 2.4[M+H]+, tR = Off-white Hz, 1H), 5.96 (s, A 46 mg 46%0.531 min solid 1H), 5.22 (s, 2H),(Method 2)5.01 - 4.81 (m,1H), 2.76 (s, 3H),2.10 - 1.98 (m,1H), 1.94 - 1.85(m, 1H), 1.85 - 1.74 (m, 2H), 1.73- 1.57 (m, 2H)2H NMR (400452.0MHz, DMSO-d6) A [M+H]+, 22.5 mg 49% White solid 6 7.51 - 7.42 (m,tR = 0.6681H), 7.36 - 7.26Atty Dkt No.: EVOM-008WO(m, 1H), 7.12 (s, min1H), 7.11 - 7.04 (Method 2)(m, 1H), 4.64 -.54 (m, 2H), 3.46- 3.24 (m, 2H),2.30 (dd, JI =14.4 Hz, J2 = 10.0Hz, 1H), 1.99 -.67 (m, 4H), 1.63(br dd, Jl = 14.4Hz, J2 = 8.4 Hz,1H), 1.09 (t, J =6.8 Hz, 3H).XH NMR (400MHz, DMSO-d6)6 7.52 - 7.42 (m,1H), 7.36 - 7.27(m, 1H), 7.12 (s,1H), 7.11 - 7.04[M+H]+:(m, 1H), 4.66 (br452.0,d, J = 2.0 Hz, 1H),A tR = 0.641 30.0 mg 66% White solid 3.33 (q, J = 6.4minHz, 2H), 2.15 - (Method 2).05 (m, 1H), 2.02- 1.91 (m, 2H),1.90 - 1.82 (m,1H), 1.77 - 1.64(m, 2H), 1.06 (t, J= 6.8 Hz, 3H).XH NMR (400MHz, DMSO-d6)6 7.52 - 7.43 (m, [M+H]+:1H), 7.35 - 7.27 437.9,(m, 1H), 7.13 (s, A tR = 0.610 15.2 mg 64% White solid 1H), 7.12 - 7.05 min(m, 1H), 6.27 - (Method 2).74 (m, 1H), 4.98- 4.86 (m, 1H),2.82 (s, 3H), 2.10Atty Dkt No.: EVOM-008WO- 2.00 (m, 1H),2.00 - 1.78 (m,3H), 1.76 - 1.62(m, 2H).XH NMR (400MHz, DMSO-d6)67.48 (m, 1 H),7.31 (td, J = 9.2,[M+H]+:5.6 Hz, 1 H), 7.13437.9,(m, 1 H), 7.08 (m, Light yellow A tR = 0.944 6.0 mg 26%1 H), 4.92 (m, 1 solid minH), 2.82 (s, 3 H),(Method 1)2.06 (m, 1 H),1.93 (m, 1 H),1.85 (m, 2 H),1.71 (m, 2 H).TH NMR (400MHz, DMSO-d6)67.24 (s, 1H),7.07 - 6.99 (m,1H), 6.92 - 6.84[M+H]+:(m, 2H), 6.20 - 438.0,.84 (m, 1H), 4.98A tR = 0.604 4.00 mg 21% White solid -4.88 (m, 1H),min2.84 (s, 3H), 2.11(Method 2)- 2.03 (m, 1H),1.98 - 1.91 (m,1H), 1.89 - 1.81(m, 2H), 1.76 - 1.67 (m, 2H)XH NMR (400MHz, DMSO-d6)67.24 (s, 1H), [M+H]+:7.08 - 6.99 (m, 438.0,1H), 6.95 - 6.83 A tR = 0.611 8.1 mg 36% White solid (m, 2H), 5.02 - min.87 (m, 1H), 2.84 (Method 2)(s, 3H), 2.12 -.01 (m, 1H), 2.00Atty Dkt No.: EVOM-008WO- 1.79 (m, 3H),1.78 - 1.62 (m,2H).XH NMR (400MHz, DMSO-d6)8 ppm 7.57 (m, 1H), 7.34 (td,J=9.6, 2.4 Hz, 1[M+H]+:H), 7.16 (m, 1 H),437.0,6.06 (s, 1 H), 5.02A tR = 0.897 8.0 mg 32% White solid (m, 1 H), 4.31 (m,min2 H), 2.90 (s, 3 H),(Method 1)2.14 (m, 1 H),2.01 (brd, J=7.6Hz, 1 H), 1.90 (m,2 H), 1.77 (m, 3H).XH NMR (400MHz, DMSO-d6)67.70 (m, 1 H),[M+H]+:7.61 (m, 1 H),438.9,7.26 (m, 1 H),A tR = 0.930 8.0 mg 32% White solid 6.07 (s, 1 H), 4.97min(m, 1 H), 2.92 (m,(Method 1)3 H), 2.14 (m, 2H), 1.93 (m, 2 H),1.77 (m, 3 H).XH NMR (400MHz, DMSO-d6)67.46 - 7.38 (m,1H), 7.19 (s, 1H), [M+H]+:7.02 - 6.89 (m, 420.1,4H), 6.01 (s, 1H), A tR = 0.603 12.4 mg 55% White solid 5.02 - 4.78 (m, min1H), 2.83 (s, 3H), (Method 2)2.10 - 2.02 (m,1H), 1.98 - 1.90(m, 1H), 1.89 -Atty Dkt No.: EVOM-008WO1.81 (m, 2H), 1.76- 1.67 (m, 2H).XH NMR (400MHz, DMSO-d6)6 7.47 (br d, J =6.8 Hz, 1H), 7.30 -.23 (m, 1H), 7.13[M+H]+:- 7.06 (m, 1H),436.9,6.00 (s, 1H), 4.99A tR = 0.544 7.3 mg 34% White solid - 4.84 (m, 1H),min4.25 (br s, 2H),(Method 2)2.83 (br s, 3H),2.11 - 2.01 (m,1H), 2.00 - 1.75(m, 4H), 1.75 - 1.64 (m, 2H).TH NMR (400MHz, DMSO-d6)6 10.96 - 10.49(m, 1H), 7.16 (d, J= 2.0 Hz, 1H), [M+H]+:6.01 (s, 1H), 4.91 327.9,(br s, 1H), 2.82 (s, A tR = 0.478 10.6 mg 44% White solid 3H), 2.11 - 2.00 min(m, 1H), 1.99 - (Method 2)1.91 (m, 1H), 1.86(br d, J = 10.4 Hz,2H), 1.76 - 1.65(m, 2H).XH NMR (400MHz, DMSO-d6)6 7.67 - 7.60 (m, [M+H]+:1H), 7.58 - 7.52 438.9,(m, 1H), 7.24 - A tR = 0.566 4.5 mg 19% White solid.16 (m, 1H), 6.03 min(br s, 1H), 5.10 - (Method 2).79 (m, 1H), 2.84(s, 3H), 2.11 -2.01 (m, 1H), 2.00Atty Dkt No.: EVOM-008WO- 1.79 (m, 4H),1.76 - 1.65 (m,2H).XH NMR (400MHz,CHLOROFORM-d)6 7.40 - 7.33 (m,1H), 7.04 (s, 1H),6.98 - 6.88 (m, [M+H]+:2H), 6.88 - 6.82 420.0,(m, 1H), 4.78 (br A tR = 0.944 13.0 mg 57% White solid s, 1H), 2.99 (s, min3H), 2.31 - 2.25 (Method 1)(m, 1H), 2.21 - 2.13 (m, 2H), 2.07- 2.00 (m, 1H),1.96 - 1.86 (m,2H).XH NMR (400MHz,CHLOROFORM-d)6 6.94 (d, J = 2.4[M+H]+:Hz, 1H), 5.09 - 328.0,4.97 (m, 1H), 2.92 Light yellow A tR = 0.846 10.0 mg 56%(s, 3H), 2.30 - solid min2.24 (m, 1H), 2.21(Method 1)- 2.15 (m, 1H),2.06 - 2.01 (m,2H), 1.89 - 1.78(m, 2H).XH NMR (400MHz, DMSO-d6)6 10.90 - 10.55 [M+H]+:(m, 1H), 7.28 - 434.1,7.19 (m, 1H), 7.13 A tR = 0.631 37.0 mg 15% White solid (s, 1H), 6.98 (t, J = min8.8 Hz, 1H), 6.84 (Method 2)(d, J = 8.8 Hz, 1H),6.02 (s, 1H), 5.01Atty Dkt No.: EVOM-008WO- 4.80 (m, 1H),2.84 (s, 3H), 2.20(d, J = 1.2 Hz, 3H),2.10 - 2.03 (m,1H), 1.95 (m, 1H),1.89 - 1.80 (m,2H), 1.78 - 1.66(m, 2H)XH NMR (400MHz, DMSO-d6)5 10.99 - 10.55(m, 1H), 7.77 (d, J= 7.6 Hz, 1H),7.69 (s, 1H), 7.36 [M+H]+:- 7.24 (m, 3H), 470.0,6.02 (s, 1H), 4.98 A tR = 0.626 72.0 mg 40% White solid - 4.81 (m, 1H), min2.84 (s, 3H), 2.13 (Method 2)- 2.02 (m, 1H),2.00 - 1.92 (m,1H), 1.91 - 1.79(m, 2H), 1.71 (m,2H)XH NMR (400MHz, DMSO-d6)5 10.96 - 10.49(m, 1H), 7.34 - 7.25 (m, 1H), 7.23- 7.16 (m, 1H), [M+H]+:7.10 - 7.02 (m, 416.2,2H), 6.99 (br d, J Light yellow A tR = 0.913 30.0 mg 14%= 8.4 Hz, 1H), solid min6.01 (s, 1H), 5.03 (Method 1)- 4.75 (m, 1H),2.83 (br s, 3H),2.29 (s, 3H), 2.09- 2.02 (m, 1H),1.93 (br dd, J =5.6, 8.8 Hz, 1H),Atty Dkt No.: EVOM-008WO1.88 - 1.79 (m,2H), 1.77 - 1.69(m, 2H)XH NMR (400MHz, DMSO-d6)6 10.82 (br d, J =2.8 Hz, 1H), 7.30 -.17 (m, 1H), 6.89(br d, J = 9.6 Hz,1H), 6.83 (br t, J = [M+H]+:5.2 Hz, 2H), 6.07 434.0,(s, 1H), 5.14 - A tR = 0.618 40.0 mg 21% White solid.82 (m, 1H), 2.90 min(s, 3H), 2.36 (s, (Method 2)3H), 2.17 - 2.08(m, 1H), 2.05 - 1.96 (m, 1H), 1.96- 1.86 (m, 2H),1.83 - 1.70 (m,2H)XH NMR (400MHz, DMSO-d6)6 11.00 - 10.69(m, 1H), 7.89 (dd,J = 1.6, 8.0 Hz,1H), 7.79 - 7.66(m, 1H), 7.36 - [M+H]+:.26 (m, 2H), 7.21 427.1,(br d, J = 8.4 Hz, A tR = 0.870 80.0 mg 29% White solid 1H), 6.02 (s, 1H), min5.03 - 4.79 (m, (Method 2)1H), 2.85 (s, 3H),2.12 - 2.02 (m,1H), 2.00 - 1.91(m, 1H), 1.90 - 1.80 (m, 2H), 1.77- 1.64 (m, 2H)XH NMR (400 A [M+H]+: 25 mg 20% White solidMHz, DMSO-d6) 402.1,Atty Dkt No.: EVOM-008WO6 10.74 (brs, 1H), tR = 0.9027.42 - 7.35 (m, min2H), 7.20 - 7.04 (Method 1)(m, 4H), 6.00 (s,1H), 5.05 - 4.79(m, 1H), 2.83 (s,3H), 2.11 - 2.01(m, 1H), 2.00 - 1.90 (m, 1H), 1.89- 1.79 (m, 2H),1.77 - 1.62 (m,2H)XH NMR (400MHz, DMSO-d6)5 10.85 - 10.53(m, 1H), 7.18 (d, J= 8.4 Hz, 2H),7.10 (s, 1H), 7.00 [M+H]+:(d, J = 8.4 Hz, 2H), 416.1,6.02 (s, 1H), 4.99 A tR = 0.930 28 mg 7% White solid -4.78 (m, 1H), min2.83 (s, 3H), 2.27 (Method 2)(s, 3H), 2.08 (m,1H), 2.00 - 1.90(m, 1H), 1.90 - 1.81 (m, 2H), 1.76- 1.70 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.99 - 10.46(m, 1H), 7.26 (t, J [M+H]+:= 7.6 Hz, 1H), 416.17.12 (s, 1H), 6.95 Light yellow A tR = 0.923 65 mg 32%(d, J = 7.6 Hz, 1H), solid min6.93 - 6.86 (m, (Method 1)2H), 6.02 (s, 1H),5.10 - 4.80 (m,1H), 2.84 (s, 3H),2.30 (s, 3H), 2.09Atty Dkt No.: EVOM-008WO- 2.01 (m, 1H),2.00 - 1.91 (m,1H), 1.91 - 1.80(m, 2H), 1.76 - 1.69 (m, 2H)XH NMR (400MHz, DMSO-d6)6 10.81 (brs, 1 H)7.32 - 7.39 (m, 1H) 7.15 - 7.25 (m, [M+H]+:3 H) 6.02 (s, 1 H) 454.04.90 (brs, 1 H) A tR = 0.627 89.0 mg 42% Yellow solid 2.83 (s, 3 H) 2.02 min- 2.11 (m, 1 H) (Method 2)1.92 - 2.00 (m, 1H) 1.80 - 1.91 (m,2 H) 1.64 - 1.76(m, 2 H)XH NMR (400MHz, DMSO-d6)6 10.73 (brs, 1H),7.27 (q, J = 9.6Hz, 1H), 7.11 (s,1H), 6.87 (brdd, J[M+H]+:= 2.0, 9.6 Hz, 1H),451.9,6.01 (s, 1H), 4.91A tR = 0.638 58 mg 19% White solid (s, 1H), 2.83 (s,min3H), 2.25 (d, J =(Method 2)2.0 Hz, 3H), 2.11 - 2.01 (m, 1H), 1.99- 1.90 (m, 1H),1.89 - 1.79 (m,2H), 1.76 - 1.64(m, 2H)XH NMR (400MHz, DMSO-d6) [M+H]+:6 10.69 (brs, 1H), A 456.1, 140 mg 46% White solid 7.52 - 7.41 (m, tR = 0.9192H), 7.01 (s, 1H),Atty Dkt No.: EVOM-008WO6.00 (s, 1H), 4.95 min-4.80 (m, 1H), (Method 1)2.82 (s, 3H), 2.11- 2.01 (m, 1H),1.93 (m, 1H), 1.89- 1.81 (m, 2H),1.77 - 1.64 (m,2H)XH NMR (400MHz, DMSO-de) 610.84 - 10.43 (m,1H), 7.20 (dd, 7 =1.2, 12.0 Hz, 1H),7.16 - 7.07 (m,2H), 7.00 (d, J = [M+H]+:8.4 Hz, 1H), 6.00 434.1,(s, 1H), 5.02 - A tR = 0.935 65 mg 28% White solid.75 (m, 1H), 2.83 min(s, 3H), 2.29 (s, (Method 1)3H), 2.12 - 2.02(m, 1H), 1.99 - 1.90 (m, 1H), 1.89- 1.78 (m, 2H),1.77 - 1.63 (m,2H)XH NMR (400MHz, DMSO-d6)6 10.97 - 10.45(m, 1H), 7.31 (t, J= 7.6 Hz, 1H), [M+H]+:7.13 (s, 1H), 6.91 434.1.0,(dt, J = 2.4, 8.4 A tR = 0.936 34 mg 12% White solid Hz, 1H), 6.84 - min6.77 (m, 1H), 6.01 (Method 1)(s, 1H), 4.92 (brs,1H), 2.84 (s, 3H),2.25 (s, 3H), 2.11- 2.06 (m, 1H),2.00 - 1.92 (m,Atty Dkt No.: EVOM-008WO1H), 1.89 - 1.81(m, 2H), 1.76 - 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)8 = 10.98 - 10.61(m, 1H), 7.62 -.55 (m, 1H), 7.44- 7.36 (m, 1H),7.35 - 7.28 (m, [M+H]+:1H), 7.15 (s, 1H), 444.1,Light yellow 6.00 (s, 1H), 4.98 A tR = 0.883 70 mg 19%solid - 4.83 (m, 1H), min2.83 (s, 3H), 2.46 (Method 1)(s, 3H), 2.11 -.01 (m, 1H), 1.98- 1.90 (m, 1H),1.89 - 1.78 (m,2H), 1.76 - 1.64(m, 2H)XH NMR (400MHz, DMSO-d6)6 = 10.73 (br d, J= 4.4 Hz, 1H),7.53 - 7.43 (m,1H), 7.42 - 7.33 [M+H]+:(m, 1H), 7.07 (s, 456.1,Light yellow 1H), 6.00 (s, 1H), A tR = 0.897 110 mg 21%solid 4.88 (br s, 1H), min2.82 (s, 3H), 2.10 (Method 1)- 2.00 (m, 1H),1.99 - 1.90 (m,1H), 1.89 - 1.80(m, 2H), 1.75 - 1.67 (m, 2H)2H NMR (400[M+H]+:MHz, DMSO-d6) Light yellow A 456.1, 100 mg 29%6 = 10.88 - 10.68 solid tR = 0.910(m, 1H), 7.90 -Atty Dkt No.: EVOM-008WO7.73 (m, 1H), 7.62 min- 7.43 (m, 1H), (Method 1)7.18 (s, 1H), 6.01(s, 1H), 5.00 - 4.82 (m, 1H), 2.84(s, 3H), 2.14 - 2.06 (m, 1H), 2.01- 1.92 (m, 1H),1.92 - 1.81 (m,2H), 1.77 - 1.68(m, 3H)TH NMR (400MHz, DMSO-d6)6 = 10.79 (br dd, J= 1.1, 4.4 Hz, 1H),7.38 - 7.27 (m,1H), 7.25 - 7.18[M+H]+:(m, 1H), 7.13 (br456.1,s, 1H), 6.01 (s, Light yellow A tR = 0.930 100 mg 20%1H), 4.96 - 4.81 solid min(m, 1H), 2.84 (s,(Method 1)3H), 2.12 - 2.02(m, 1H), 2.00 - 1.91 (m, 1H), 1.91- 1.80 (m, 2H),1.77 - 1.66 (m,2H)XH NMR (400MHz, DMSO-d6)5 = 10.93 - 10.63(m, 1H), 7.71 - [M+H]+:7.55 (m, 1H), 7.32 454.1,- 7.22 (m, 2H), Light yellow A tR = 0.943 100 mg 39%7.19 (s, 1H), 6.01 solid min(s, 1H), 4.90 (br d, (Method 1)J = 4.8 Hz, 1H),2.84 (s, 3H), 2.12- 2.03 (m, 1H),2.01 - 1.92 (m,Atty Dkt No.: EVOM-008WO1H), 1.90 - 1.81(m, 2H), 1.77 - 1.66 (m, 2H)XH NMR (400MHz, DMSO-d6)10.84 (br s, 1H),7.27 - 6.94 (m,3H), 6.00 (s, 1H), [M+H]+:5.09 - 4.68 (m, 452.0,1H), 2.83 (s, 3H), A tR = 0.630 12.0 mg 9% White solid 2.21 (s, 3H), 2.12 min- 2.02 (m, 1H), (Method 2)2.00 - 1.91 (m,1H), 1.90 - 1.80(m, 2H), 1.77 - 1.67 (m, 2H)TH NMR (400MHz, CDCI3) 6.30 (t, J = 8.0 Hz,1H), 7.19 (s, 1H),7.03 - 6.92 (m,2H), 6.83 (br d, J [M+H]+:= 8.4 Hz, 1H), 441.2,5.01 - 4.88 (m, A tR = 0.901 38.0 mg 18% White solid 1H), 2.85 (s, 3H), min2.50 (s, 3H), 2.24 (Method 1)- 2.14 (m, 1H),2.13 - 2.04 (m,1H), 2.00 - 1.91(m, 2H), 1.81 - 1.64 (m, 2H)XH NMR (400MHz, DMSO-d6)5 10.86 - 10.53 [M+H]+:(m, 1H), 7.23 (s, 410.2; tR=A 20.4 mg 25.2% White solid 1H), 7.04 (t, J = 0.600 min9.2 Hz, 1H), 6.88 (Method 4)(dd, J = 2.0, 8.4Hz, 2H), 4.90 (brAtty Dkt No.: EVOM-008WOd, J = 3.6 Hz, 1H),4.06 (s, 1H), 2.82(s, 3H), 1.98 -.87 (m, 1H), 1.71- 1.63 (m, 1H),1.63 - 1.46 (m,4H), 1.00 - 0.91(m, 1H), 0.35 - 0.22 (m, 4H).2H NMR (400MHz, DMSO-d6)6 7.22 (s, 1H),7.05-6.99 (m,1H), 6.94 - 6.81(m, 2H), 5.01 - [M+H]+:.84 (m, 1H), 3.98412.2; tR =(s, 1H), 2.80 (s, A 11.7 mg 19.4% White solid 0.619 min3H), 2.00-1.89(Method 4)(m, 1H), 1.67 -.61 (m, 2H), 1.58- 1.48 (m, 3H),1.23 (s, 2H), 0.86(dd, J = 2.4, 6.8Hz, 6H)XH NMR (400MHz, DMSO-d6)6 10.94 - 10.46(m, 1H), 7.22 (s,1H), 7.02 (br t, J =.2 Hz, 1H), 6.92 - [M+H]+:.82 (m, 2H), 5.02 404.2; tR=A 33.7 mg 40.4% Yellow solid -4.78 (m, 1H), 0.495 min4.14 (s, 1H), 2.80 (Method 4)(s, 3H), 1.96 -.85 (m, 1H), 1.63(br dd, J = 7.6,12.0 Hz, 2H), 1.58- 1.46 (m, 5H),Atty Dkt No.: EVOM-008WO0.88 (brt, J = 7.2Hz, 3H).XH NMR (400MHz, DMSO-d6)5 = 8.41 (s, 1H),7.44 (brd, J = 6.8Hz, 2H), 7.20 - [M+H]+:.04 (m, 1H), 6.60365.2; tR =(s, 1H), 5.01 - B 10.0 mg 9.2% White solid 0.445 min.75 (m, 1H), 3.63(Method 2)(s, 3H), 2.81 (s,3H), 1.99 - 1.89(m, 1H), 1.78 -.63 (m, 2H), 1.62- 1.50 (m, 3H)XH NMR (400MHz, DMSO-d6)6 = 8.38 (s, 1H),7.63 - 7.57 (m,1H), 7.56 - 7.49(m, 1H), 7.46 -.37 (m, 1H), 7.10 [M+H]+:(dt, J = 2.0, 8.8 347.2; tR =B 10.0 mg 9.2% White solid Hz, 1H), 6.53 (s, 0.427 min1H), 4.96 - 4.80 (Method 2)(m, 1H), 3.45 (brs, 3H), 2.81 (s,3H), 2.00 - 1.87(m, 1H), 1.77 -.64 (m, 2H), 1.62- 1.50 (m, 3H)XH NMR (400MHz, DMSO-d6)6 = 8.4 (s, 1H), [M+H]+:7.44 (br d, J = 6.8 419.1; tR =B 30.0 mg 30% White solid Hz, 2H), 7.13 (br 0.534 mint, J = 9.3 Hz, 1H), (Method 2)6.62 (s, 1H), 6.01(s, 1H), 4.98 -Atty Dkt No.: EVOM-008WO.83 (m, 1H), 3.64(s, 3H), 2.85 (s,3H), 2.14 - 2.03(m, 1H), 1.99 -.92 (m, 1H), 1.91- 1.80 (m, 2H),1.78 - 1.67 (m,2H)XH NMR (400MHz, DMSO-d6)6 = 8.54 (s, 1H),7.66 (d, J = 7.6Hz, 1H), 7.59 (brd, J = 9.6 Hz, 1H),7.53 - 7.45 (m,1H), 7.16 (dt, J =[M+H]+:2.4, 8.8 Hz, 1H),401.2; tR =6.60 (s, 1H), 6.07 B 38.0 mg 38% White solid 0506 min(s, 1H), 5.06 - (Method 2).91 (m, 1H), 3.70(s, 3H), 2.91 (s,3H), 2.19 - 2.09(m, 1H), 2.06 -.99 (m, 1H), 1.98- 1.88 (m, 2H),1.87 - 1.69 (m,2H)XH NMR (400MHz, DMSO-d6)6 8.40 (s, 1H),7.92 (dt, J = 4.0,8.0 Hz, 1H), 7.30 [M+H]+:(ddd, J = 4.0, 8.0, 365.2; tR=B 20.0 mg 27.3% White solid 12.0 Hz, 1H), 7.13 0.439 min(dt, J = 4.0, 8.0 (Method 2)Hz, 1H), 6.38 -.32 (m, 1H), 4.95- 4.81 (m, 1H),3.64 (s, 3H), 3.61Atty Dkt No.: EVOM-008WO(s, 1H), 2.81 (s,3H), 1.99 - 1.88(m, 1H), 1.74 - 1.64 (m, 2H), 1.63- 1.52 (m, 3H),1.26 (s, 3H)TH NMR (400MHz, DMSO-d6)68.54 - 8.46 (m,1H), 7.99 - 7.85(m, 1H), 7.36 - 7.25 (m, 1H), 7.19-7.08 (m, 1H),[M+H]+:6.37 (d, J = 4.0419.2; tR= Light yellow Hz, 1H), 6.01 (s, B 25.0 mg 39.7%0.523 min solid 1H), 4.99 - 4.85(Method 2)(m, 1H), 3.65 (s,3H), 2.85 (s, 3H),2.12 - 2.02 (m,1H), 1.99 - 1.92(m, 1H), 1.91 - 1.84 (m, 2H), 1.77- 1.67 (m, 2H)XH NMR (400MHz, DMSO-d6)57.43 - 7.38 (m,1H), 7.33 (s, 1H),[M+H]+:6.99 (d, J = 9.6409.1; tR =Hz, 1H), 4.91 (t, J A 20.0 mg 17.7% White solid 0.509 min= 7.6 Hz, 1H),(Method 2)2.81 (s, 3H), 1.94- 1.91 (m, 1H),1.70 - 1.52 (m,5H), 1.25 (s, 3H)XH NMR (400 [M+H]+:MHz, DMSO-d6) 391.1; tR =6 10.77 (br.s, 1H), A 8.9 mg 15.2% Yellow solid 0.495 min7.77 - 7.71 (m, (Method 2)1H), 7.32 (s, 1H),Atty Dkt No.: EVOM-008WO7.29 - 7.25 (m,1H), 7.04 (d, J =7.6 Hz, 1H), 4.90(br.s, 1H), 4.34 (s,1H), 2.80 (s, 3H),1.92 - 1.90 (m,1H), 1.70 - 1.52(m, 5H), 1.25 (s,3H)2H NMR (400MHz, DMSO-d6)6 10.85 (br.s, 1H),7.28 (s, 1H), 7.26(s, 1H), 7.23 (s, [M+H]+:1H), 4.92 - 4.91 409.3; tR =A 25.0 mg 51.7% White solid (m, 1H), 4.33 (s, 0.540 min1H), 2.80 (s, 3H), (Method 2)1.91 - 1.90 (m,1H), 1.69 - 1.52(m, 5H), 1.25 (s,3H)TH NMR (400MHz, DMSO-d6)6 10.81 (br.s, 1H),8.02 - 7.98 (m,1H), 7.31 (s, 1H),7.22 - 7.17 (m, [M+H]+:1H),7. O9 (d, J = 391.1; tR =A 10.6 mg 11.9% Yellow solid 10.0 Hz, 1H), 4.91 0.480 min(br.s, 1H), 4.34 (s, (Method 2)1H), 2.81 (s, 3H),1.91 - 1.88 (m,1H), 1.70 - 1.52(m, 5H), 1.25 (s,3H)2H NMR (400MHz, DMSO-d6) A [M+H]+:427. 12.1 mg 17.7% White solid 5 11.07- 10.61 1; tR= 0.552(m, 1H), 7.84 (brAtty Dkt No.: EVOM-008WOt, J = 6.0 Hz, 1H), min7.22 (s, 1H), 5.00 (Method 4)-4.83 (m, 1H),4.34 (s, 1H), 2.80(s, 3H), 1.95 -.86 (m, 1H), 1.71- 1.62 (m, 2H),1.62 - 1.50 (m,3H), 1.26 (s, 3H).2H NMR (400MHz, DMSO-d6)610.64 (br, 1H),7.91-7.86 (m,1H), 7.07 (s, 1H), [M+H]+:4.86 (br, 1H), 427.1; tR= Off-white A 30.0 mg 39.7%4.33 (s, 1H), 2.78 0.623 min solid (s, 3H), 1.90 - (Method 1).68 (m, 1H), 1.66- 1.63 (m, 2H),1.57 - 1.50 (m,3H), 1.25 (s, 3H).TH NMR (400MHz, DMSO-d6)67.30 (s, 2H),[M+H]+:4.93-4.89 (m,427.1; tR=1H), 4.37 (s, 1H), A 26.0 mg 35.9% Yellow solid 0.537 min2.80 (s, 3H), 1.93(Method 4)- 1.88 (m, 1H),1.67 - 1.55 (m,5H), 1.25 (s, 3H)XH NMR (400MHz, CDCI3) 6 =7.42 - 7.34 (m, [M+H]+:1H), 7.04 (s, 1H), 409.1, tR = Off-white 7.02 - 6.94 (m, A 40.0 mg 33.4%0.513 min solid 1H), 4.93 - 4.79 (Method 2)(m, 1H), 2.91 (s,3H), 2.22 - 2.15(m, 1H), 1.96 (brAtty Dkt No.: EVOM-008WOd, J = 6.0 Hz, 1H),1.85 - 1.80 (m,2H), 1.70 (brdd, J= 2.4, 13.4 Hz,2H), 1.43 (s, 3H)XH NMR (400MHz, CDCI3) 6 =7.39 - 7.32 (m,1H), 7.13 - 7.03(m, 2H), 4.94 - [M+H]+:.79 (m, 1H), 2.91409.1; tR = Off-white (s, 3H), 2.24 - A 27.0 mg 22%0.503 min solid.14 (m, 1H), 1.97(Method 2)(br dd, J = 7.2,12.8 Hz, 1H), 1.88- 1.77 (m, 2H),1.73 - 1.64 (m,2H), 1.43 (s, 3H)XH NMR (400MHz, DMSO-d6)10.73 (brs, 1H),8.02 - 7.91 (m,1H), 7.64 (brd, J= 4.8 Hz, 1H), [M+H]+:1. T1 (s, 1H), 4.97 409.1; tR =A 20.0 mg 24.8% White solid -4.77 (m, 1H), 0.522 min4.34 (s, 1H), 2.81 (Method 4)(s, 3H), 1.97 -.83 (m, 1H), 1.73- 1.62 (m, 2H),1.61 - 1.50 (m,3H), 1.26 (s, 3H).XH NMR (400MHz, DMSO-d6) [M+H]+:6 10.94 - 10.52 409.2; tR =(m, 1H), 7.74 (td, A 23.7 mg 19.4% White solid 0.517 minJ = 3.6, 7.2 Hz, (Method 4)1H), 7.60 - 7.49(m, 1H), 7.26 (s,Atty Dkt No.: EVOM-008WO1H), 5.05 - 4.74(m, 1H), 4.34 (s,1H), 2.80 (s, 3H),1.96 - 1.85 (m,1H), 1.72 - 1.62(m, 2H), 1.61 -.51 (m, 3H), 1.26(s, 3H)XH NMR (400MHz, DMSO-d6)6 11.07- 10.61(m, 1H), 7.84 (brt, J = 6.0 Hz, 1H),[M+H]+:427.7.22 (s, 1H), 5.001; tR= 0.552- 4.83 (m, 1H), A 12.1 mg 17.7% White solid min4.34 (s, 1H), 2.80(Method 4)(s, 3H), 1.95 -.86 (m, 1H), 1.71- 1.62 (m, 2H),1.62 - 1.50 (m,3H), 1.26 (s, 3H).TH NMR (400MHz, DMSO-d6)5 7.73 - 7.79 (m,1 H), 7.55 (br d, J= 7.8 Hz, 2 H),7.35 - 7.42 (m, 2H), 7.23 - 7.29 [M+H]+:(m, 1 H), 5.85 - 386.2 tR=C 11.0 mg 27.5% White solid 6.24 (m, 1 H), 0.553 min5.00 (br s, 1 H), (Method 2)2.86 (s, 3 H), 2.04- 2.10 (m, 1 H),1.94 - 2.01 (m, 1H), 1.84 - 1.91(m, 2 H), 1.71 (brd, J = 5.2 Hz, 2 H)Atty Dkt No.: EVOM-008WOXH NMR (400MHz, DMSO-d6)5 7.78 - 7.70 (m,1H), 7.66 - 7.56(m, 1H), 7.31 - 7.14 (m, 1H), 7.07- 7.01 (m, 1H),6.83 (dt, J = 2.4, [M+H]+:8.4 Hz, 1H), 5.38 - 434.1; tR= Off-white C 9.6 mg 19.1%5.26 (m, 1H), 5.08 0.546 min solid - 4.91 (m, 1H), (Method 2)3.90 (s, 3H), 2.86(s, 3H), 2.12 - 2.03 (m, 1H), 2.01- 1.95 (m, 2H),1.91 - 1.82 (m,2H), 1.77 - 1.71(m, 1H).XH NMR (400MHz, DMSO-d6)6 7.86 - 7.75 (m,1H), 7.67 - 7.57(m, 1H), 7.33 - 7.22 (m, 1H), 7.11(d, J = 7.6 Hz, 1H),7.04 - 6.94 (m, [M+H]+:1H), 6.12 - 5.94 416.2; tR =C 6.0 mg 11.6% White solid (m, 1H), 5.09 - 0.537 min4.88 (m, 1H), 3.89 (Method 2)(s, 3H), 2.86 (s,3H), 2.12 - 2.03(m, 1H), 2.01 - 1.93 (m, 1H), 1.91- 1.85 (m, 2H),1.79 - 1.69 (m,2H).XH NMR (400 [M+H]+:MHz, DMSO-d6) C found 7.00 mg 11.1% White solid5 7.98 - 7.84 (m, 434.2; tR =Atty Dkt No.: EVOM-008WO1H), 7.60 - 7.47 0.560min(m, 1H), 7.17 - (Method 2)7.02 (m, 3H), 6.08- 6.01 (m, 1H),5.02 - 4.90 (m,1H), 3.92 - 3.85(m, 5H), 2.85 (s,4H), 2.12 - 2.02(m, 1H), 2.00 - 1.91 (m, 1H), 1.90- 1.83 (m, 2H),1.77 - 1.66 (m,2H)XH NMR (400MHz, DMSO-d6)6 10.91 (br s, 1H),7.86 (d, J = 7.6Hz, 1H), 7.75 - 7.69 (m, 1H), 7.64[M+H]+:- 7.59 (m, 1H),454.1 tR= Off-white 7.57 (d, J = 7.6 C 12.3 mg 26.5%0.593 min solid Hz, 1H), 6.03 (s,(Method 2)1H), 5.01 - 4.87(m, 1H), 2.87 (s,3H), 2.12 - 1.93(m, 3H), 1.92 - 1.84 (m, 2H), 1.77- 1.67 (m, 2H).XH NMR (400MHz, DMSO-d6)6 7.90 (br s, 1H),7.53 (d, J = 6.4 [M+H]+:Hz, 1H), 7.20 - 434.1 tR=7.12 (m, 1H), 6.03 C 5.0 mg 50% White solid 0.557 min(m, 1H), 5.02 - (Method 2)4.97 (m, 1H), 3.84(s, 3H), 2.86 (s,3H),2.02 - 2.00(m, 1H), 1.98 -Atty Dkt No.: EVOM-008WO1.97 (m, 2H), 1.89- 1.88 (m,2H), 1.73 - 1.72(m, 2H).XH NMR (400MHz, CDCI3) 6 =7.42 (dd, J = 3.2,5.6 Hz, 1H), 7.25(dd, J = 3.2, 4.4Hz, 1H), 7.11 (s,1H), 4.84 (brdd, J [M+H]+:= 3.6, 6.0 Hz, 1H), 425.1; tR = Off-white A 15.0 mg 23.8%2.97 (s, 3H), 2.16 0.563 min solid (br dd, J = 6.8, (Method 2)12.8 Hz, 1H), 2.00(br dd, J = 6.8,12.8 Hz, 1H), 1.88- 1.82 (m, 2H),1.77 - 1.66 (m,2H), 1.42 (s, 3H)XH NMR (400MHz, CDCI3) 6 =7.59 (d, J = 8.4Hz, 1H), 7.17 (dd,J = 1.6, 8.4 Hz,1H), 7.13 (s, 1H), [M+H]+:7.08 (d, J = 1.6 461.1; tR = Off-white A 60.0 mg 40.9%Hz, 1H), 5.10 - 0.584 min solid 4.98 (m, 1H), 2.94 (Method 2)(s, 3H), 2.33 - 2.14 (m, 2H), 2.08- 2.01 (m, 2H),1.89 - 1.75 (m,2H)XH NMR (400 [M+H]+:MHz, CDCI3) 6 = 461.0; tR = Off-white 7.66 - 7.60 (m, A 50.0 mg 34.1%0.587 min solid 1H), 7.19 (d, J = (Method 2)2.4 Hz, 1H), 7.10 -Atty Dkt No.: EVOM-008WO7.04 (m, 2H), 5.09- 4.98 (m, 1H),2.94 (s, 3H), 2.33- 2.23 (m, 1H),2.23 - 2.13 (m,1H), 2.04 (d, J =9.2 Hz, 2H), 1.88 - 1.76 (m, 2H)XH NMR (400MHz, CDCI3) 6 =7.40 - 7.35 (m,1H), 7.31 (t, J =2.0 Hz, 1H), 7.24(dd, J = 1.2, 2.4[M+H]+:Hz, 1H), 7.07 (s,461.0; tR = Off-white 1H), 5.08 - 4.97 A 50.0 mg 34.1%0.614 min solid (m, 1H), 2.94 (s,(Method 2)3H), 2.33 - 2.22(m, 1H), 2.22 - 2.12 (m, 1H), 2.07- 2.01 (m, 2H),1.89 - 1.75 (m,2H)XH NMR (400MHz, CDCI3) 6 =7.43 (dd, J = 3.2,5.6 Hz, 1H), 7.27 - 7.23 (m, 1H), 7.13[M+H]+:(s, 1H), 4.92 - 479.1; tR = Off-white 4.74 (m, 1H), 3.00 A 33.0 mg 46.4%0.625 min solid (s, 3H), 2.31 - (Method 2)2.27 (m, 1H), 2.19- 2.11 (m, 2H),2.08 - 2.01 (m,1H), 1.96 - 1.87(m, 2H)XH NMR (400[M+H]+:MHz, DMSO-d6)6 A 17.0 mg 19.1% Yellow solid 479.1; tR == 11.2-10.7 (m,Atty Dkt No.: EVOM-008WO1H), 8.19 (d, J = 0.702 min8.8 Hz, 1H), 7.46 (Method 1)(d, J = 5.6 Hz, 1H),7.30 (s, 1H), 6.01(s, 1H), 4.99-4.90(m, 1H), 2.84 (s,3H), 2.08-1.95(m, 2H), 1.88- 1.84 (m, 2H),1.74-1.69 (m,2H).TH NMR (400MHz, DMSO-d6)6= 11.1-10.4 (m,1H), 8.19 (d, J =8.8 Hz, 1H), 7.46(d, J = 6.0 Hz, 1H), [M+H]+;7.29 (s, 1H), 4.89 425.1; tR =A 4.0 mg 5.08% Yellow solid (br, 1H), 4.34 (s, 0.635 min1H), 2.80 (s, 3H), (Method 1)1.92-1.90 (m, 2H), 1.70-1.65 (m,2H), 1.64-1.55(m, 2H), 1.25- 1.23 (m, 3H).XH NMR (400MHz, DMSO-d6)6 = 8.15 - 8.29(m, 1 H), 7.04 - [M+H]+:7.15 (m, 1 H),427.1; tR = Light yellow 4.81 -4.96 (m, 1 A 25.0 mg 27.7%0.533 min solid H), 2.79 (s, 3 H),(Method 4)1.85 - 1.98 (m, 1H), 1.50 - 1.70(m, 5 H), 1.25 (s,3 H)XH NMR (400[M+H]+:MHz, DMSO-d6) A 8.0 mg 8.0% White solid 409.2; tR =6 10.88 - 10.66Atty Dkt No.: EVOM-008WO(m, 1H), 8.32 - 0.511 min.21 (m, 1H), 7.48 (Method 4)- 7.38 (m, 1H),7.29 (s, 1H), 4.95-4.84 (m, 1H),4.33 (s, 1H), 2.84- 2.77 (m, 3H),1.98 - 1.84 (m,1H), 1.72 (s, 2H),1.61 - 1.51 (m,3H), 1.29 - 1.24(m, 3H)XH NMR (400MHz, DMSO-d6)5 10.95 - 10.62(m, 1H), 7.82 (q, J= 9.6 Hz, 1H),[M+H]+:7.31 (s, 1H), 7.10409.2; tR =-7.00 (m, 1H), A 17.8 mg 23.0% White solid 0.618min5.00 - 4.79 (m,(Method 1)1H), 4.34 (s, 1H),2.81 (s, 3H), 1.98- 1.85 (m, 1H),1.72 - 1.49 (m,5H), 1.26 (s, 3H)XH NMR (400MHz, DMSO-d6)6 10.78 - 10.72(m, 1H), 7.84 -.74 (m, 1H), 7.29(s, 1H), 7.24 - [M+H]+:.21 (m, 1H), 4.90 425.1; tR =A 50.0 mg 50.0% White solid -4.87 (m, 1H), 0.644min4.33 (s, 1H), 2.80 (Method 1)(s, 3H), 1.93 - 1.85 (m, 1H), 1.70- 1.62 (m, 2H),1.59 - 1.52 (m,3H), 1.25 (s, 3H)Atty Dkt No.: EVOM-008WOXH NMR (400MHz, DMSO-d6)5 11.01 - 10.84(m, 1H), 7.79 -.75 (m, 1H), 7.31(s, 1H), 7.25 - [M+H]+:.22 (m, 1H), 6.01479.1; tR =(s, 1H), 4.92 - A 50.0 mg 50.0% White solid 0.71 min.90 (m, 1H), 2.84(Method 1)(s, 3H), 2.05 -.07 (m, 1H), 1.95- 1.86 (m, 1H),1.84 - 1.75 (m,2H), 1.75 - 1.69(s, 2H)XH NMR (400MHz, CD3CN) 6 =7.42 - 7.30 (m,1H), 7.03 (s, 1H),6.97 - 6.82 (m,3H), 4.98 - 4.82(m, 1H), 2.85 (s, [M+H]+:3H), 2.06 - 2.00 392.2; tR = Off-white D 5.00 mg 13.4%(m, 1H), 1.79 - 0.574 min solid.71 (m, 1H), 1.70 (Method 2)- 1.58 (m, 3H),1.54 (ddt, J = 1.6,4.0, 8.4 Hz, 1H),1.07 - 0.96 (m,1H), 0.40 - 0.28(m, 4H)XH NMR (400MHz, CDCI3) 6 =.59 (t, J = 8.0 Hz, [M+H]+:1H), 7.08 (br s, 417.2; tR = Off-white D 10.0 mg 14.5%1H), 7.00 - 6.88 0.556 min solid (m, 2H), 4.90 - (Method 2).78 (m, 1H), 2.93(s, 3H), 2.21 -Atty Dkt No.: EVOM-008WO.14 (m, 1H), 1.90- 1.81 (m, 3H),1.31 - 1.24 (m,2H), 1.16 - 1.07(m, 1H), 0.52 -.45 (m, 2H), 0.35(br d, J = 1.6 Hz,2H)XH NMR (400MHz, DMSO-d6)6= 7.24-7.18 (m,2H), 7.15-7.10(m, 3H), 4.91- [M+H]+:.87 (m, 1H), 4.06392.2; tR =(s, 1H), 2.79 (s, D 4.00 mg 21.4% Yellow solid 0.569 min3H), 1.93-1.90(Method 2)(m, 2H), 1.67- 1.49 (m, 5H),0.95-0.92 (m,1H), 0.30-0.24(m, 4H).TH NMR (400MHz, DMSO-d6)6 7.74-7.72 (m,1H), 7.54-7.51(m, 2H), 7.17 (s,1H), 4.98 (br, 1H), [M+H]+:4.06 (s, 1H), 2.80 417.3; tR=D 7.00 mg 26.3% Yellow solid (s, 3H), 1.95-1.90 0.652 min(m, 1H), 1.59- (Method 1)1.49 (m, 5H),1.34-1.29 (m,1H), 0.94-0.93(m, 1H), 0.30- 0.24 (m, 4H).2H NMR (400MHz, DMSO-d6) D [M+H]+: 10.0 mg 36.6% White solid 5 10.71 (dt, J = 417.2; tR=2.6, 6.1 Hz, 1H),Atty Dkt No.: EVOM-008WO7.64 (brd, J = 8.0 0.544 minHz, 1H), 7.50 (br (Method 4)s, 1H), 7.42 (brd,J = 9.6 Hz, 1H),7.24 (s, 1H), 4.96-4.81 (m, 1H),4.05 (s, 1H), 2.81(brs, 3H), 1.96- 1.88 (m, 1H),1.70-1.62 (m,1H), 1.62-1.48(m, 4H), 0.99- 0.91 (m, 1H),0.88-0.81 (m,1H), 0.33-0.22(m, 4H).TH NMR (400MHz, DMSO-d6)6 11.07-10.51 (m,1H), 7.29 (s, 1H),7.25 (d, J = 9.5Hz, 2H), 5.05-4.78(m, 1H), 4.06 (s, [M+H]+:1H), 2.82 (s, 3H), 435.1; tR=D 8.60 mg 30.7% White solid 1.95-1.86 (m, 0.581 min1H), 1.70-1.62 (Method 2)(m, 1H), 1.60- 1.52 (m, 3H),1.51-1.44 (m,1H), 0.99-0.91(m, 1H), 0.33- 0.23 (m, 4H).XH NMR (400MHz, DMSO-d6) [M+H]+:6 = 10.71 (brdd, J 435.2; tR == 2.8, 4.4 Hz, 1H), D 12.0 mg 34.9% White solid 0.58 min7.76 (ddd, J = 3.2, (Method 2)6.8, 11.2 Hz, 1H),7.61 (brs, 1H),Atty Dkt No.: EVOM-008WO7.21 (s, 1H), 4.99-.82 (m, 1H), 4.04(s, 1H), 2.81 (s,3H), 2.06-1.84(m, 1H), 1.72- 1.62 (m, 1H),1.60-1.47 (m,4H), 0.99-0.91(m, 1H), 0.33- 0.22 (m, 4H).XH NMR (400MHz, DMSO-d6)5 = 10.74 (br s, 1H), 7.09 -7.24(m, 3 H), 4.82 - 4.99 (m, 1 H),4.04 - 4.13 (m, 1 [M+H]+:H), 2.76 - 2.85 428.2; tR = Light yellow D 8.00 mg 28.1%(m, 3 H), 1.86- 0.599 min solid 1.96 (m, 1 H), (Method 2)1.62 - 1.72 (m, 1H), 1.46 - 1.61(m, 4 H), 0.90 - 0.99 (m, 1 H),0.21 - 0.32 (m, 4H).XH NMR (400MHz, DMSO-d6)6 = 10.68-10.50(m, 1H), 7.31-.24 (m, 1H), 7.20 [M+H]+:(br s, 1H), 7.16 (s, 410.1; tR=1H), 6.98-6.92 D 8.40 mg 31.8% White solid 0.514 min(m, 1H), 4.96- (Method 4).79 (m, 1H), 4.05(s, 1H), 2.81 (s,3H), 1.93-1.87(m, 1H), 1.68 -1.63 (m, 1H),Atty Dkt No.: EVOM-008WO1.59-1.51 (m,4H), 0.97-0.93(m, 1H), 0.31- 0.24 (m, 4H).XH NMR (400MHz, DMSO-d6)6 10.93 - 10.60(m, 1H), 8.05 (dd,J = 2.0, 11.2 Hz,1H), 7.69 (dd, J =1.2, 8.8 Hz, 1H),[M+H]+:7.31 (t, J = 8.4 Hz,391.1; tR =1H), 7.21 (s, 1H), A 12.0 mg 19.8% White solid 0.483 min5.00 - 4.79 (m,(Method 2)1H), 4.34 (s, 1H),2.80 (s, 3H), 1.95- 1.87 (m, 1H),1.64 (brs, 2H),1.56 (brd, J =10.8 Hz, 3H), 1.26(s, 3H).TH NMR (400MHz, DMSO-d6)6 10.90 - 10.53(m, 1H), 7.92 -.80 (m, 2H), 7.30-7.20 (m, 3H), [M+H]+:5.04 - 4.71 (m, 373.1; tR =A 8.0 mg 13.8% White solid 1H), 4.33 (s, 1H), 0.474 min2.80 (s, 3H), 1.95 (Method 2)- 1.85 (m, 1H),1.71 - 1.61 (m,2H), 1.61 - 1.50(m, 3H), 1.25 (s,3H).2H NMR (400MHz, DMSO-d6) A [M+H]+: 6.0 mg 10.5% White solid 6 10.89 - 10.66 391.1; tR =(m, 1H), 7.95 (dd,Atty Dkt No.: EVOM-008WOJ = 8.0, 8.8 Hz, 0.497 min1H), 7.33 (dd, J = (Method 2)2.4, 11.2 Hz, 1H),7.11 (s, 1H), 7.13(dd, J = 2.4, 8.8Hz, 1H), 5.03 -.82 (m, 1H), 4.35(s, 1H), 2.81 (s,3H), 1.97 - 1.86(m, 1H), 1.71 -.64 (m, 2H), 1.61- 1.53 (m, 3H),1.27 (s, 3H)XH NMR (400MHz, DMSO-d6)5 10.70 - 10.52(m, 1H), 7.52 -.43 (m, 1H), 7.42[M+H]+:- 7.33 (m, 1H),402.2; tR= Off-white 7.05 (s, 1H), 4.94 A 27.6 mg 35.5%0.542 min solid - 4.77 (m, 1H),(Method 2)4.32 (s, 1H), 2.78(s, 3H), 1.96 -.85 (m, 1H), 1.69- 1.48 (m, 5H),1.25 (s, 3H).XH NMR (400MHz, DMSO-d6)10.72 (br s, 1H),7.67 - 7.62 (m,1H), 7.51 (br s, [M+H]+:1H), 7.43 (br d, J 391.3; tR== 10.0 Hz, 1H), A 31.5 mg 41.7% White solid 0.517 min7.24 (s, 1H), 4.96 (Method 2)- 4.81 (m, 1H),4.34 (s, 1H), 2.81(s, 3H), 1.96 -.86 (m, 1H), 1.71- 1.61 (m, 2H),Atty Dkt No.: EVOM-008WO1.61 - 1.50 (m,3H), 1.26 (s, 3H).XH NMR (400MHz, DMSO-d6)6 10.79 (br s, 1H),8.00 (dd, J = 3.2,8.0 Hz, 1H), 7.68- 7.61 (m, 1H),M+H]+:7.35 - 7.29 (m,391.3; tR= Off-white 2H), 5.02 - 4.87 A 22.4 mg 29.4%0.499 min solid (m, 1H), 4.40 (s,(Method 2)1H), 2.87 (s, 3H),2.04 - 1.93 (m,1H), 1.77 - 1.68(m, 2H), 1.68 - 1.58 (m, 3H), 1.32(s, 3H).XH NMR (400MHz, Methanol- d4) 6 7.51 - 7.42(m, 2H), 7.41 - 7.32 (m, 1H), 7.06[M+H]+:(br s, 1H), 4.64 - 391.3; tR =4.61 (m, 1H), 4.60 A 8.3 mg 27.6% White solid 0.511 min(br s, 1H), 2.91 (s,(Method 2)3H), 2.15 - 2.01(m, 1H), 1.94 - 1.79 (m, 2H), 1.78- 1.69 (m, 3H),1.37 (s, 4H)XH NMR (400MHz, DMSO-d6)6 10.84 - 10.53 [M+H]+:(m, 1H), 7.69 - 416.3; tR =7.58 (m, 1H), 7.51 A 19.4 mg 30.1% White solid 0.579 min(br d, J = 7.2 Hz, (Method 2)1H), 7.46 - 7.34(m, 2H), 7.22 (s,1H), 4.99 - 4.73Atty Dkt No.: EVOM-008WO(m, 1H), 4.33 (s,1H), 2.81 (br s,3H), 1.97 - 1.84(m, 1H), 1.73 - 1.62 (m, 2H), 1.62- 1.50 (m, 3H),1.26 (s, 3H)XH NMR (400MHz, Methanol- d4) 5 7.59 - 7.37(m, 4H), 7.07 (br [M+H]+:s, 1H), 4.60 (br s, 373.3; tR =A 12.4 mg 41.3% White solid 1H), 2.91 (s, 3H), 0.487 min2.17 - 2.04 (m, (Method 4)1H), 1.92 - 1.65(m, 6H), 1.37 (s,3H)XH NMR (400MHz, DMSO-d6)6 10.58 (br s, 1H),7.24 - 7.18 (m,2H), 7.17 - 7.09 [M+H]+:(m, 3H), 4.87 (br 366.1; tR =A 7.0 mg 10.9% White solid s, 1H), 2.79 (s, 0.506 min3H), 1.98 - 1.82 (Method 2)(m, 2H), 1.64 (brs, 2H), 1.58 - 1.53(m, 2H), 1.25 (s,3H)XH NMR (400MHz, DMSO-d6)6 10.66 (br d, J =1.6 Hz, 1H), 7.37 - [M+H]+:.26 (m, 1H), 7.22 402.1; tR =A 30.0 mg 44% White solid - 7.16 (m, 1H), 0.547 min7.15 - 7.05 (m, (Method 2)1H), 4.88 (br d, J= 8.0 Hz, 1H),4.34 (s, 1H), 2.79Atty Dkt No.: EVOM-008WO(s, 3H), 1.90 (brdd, J = 8.0, 12.0Hz, 1H), 1.70 -.61 (m, 2H), 1.61- 1.51 (m, 3H),1.25 (s, 3H)TH NMR (400MHz, DMSO-d6)10.65 (brs, 1H),.45 (brd, J = 8.8Hz, 1H), 7.34 -.23 (m, 1H), 7.21-7.12 (m, 1H),[M+H]+:7.01 - 6.89 (m,384.1; tR = Light yellow 1H), 4.94 - 4.82 A 13.0 mg 16%0.534 min solid (m, 1H), 4.39 - (Method 2).28 (m, 1H), 2.80(brs, 3H), 1.95 -.87 (m, 2H), 1.66- 1.63 (m, 2H),1.57 - 1.54 (m,2H), 1.23 (br s,3H)XH NMR (400MHz, DMSO-d6)5 10.68 - 10.49(m, 1H), 7.51 -.40 (m, 2H), 6.99(s, 1H), 4.97 - [M+H]+:.69 (m, 1H), 4.32 402.1; tR =A 18.7 mg 26.7% White solid (s, 1H), 2.89 - 0.529 min.70 (m, 3H), 1.96 (Method 2)- 1.85 (m, 1H),1.70 - 1.62 (m,2H), 1.61 - 1.49(m, 3H), 1.25 (s,3H)1H NMR (400 A [M+H]+: 19.6 mg 28% White solidMHz, DMSO-d6) 402.1; tR =Atty Dkt No.: EVOM-008WO6 10.70 (br s, 1H), 0.565 min7.23 - 7.13 (m, (Method 2)3H), 5.02 - 4.80(m, 1H), 4.33 (s,1H), 2.80 (s, 3H),1.94 - 1.85 (m,1H), 1.71 - 1.62(m, 2H), 1.61 - 1.50 (m, 3H), 1.26(s, 3H)XH NMR (400MHz, DMSO-d6)6 = 10.65 (br s,1H), 7.80 (dt, J =80, 12.0 Hz, 1H),7.55 - 7.44 (m,[M+H]+:1H), 7.16 (s, 1H),402.1; tR =4.96 - 4.79 (m, A 12.8 mg 17.9% White solid 0.534 min1H), 4.33 (s, 1H),(Method 2)2.86 - 2.75 (m,3H), 1.95 - 1.82(m, 1H), 1.72 - 1.62 (m, 2H), 1.61- 1.49 (m, 3H),1.25 (s, 3H)XH NMR (400MHz, DMSO-d6)6 10.77 - 10.53(m, 1H), 8.11 (brs, 1H), 7.83 - 7.74(m, 1H), 7.26 - [M+H]+:.15 (m, 2H), 5.01 367.1; tR =A 22.0 mg 22% White solid - 4.74 (m, 1H), 0.429 min4.33 (s, 1H), 2.80 (Method 2)(s, 3H), 1.98 - 1.88 (m, 1H), 1.71- 1.63 (m, 2H),1.60 - 1.52 (m,3H), 1.25 (s, 3H)Atty Dkt No.: EVOM-008WOXH NMR (400MHz, DMSO-d6)6 10.70 (brs, 1H),8.42 - 8.35 (m,2H), 7.59 (brd, J= 12.0 Hz, 1H), [M+H]+:7.25 (s, 1H), 4.88 367.1; tR = Light yellow A 25.0 mg 25%(br s, 1H), 4.33 (s, 0.417 min solid 1H), 2.80 (s, 3H), (Method 2)1.97 - 1.85 (m,1H), 1.65 (brd, J= 8.0 Hz, 2H),1.61 - 1.49 (m,3H), 1.26 (s, 3H)XH NMR (400MHz, DMSO-d6)6 11.01 - 10.53(m, 1H), 8.18 (dd,J = 4.0, 8.0 Hz,1H), 7.29 (d, J =4.0 Hz, 1H), 7.09(brd, J = 8.0 Hz, [M+H]+:1H), 6.94 - 6.83 367.1; tR = Light yellow A 28.0 mg 28%(m, 1H), 5.02 - 0.547 min solid.76 (m, 1H), 4.34 (Method 2)(s, 1H), 2.81 (s,3H), 2.01 - 1.84(m, 1H), 1.71 - 1.63 (m, 2H), 1.61- 1.51 (m, 3H),1.26 (d, J = 4.0Hz, 3H)XH NMR (400MHz, CDCI3) 6 = [M+H]+:7.50 (s, 1H), 6.78 420.1; tR = Off-white (brd, J = 6.0 Hz, A 5.0 mg 6.3%0.567 min solid 2H), 6.73 - 6.64 (Method 2)(m, 1H), 6.01 (s,1H), 5.00 (quin, JAtty Dkt No.: EVOM-008WO= 8.8 Hz, 1H),3.91 (s, 2H), 2.91(s, 3H), 2.71 (brs,1H), 2.25 (dq, J =5.2, 9.2 Hz, 1H),2.19 - 2.11 (m,1H), 1.99 (s, 1H),1.88 - 1.70 (m,2H)2H NMR (400MHz, CDCI3) 6 =7.69 (brs, 1H),6.81 - 6.76 (m,2H), 6.72 - 6.64(m, 1H), 6.02 (d, J= 2.0 Hz, 1H), [M+H]+;4.87 - 4.74 (m, 366.2; tR = Off-white A 4.0 mg 9.2%1H), 3.91 (br s, 0.501 min solid 2H), 2.89 (d, J = (Method 2)2.0 Hz, 3H), 2.27 - 1.99 (m, 2H), 1.98- 1.83 (m, 2H),1.83 - 1.76 (m,2H), 1.43 (brd, J= 2.0 Hz, 3H)XH NMR (400MHz, DMSO-d6)6 = 8.69 (br s,1H), 7.13 - 7.09(m, 2H), 6.08 (s, [M+H]+:1H), 5.96 (s, 1H), 433.2; tR =4.92 - 4.84 (m, A 12.2 mg 25.1% White solid 0.537 min1H), 4.00 (s, 1H), (Method 2)3.57 (s, 3H), 2.74(s, 3H), 2.04 - 2.02 (m, 1H), 1.90- 1.82 (m, 1H),1.79 - 1.78 (m,Atty Dkt No.: EVOM-008WO2H), 1.70 - 1.65(m, 2H)XH NMR (400MHz, DMSO-d6)6 = 8.53 (br s,1H), 7.13 - 7.09(m, 2H), 7.13 -.09 (m, 2H), 6.08(s, 1H), 4.89 - [M+H]+:.81 (m, 1H), 4.28 379.3; tR =A 5.8 mg 13.7% White solid (s, 1H), 4.00 (s, 0.461 min1H), 3.57 (s, 3H), (Method 2)2.71 (s, 3H), 1.87- 1.64 (m, 1H),1.63 - 1.59 (m,3H), 1.55 - 1.45(m, 2H), 1.23(s,2H)XH NMR (400MHz, DMSO-d6)6 8.71 (s, 1H),7.20 - 7.13 (m,1H), 7.11 - 7.04(m, 2H), 6.32 (d, J= 5.6 Hz, 1H),5.96 - 5.90 (m, [M+H]+:2H), 5.84 (d, J = 449.2; tR =A 10.6 mg 21.3% White solid 5.2 Hz, 1H), 4.92 - 0.488 min.80 (m, 1H), 3.67 (Method 2)(s, 3H), 2.74 (s,3H), 2.09 - 1.98(m, 1H), 1.93 - 1.83 (m, 1H), 1.83- 1.73 (m, 2H),1.73 - 1.58 (m,2H)XH NMR (400[M+H]+::MHz, DMSO-d6) A 8.9 mg 19.8% White solid 395.2; tR =6 8.55 (s, 1H),Atty Dkt No.: EVOM-008WO7.16 (tt, J = 2.4, 0.416min9.2Hz, 1H), 7.08 (Method 2)(br d, J = 6.4Hz,2H), 6.31 (d, J =5.6Hz, 1H), 5.92(s, 1H), 5.84 (d, J= 5.2z, 1H), 4.89 -.76 (m, 1H), 4.27(s, 1H), 3.66 (s,3H), 2.70 (s, 3H),1.91 - 1.79 (m,1H), 1.67 - 1.53(m, 3H), 1.52 - 1.44 (m, 2H), 1.23(s, 3H)XH NMR (400MHz, DMSO-d6)5 9.98 (br s, 1H),7.78 - 7.61 (m,3H), 7.43 (s, 1H),[M+H]+:6.04 (s, 1H), 5.00434.2; tR =- 4.82 (m, 1H), A 4.4 mg 14.6% White solid 0.678min2.84 (s, 3H), 2.09(Method 1)- 2.02 (m, 1H),2.00 - 1.94 (m,1H), 1.90 - 1.82(m, 2H), 1.76 - 1.66 (m, 2H)XH NMR (400MHz, DMSO-d6)6 9.54 (s, 1H),7.24 - 7.04 (m, [M+H]+:3H), 6.57 (s, 1H), 436.3; tR =6.16 - 5.91 (m, A 13 mg 22.1% White solid 0.504min1H), 5.86 (s, 1H), (Method 2)4.99 - 4.73 (m,1H), 2.79 (s, 3H),2.11 - 1.99 (m,1H), 1.99 - 1.88Atty Dkt No.: EVOM-008WO(m, 1H), 1.87 - 1.78 (m, 2H), 1.75- 1.62 (m, 2H)XH NMR (400MHz, DMSO-d6)59.86 (s, 1H),7.73 - 7.65 (m,3H), 7.43 (s, 1H),4.95 -4.85 (m, [M+H]+:1H), 4.34 (s, 1H), 380.1; tR =A 7 mg 10.9% White solid 2.81 (s, 3H), 2.80 3.542min-2.79 (m, 1H), (Method 5)1.99 (s, 1H), 1.73- 1.62 (m, 2H),1.56 (brd, J =12.4 Hz, 3H), 1.26(s, 3H)XH NMR (400MHz, DMSO-d6)59.43 (s, 1H),7.27 - 7.08 (m,3H), 6.65 (brd, J= 5.2 Hz, 1H),[M+H]+:6.57 (s, 1H), 5.86382.4; tR =(brd, J = 4.4 Hz, A 4 mg 22.5% White solid 0.441min1H), 4.92 - 4.77(Method 2)(m, 1H), 4.32 (brs, 1H), 2.75 (s,3H), 1.97 - 1.81(m, 1H), 1.70 - 1.45 (m, 5H), 1.29- 1.21 (m, 3H)XH NMR (400MHz, DMSO-d6) [M+H]+::69.06 (s, 1H), 447.2; tR =7.65 (tt, J = 2.4, A 25.1 mg 38.1% White solid 0.558min9.2 Hz, 1H), 7.50 (Method 4)(dd, J = 2.47.8 Hz,2H), 6.77 (s, 1H),Atty Dkt No.: EVOM-008WO4.97 - 4.78 (m,H), 4.29 (s, 1H),.01 (s, 3H), 2.75(s, 3H), 1.94 -.80 (m, 1H), 1.70- 1.60 (m, 2H),1.58 - 1.44 (m,3H), 1.24 (s, 3H)XH NMR (400MHz, DMSO-d6)5 9.06 (s, 1H),7.65 (tt, J = 2.4,9.2 Hz, 1H), 7.50(dd, J = 2.4, 7.8Hz, 2H), 6.77 (s, [M+H]+:1H), 4.97 - 4.78 393.2; tR =A 18.4 mg 30.7% Yellow solid (m, 1H), 4.29 (s, 0.501minH), 4.01 (s, 3H), (Method 4).75 (s, 3H), 1.94- 1.80 (m, 1H),1.70 - 1.60 (m,2H), 1.58 - 1.44(m, 3H), 1.24 (s,3H)XH NMR (400MHz, DMSO-d6)6 7.47 - 7.38 (m,H), 7.20 (s, 1H),7.03 - 6.92 (m,H), 6.49 (s, 1H), [M+H]+:4.43 - 4.32 (m, 446.2; tR= Off-white A 28.6 mg 70.7%H), 2.96 (s, 3H), 0.744 min solid 2.33 - 2.22 (m, (Method 2)2H), 2.13 - 2.03(m, 2H), 2.03 -.97 (m, 1H), 1.80- 1.71 (m, 1H),1.69 - 1.57 (m,Atty Dkt No.: EVOM-008WO2H), 1.50 - 1.40(m, 1H).XH NMR (400MHz, DMSO-d6)6 7.25 (s, 1H),7.07 - 7.00 (m,1H), 6.95 - 6.85(m, 2H), 6.50 (s, [M+H]+:1H), 4.48 - 4.28 464.1; tR= Off-white A 28.6 mg 67.9%(m, 1H), 2.96 (s, 0.774 min solid 3H), 2.34 - 2.23 (Method 2)(m, 2H), 2.19 -.92 (m, 3H), 1.80- 1.71 (m, 1H),1.69 - 1.57 (m,2H).TH NMR (400MHz, DMSO-d6)5 7.46 - 7.39 (m,H), 7.19 (s, 1H),7.02 - 6.94 (m,H), 4.85 (s, 1H),4.14 - 4.01 (m,[M+H]+:H), 2.91 (s, 3H),392.2; tR= Off-white 2.22 - 2.17 (m, A 14.2 mg 74.1%0.680 min solid 1H), 2.14 - 2.07(Method 2)(m, 1H), 2.02 -.97 (m, 2H), 1.94- 1.86 (m, 2H),1.72 - 1.64 (m,1H), 1.60 - 1.52(m, 2H), 1.18 (s,3H).XH NMR (400MHz, DMSO-d6) [M+H]+:6 7.24 (s, 1H), 410.2; tR= Off-white A 16.3 mg 83.2%7.03 (tt, J = 2.0, 0.710 min solid 9.2 Hz, 1H), 6.89 (Method 2)(dd, J = 2.0, 8.4Atty Dkt No.: EVOM-008WOHz, 2H), 4.85 (s,1H), 4.14 - 4.04(m, 1H), 2.91 (s,3H), 2.25 - 2.17(m, 1H), 2.14 - 2.07 (m, 1H), 2.06- 1.98 (m, 2H),1.91 (br s, 2H),1.73 - 1.64 (m,1H), 1.62 - 1.50(m, 2H), 1.19 (s,3H).XH NMR (400MHz, DMSO-d6)6= 10.96 - 10.52(m, 1H), 7.23 (s,1H), 7.09 - 6.99(m, 1H), 6.94 - 6.85 (m, 2H), 4.60[M+H]+:- 4.46 (m, 1H),396.3; tR =4.03 (dd, J = 6.0, E 4.5 mg 6.4% White solid 0.572 min7.1 Hz, 1H), 2.87(Method 2)(s, 3H), 2.35 - 2.30 (m, 1H), 2.25(br d, J = 6.4 Hz,1H), 1.96 (ddd, J=4.8, 9.8, 12.9 Hz,1H), 1.81 - 1.67(m, 5H)XH NMR (400MHz, DMSO-d6)6 =11.03 - 10.36(m, 1H), 7.24 (s, [M+H]+:1H), 7.09 - 6.99 396.3; tR =E 15 mg 21.1% White solid (m, 1H), 6.90 (dd, 0.589 minJ = 2.0, 8.5 Hz, (Method 2)2H), 3.98 (br t, J =8.8 Hz, 1H), 3.68(t, J = 7.6 Hz, 1H),Atty Dkt No.: EVOM-008WO2.90 (s, 3H), 2.32-2.26 (m, 1H),2.23 - 2.14 (m,2H), 1.88 - 1.78(m, 2H), 1.77 -.65 (m, 2H), 1.64- 1.55 (m, 1H)XH NMR (500MHz, DMSO) 610.81 (s, 1H),7.47 (dtd, J = 8.0,6.9, 1.5 Hz, 1H),7.22 (s, 1H), 7.09 [M+H]+:- 6.97 (m, 3H), 324.0; tR =F 13.3 mg 68.6%4.49 (td, J = 9.2, 2.27 min5.4 Hz, 2H), 4.23 (Method 6)-4.16 (m, 1H),3.81 (dd, J = 9.4,4.0 Hz, 1H), 2.60(s, 5H), 1.29 (d, J= 6.1 Hz, 3H).1H NMR (500MHz, DMSO) 57.52-7.43 (m,1H), 7.25 (s, 1H),7.08-6.98 (m,3H), 4.08 (s, 1H),3.93-3.85 (m, [M+H]+:2H), 3.60 (td, J = 367.9; tR =F 14.4 mg 65.4%9.9, 5.0 Hz, 1H), 2.28 min3.41 (t, J = 11.6 (Method 6)Hz, 1H), 3.06 (t, J= 10.4 Hz, 1H),2.60 (s, 5H), 1.79(qd, J = 12.3, 4.8Hz, 1H), 1.66- 1.59 (m, 1H).XH NMR (500 F [M+H]+: 17.2 mg 82.1%MHz, DMSO) 5 349.9; tR =Atty Dkt No.: EVOM-008WO10.67 (s, 2H), 2.30 min7.47 (td, J = 8.4, (Method 6)6.8 Hz, 2H), 7.22(d, J = 2.6 Hz, 2H),7.02 (dddd, J =14.3, 10.2, 6.2,2.2 Hz, 6H), 4.54(s, 1H), 4.29 - 4.22 (m, 1H), 4.18(s, 1H), 3.91 - 3.84 (m, 1H), 3.73(d, J = 9.4 Hz, 1H),2.95 (d, J = 10.0Hz, 1H), 2.60 (s,11H), 2.44 (s, 1H),1.96 (ddd, J =13.2, 6.9, 2.4 Hz,2H), 1.80 (d, J =9.8 Hz, 1H), 1.66(s, 1H), 1.58 (s,1H), 1.52 (d, J =12.4 Hz, 1H), 1.39(dt, J = 13.4, 2.8Hz, 1H), 1.22 (d, J= 13.1 Hz, 1H).XH NMR (500MHz, DMSO) 610.79 (s, 1H),7.53-7.43 (m,1H), 7.24 (s, 1H),[M+H]+:7.09-6.97 (m,391.9; tR =3H), 4.39 (s, 2H), F 15.5 mg 66%2.66 min4.26 (s, 2H), 4.06(Method 6)- 3.98 (m, 1H),2.82 (s, 3H), 2.60(s, 5H), 2.19 - 2.12 (m, 2H), 1.61- 1.42 (m, 6H).Atty Dkt No.: EVOM-008WOXH NMR (500MHz, DMSO) 610.79 (s, 1H),7.68 (s, 1H), 7.33- 7.23 (m, 1H),7.06 (s, 1H), 6.89- 6.78 (m, 3H), [M+H]+:4.79 (d, J = 8.1 376.9; tR =F 15 mg 66.5%Hz, 1H), 3.55 (dd, 2.23 minJ = 11.1, 8.5 Hz, (Method 6)1H), 3.18 - 3.10(m, 1H), 2.73 (s,3H), 2.41 (s, 8H),0.86- 0.71 (m,3H), 0.49 (td, J =8.1, 2.8 Hz, 1H).1H NMR (500MHz, DMSO) 510.59 (s, 1H),7.34 - 7.25 (m,1H), 7.05 (s, 1H),6.91 - 6.79 (m, [M+H]+:2H), 4.10 (s, 1H), 425.9; tR =F 16.8 mg 65.9%4.00 (s, 1H), 3.25 2.54 min(s, 1H), 2.79 (s, (Method 6)2H), 2.41 (s, 5H),2.17 (ddd, J =10.2, 7.9, 2.7 Hz,1H), 1.94 (td, J =8.9, 2.7 Hz, 1H).2H NMR (500MHz, DMSO) 610.81 (s, 1H), [M+H]+:7.52 - 7.43 (m, 391.9; tR =1H), 7.23 (s, 1H), F 17 mg 72.4%2.63 min7.09 - 6.97 (m, (Method 6)3H), 4.57 (q, J =8.5 Hz, 1H), 4.47(s, 1H), 3.37 (s,Atty Dkt No.: EVOM-008WO1H), 2.90 (s, 3H),2.60 (s, 4H), 2.36- 2.26 (m, 1H),2.28 - 2.22 (m,1H), 2.21 - 2.04(m, 4H), 1.97(ddd, J = 11.3,8.2, 3.1 Hz, 1H),1.84 (dd, J = 11.1,7.3 Hz, 1H), 1.75(dd, J = 11.5, 7.3Hz, 1H).XH NMR (500MHz, DMSO) 510.20 (s, 1H),7.48 (dtd, J = 8.1,6.8, 1.7 Hz, 1H),7.20 (s, 1H), 7.08- 6.97 (m, 3H), [M+H]+:5.64 (s, 1H), 3.59 391.9; tR =F 16.6 mg 70.7%(s, 2H), 2.82 (s, 2.96 min3H), 2.60 (s, 5H), (Method 6)2.33 - 2.27 (m,2H), 2.16 - 2.00(m, 4H), 1.97 (dd,J = 8.9, 6.3 Hz,2H), 1.88 - 1.78(m, 2H).XH NMR (500MHz, DMSO) 610.69 (s, 1H),7.36 (td, J = 8.5, [M+H]+:6.7 Hz, 1H), 7.13 377.9; tR =(s, 1H), 6.98 - F 16.9 mg 74.7%2.61 min6.86 (m, 3H), 5.09 (Method 6)(d, J = 6.1 Hz, 1H),3.91 (t, J = 9.1 Hz,1H), 3.61 (q, J =7.0 Hz, 1H), 2.83Atty Dkt No.: EVOM-008WO(s, 3H), 2.48 (s,5H), 2.22 (ddd, J= 11.0, 8.0, 6.8Hz, 1H), 2.12(tdd, J = 10.6, 6.1,2.5 Hz, 2H), 1.80- 1.58 (m, 4H),1.53 (ddd, J =13.5, 9.1, 4.6 Hz,1H).XH NMR (500MHz, DMSO) 610.82 (s, 1H),7.53 - 7.43 (m,1H), 7.23 (s, 1H),7.09 - 6.97 (m,3H), 4.96 (s, 1H),[M+H]+:4.61 (q, J = 8.8377.9; tR =Hz, 1H), 4.02 (p, J F 20.4 mg 90.2%2.52 min= 7.3 Hz, 1H),(Method 6)2.90 (s, 3H), 2.60(s, 5H), 2.50 - 2.37 (m, 1H), 2.26- 2.04 (m, 5H),1.88 (ddd, J =13.8, 10.9, 7.7 Hz,2H).XH NMR (500MHz, DMSO) 510.73 (s, 1H),7.32 - 7.20 (m,[M+H]+:1H), 7.03 (s, 1H),457.9; tR =6.88 - 6.77 (m, F 17.2 mg 62.7%2.76 min2H), 6.20 (s, 1H),(Method 6)3.80 (s, 3H), 2.41(s, 5H), 2.31 - 2.23 (m, 2H), 2.14- 1.97 (m, 5H).Atty Dkt No.: EVOM-008WOXH NMR (500MHz, DMSO) 610.74 (s, 1H),7.33-7.24 (m,1H), 7.04 (s, 1H),[M+H]+:6.90-6.78 (m,445.9; tR =3H), 5.62 (s, 1H), F 18.1 mg 67.8%2.7 min3.52 (s, 2H), 2.41(Method 6)(s, 7H), 1.64- 1.59 (m, 4H), 1.59- 1.49 (m, 2H),1.32 (dt, J = 13.3,8.7 Hz, 2H).XH NMR (500MHz, DMSO) 510.79 (s, 1H),7.28 (td, J = 8.3,6.9 Hz, 1H), 7.03[M+H]+:(s, 1H), 6.90 - 417.9; tR =6.77 (m, 3H), 6.37 F 18.4 mg 73.5%2.58 min(s, 1H), 3.90 (s,(Method 6)2H), 3.85 (s, 2H),2.53-2.44 (m,2H), 2.41 (s, 7H),2.22 (d, J = 13.5Hz, 2H).XH NMR (500MHz, DMSO) 610.76 (s, 1H),7.34-7.23 (m,1H), 7.03 (s, 1H), [M+H]+:6.90-6.77 (m, 399.9; tR =F 16.3 mg 68.1%3H), 5.66 (s, 1H), 2.46 min3.87 (s, 2H), 3.79 (Method 6)(s, 2H), 2.41 (s,5H), 2.34 (s, 1H),2.10-2.03 (m,2H).Atty Dkt No.: EVOM-008WOXH NMR (500MHz, DMSO) 610.70 (s, 1H),7.33-7.24 (m,1H), 7.05 (s, 1H),6.90-6.78 (m,3H), 6.26 (s, 1H), [M+H]+:3.31 (t, J = 5.6 Hz, 445.9; tR =F 8.1 mg 30.3%2H), 3.25 (t, J = 2.78 min5.6 Hz, 2H), 2.41 (Method 6)(s, 7H), 2.06- 2.00 (m, 2H), 1.76(d, J = 13.2 Hz,2H), 1.54 (t, J =5.5 Hz, 2H), 1.34- 1.28 (m, 2H).1H NMR (500MHz, DMSO) 510.52 (s, 1H),7.33-7.23 (m,1H), 7.04 (d, J =[M+H]+:2.7 Hz, 1H), 6.90431.9; tR =- 6.78 (m, 3H), F 17.4 mg 67.3%2.67 min3.39 (s, 1H), 2.41(Method 6)(s, 5H), 2.26 (t, J =14.2 Hz, 2H), 1.93(d, J = 13.6 Hz,2H), 1.74 (d, J =8.2 Hz, 1H).XH NMR (500MHz, DMSO) 67.52-7.44 (m,1H), 7.26 (s, 1H), [M+H]+:7.08-6.98 (m, 425.9; tR =F 18.5 mg 72.5%3H), 4.23 (s, 1H), 2.3 min4.05 (s, 1H), 3.85 (Method 6)(s, 1H), 3.84 - 3.69 (m, 2H), 3.59- 3.50 (m, 1H),Atty Dkt No.: EVOM-008WO3.37 (s, 1H), 3.28(t, J = 12.4 Hz,1H), 2.60 (s, 8H),1.96 (td, J = 13.0,4.8 Hz, 1H), 1.69(td, J = 12.8, 4.9Hz, 1H), 1.57 (d, J= 13.5 Hz, 1H),1.35- 1.24 (m,1H).XH NMR (500MHz, DMSO) 610.92 (s, 1H),7.48-7.37 (m,1H), 7.17 (s, 1H),[M+H]+:7.04-6.92 (m,413.9; tR =3H), 4.02 (s, 2H), F 17.2 mg 69.4%2.53 min3.91 (s, 2H), 3.53(Method 6)(t, J = 13.4 Hz,2H), 2.77 (tp, J =16.7, 8.4 Hz, 1H),2.55 (s, 7H), 2.31- 2.15 (m, 4H).XH NMR (500MHz, DMSO) 510.68 (s, 1H),7.33-7.24 (m,1H), 7.05 (s, 1H),6.89-6.79 (m,[M+H]+:3H), 6.32 (s, 1H),445.9; tR =3.41 (s, 2H), 2.41 F 7.7 mg 28.8%2.82 min(s, 7H), 1.92 (d, J(Method 6)= 14.1 Hz, 2H),1.72 (d, J = 13.4Hz, 2H), 1.39 (t, J= 5.9 Hz, 2H),1.30 (d, J = 7.3Hz, 2H).Atty Dkt No.: EVOM-008WOXH NMR (500MHz, DMSO) 67.48- 7.36 (m,1H), 7.20 (s, 1H),7.06-6.93 (m, [M+H]+:3H), 3.92 - 3.73 395.9; tR =F 16.1 mg 67.9%(m, 2H), 2.55 (s, 2.54 min5H), 2.33 (s, 1H), (Method 6)2.18 (q, J = 8.7Hz, 1H), 1.92 - 1.73 (m, 2H), 1.80(s, 1H).XH NMR (500MHz, DMSO) 57.52-7.43 (m,1H), 7.26 (s, 1H),7.08-6.98 (m,3H), 4.81 (d, J =6.5 Hz, 1H), 4.77(dd, J = 6.9, 1.4 [M+H]+:Hz, 1H), 4.52 (d, J 397.9; tR =F 15.1 mg 63.4%= 6.6 Hz, 1H), 2.16 min4.44 (dd, J = 6.8, (Method 6)2.3 Hz, 1H), 4.12-4.05 (m, 1H),4.05- 3.96 (m,1H), 3.78 (d, J =11.2 Hz, 1H), 3.72(s, 1H), 3.66 (s,1H), 2.60 (s, 7H).2H NMR (500MHz, DMSO) 67.48 (td, J = 8.4, [M+H]+:6.7 Hz, 1H), 7.25 413.9; tR =(s, 1H), 7.10 - F 16.7 mg 67.4%2.54 min6.99 (m, 3H), 4.01 (Method 6)(d, J = 12.9 Hz,1H), 3.94 - 3.87(m, 1H), 3.56 (tt, JAtty Dkt No.: EVOM-008WO= 8.8, 4.0 Hz, 1H),3.16 (s, 1H), 2.87(s, 1H), 2.60 (s,7H), 2.51 (ddd, J= 18.3, 13.2, 6.5Hz, 1H), 2.48 (s,1H), 2.49 - 2.32(m, 2H), 1.97 (dd,J = 12.7, 3.8 Hz,1H), 1.59 (dd, J =12.8, 9.1 Hz, 1H).1H NMR (500MHz, DMSO) 510.73 (s, 1H),7.53-7.37 (m,1H), 7.20 (s, 1H),7.03-6.95 (m,2H), 6.99 - 6.90(m, 1H), 6.26 (s,[M+H]+:1H), 4.29 (d, J =445.9; tR =172 11.0 Hz, 1H), 3.13 F 10.9 mg 32.7%2.88 min(s, 2H), 2.55 (s,(Method 6)5H), 2.39 (d, J =4.5 Hz, 1H), 2.12(dt, J = 13.7, 4.0Hz, 1H), 1.80 - 1.70 (m, 2H), 1.68(d, J = 10.7 Hz,1H), 1.49 (d, J =12.4 Hz, 2H).Example 9: Human MRGPRX2 antagonist 3-Arrestin Assay

[0264] This assay was conducted at Eurofins Discovery using Eurofins PathHunter -Arrestin MRGPRX2 assay technology. In short, The PathHunter® P-Arrestin assay monitors the activation of a GPCR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC) with -galactosidase ( -Gal) as the functional reporter. The PathHunter P-Arrestin MRGPRX2 cell lines (CHO-kl) are engineered toAtty Dkt No.: EVOM-008WOco-express two inactive complementary portions: a small peptide, called ProLink™ (PK) tagged MRGPRX2 and the Enzyme Acceptor (EA) tagged -Arrestin. When the target GPCR is activated and -Arrestin is recruited to the receptor, PK and EA complementation occurs, restoring -Gal activity which is measured using chemiluminescent PathHunter® Detection Reagents. Activation of the MRGPRX2-PK induces -Arrestin-EA recruitment, forcing complementation of the two enzyme fragments. The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal.

[0265] Cell Handling: PathHunter cell lines were expanded from freezer stocks according to standard procedures. Cells were seeded in a total volume of 20 pL into white walled, 384-well microplates and incubated at 37°C for the appropriate time prior to testing.

[0266] Assay: 1) For antagonist determination, cells were pre-incubated with antagonist followed by agonist (Cortistatin 14) challenge at the EC80 concentration. 2) Intermediate dilution of sample stocks was performed to generate 5X sample in assay buffer. 3) 5 pL of 5X sample was added to cells and incubated at 37°C or room temperature for 30 minutes. Vehicle concentration was 1%. 4) 5 pL of 6X EC80 agonist in assay buffer was added to the cells and incubated at 37°C or room temperature for at least 120 minutes.

[0267] A control dose curve was performed for MRGPRX2 Biosensor Assay. Data was normalized to the maximal and minimal response observed in the presence of control compound and vehicle respectively.

[0268] Signal Detection: 1) Assay signal was generated through a single addition of 15 pL (50% v / v) of PathHunter Detection reagent cocktail, followed by a one hour incubation at room temperature. 2) Microplates were read following signal generation with a PerkinElmer EnvisionTM instrument for chemiluminescent signal detection.

[0269] Data Analysis: 1) Compound activity was analyzed using CBIS data analysis suite (Chemlnnovation, CA). 2) Percentage inhibition was calculated using the following formula:

[0270] % l nhibition = 100% x (1 — (mean RLU of test sample — mean RLU of vehicle control) / (mean RLU of EC80 control — mean RLU of vehicle control)).

[0271] Data was normalized to the maximal and minimal response observed in the presence of EC80 ligand and vehicle. The following EC80 concentrations were used:Atty Dkt No.: EVOM-008WO

[0272] MRGPRX2 Arrestin: 0.578 uM Cortistatin 14

[0273] Normalized data was plotted as a function of the concentration of test compound and the 50% inhibition (IC50) values were determined using a fit of the data to a four-parameter equation. Activity ranges are given as follows: " A" denotes an IC50 value <100 nM, " B" denotes an IC50 value betweenlOO.l nM and 1000 nM, " C" denotes an IC50 value > 1000 nM, " D" denotes not determined.Example 10: Human MRGPRX2 antagonist Calcium Flux Assay

[0274] This assay was conducted at Eurofins Discovery. The Calcium No WashPLUS assay monitors GPCR activity via Gq secondary messenger signaling in a live cell, non-imaging assay format. Calcium mobilization in CHO-K1 cell lines stably expressing Gq-coupled MRGPRX2 is monitored using a calcium-sensitive dye that is loaded into cells. GPCR activation by a compound results in the release of calcium from intracellular stores and an increase in dye fluorescence that is measured in real-time.

[0275] Cell Handling: 1) Cell lines were expanded from freezer stocks according to standard procedures. 2) Cells were seeded in a total volume of 20 pL into black-walled, clear-bottom, Poly-D-lysine coated 384-well microplates and incubated at 37°C for the appropriate time prior to testing.

[0276] Dye Loading: 1) Assays were performed in 1 x Dye Loading Buffer consisting of lx Dye, lx Additive A and 2.5 mM Probenecid in HBSS / 20 mM Hepes. Probenicid was prepared fresh. 2) Cells were loaded with dye prior to testing. Media was aspirated from cells and replaced with 20 pL Dye Loading Buffer. 3) Cells were incubated for 30-60 minutes at 37°C.

[0277] Assay: 1) For antagonist determination, cells were pre-incubated with sample followed by agonist challenge at the EC80 concentration. 2) Intermediate dilution of sample stocks was performed to generate 3X sample in assay buffer. 3) After dye loading, cells were removed from the incubator and 10 pL 3X sample was added. Cells were incubated for 30 minutes at room temperature in the dark to equilibrate plate temperature. Vehicle concentration was 1%. 4) Compound antagonist activity was measured on a FLIPR Tetra (MDS). Calcium mobilization wasAtty Dkt No.: EVOM-008WOmonitored for 2 minutes and 10 pL EC80 agonist in HBSS / 20 mM Hepes was added to the cells 5 seconds into the assay.

[0278] Data Analysis: 1) Compound activity was analyzed using CBIS data analysis suite (Chemlnnovation, CA). 2) Percentage inhibition is calculated using the following formula:

[0279] % Inhibition = 100% x (1 - (mean RFU of test sample - mean RFU of vehicle control) / (mean RFU of EC80 control - mean RFU of vehicle control)).

[0280] Data was normalized to the maximal and minimal response observed in the presence of EC80 ligand and vehicle. The following EC80 concentrations were used:

[0281] MRGPRX2 Calcium Flux: 0.282 uM Cortistatin 14

[0282] Normalized data was plotted as a function of the concentration of test compound and the 50% inhibition (IC50) values were determined using a fit of the data to a four-parameter equation. Activity ranges are given as follows: " A" denotes an IC50 value <100 nM, " B" denotes an IC50 value between 100.1 nM and 1000 nM, " C" denotes an IC50 value > 1000 nM, " D" denotes not determined.

[0283] Activity data forexemplary MRGPRX2 antagonists in the Human MRGPRX2 Calcium Flux and |3-Arrestin Assay are shown in Table 3 below.Table 3: MRGPRX2 Inhibition Data for Exemplary CompoundsMRGPRX2 MRGPRX2inhibition inhibitionCompound (Calcium Flux (P-Arrestin# assay) assay)1 A A2 A A3 A A4 A A5 A A6 A A7 A A8 A B9 A A10 A A11 B B12 A AAtty Dkt No.: EVOM-008WOA B A A A A A B A A A A A A A A A A A A C C A A A A A B A A A A A A C C C C B C B C B C A A A A A A C C C C B B C C C C C C A A A B A A A B A A A A B B A A A AA AAtty Dkt No.: EVOM-008WOA A A A A A A A A A B B A A A A A A A A A A B B D A D A D A D C D C D C D C D C D C D C D C D A D B D A D A D C D B D B D B D A D A D C D B D C D C D A D C D B D C D AD AAtty Dkt No.: EVOM-008WOD B D C D C D C D C D C D C D C D A D B D B D B D A D B D A D A D A D B D B D A D A D A D C D B D B D A D A D A D A D B D A D A D B D A D A D C D C D B D C D C D C D CD C97Atty Dkt No.: EVOM-008WO140 D C141 D C142 D C143 D C144 D B145 D A146 D B147 D A148 D A149 D A150 D C151 D C152 D B153 D B154 D B155 D B156 D A157 D B158 D A159 D A160 D B161 D B162 D C163 D C164 D C165 D A166 D C167 D B168 D A169 D B170 D C171 D C172 D B

[0284] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.Atty Dkt No.: EVOM-008WO

[0285] Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims.

[0286] The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. In the claims, 35 U. S. C. §112(f) or 35 U. S. C. §112(6) is expressly defined as being invoked for a limitation in the claim only when the exact phrase "means for" or the exact phrase "step for" is recited at the beginning of such limitation in the claim; if such exact phrase is not used in a limitation in the claim, then 35 U. S. C. § 112 (f) or 35 U. S. C. §112(6) is not invoked.

Claims

Atty Dkt No.: EVOM-008WOCLAIMSWhat Is Claimed Is:

1. A compound of formula (la):R1(la)wherein:R1and R2are each independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, spirocycloalkyl, substituted spirocycloalkyl, bicycloalkyl and substituted bicycloalkyl, or R1and R2together with the N to which they are attached form a heterocycloalkyl ring, substituted heterocycloalkyl ring, heterospirocycloalkyl ring, substituted heterospirocycloalkyl ring, heterobicycloalkyl ring or substituted heterobicycloalkyl ring;G1, G2, G3and G4are each independently selected from N, S, 0, C-H, C-L^M1and N-L1-M1;each L1is independently selected from a bond, 0, C(=0), C(=O)NH, CHOH and CH2; and each M1is independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

2. The compound of claim 1, wherein the compound has formula (lb):(lb)wherein:R1is selected from H and alkyl;Atty Dkt No.: EVOM-008WOW1is selected from cycloalkyl, spirocycloalkyl and bicycloalkyl.p is 0 or an integer from 1 to 10; andeach R3is independently selected from H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, halogen, alkoxy, hydroxy, cyano and oxo.

3. The compound of claim 2, wherein W1is C4.7 cycloalkyl.

4. The compound of claims 2 or 3, wherein the compound has formula (II):wherein:m is 0 or 1; andn is 1 or 2.

5. The compound of claim 4, wherein the compound has formula (III):

6. The compound of claim 5, wherein each R3is independently selected from haloalkyl and hydroxy.

7. The compound of any one of claims 4 to 6, wherein the compound has formula (IV):Atty Dkt No.: EVOM-008WOR1(IV).

8. The compound of any one of claims 4 to 7, wherein m is 1 and n is 1.

9. The compound of any one of claims 4 to 7, wherein m is 0 and n is 1.

10. The compound of any one of claims 4 to 7, wherein m is 1 and n is 2.

11. The compound of claim 7, wherein the compound has formula (V):R112. The compound of any of the previous claims, wherein at least one of G1, G2, G3and G4is13. The compound of any of the previous claims, wherein at least one of G1, G2, G3and G4is S.

14. The compound of any of the previous claims, wherein at least one of G1, G2, G3and G4is C-U-M1.

15. The compound of claim 14, wherein one of G1, G2, G3and G4is C- -M1.Atty Dkt No.: EVOM-008WO16. The compound of claim 15, wherein G3is C- -M1.

17. The compound of claim 16, wherein G1is N, G2is C-H, G3is C-L^M1and G4is S.

18. The compound of claim 16, wherein G1is N, G2is N, G3is C-L1-M1and G4is S.

19. The compound of any one of claims 1 to 13, wherein at least one of G1, G2, G3and G4is N-l^-M1.

20. The compound of claim 19, wherein one of G1, G2, G3and G4is N-l^-M1.

21. The compound of claim 20, wherein G3is N-lJ-M1.

22. The compound of claim 21, wherein G1is C-H, G2is C-H, G3is N-^-M1and G4is N.

23. The compound of any of the previous claims, wherein M1is selected from aryl and heteroaryl or substituted versions thereof.

24. The compound of claim 11, wherein the compound has formula (VI):(VI)wherein:Q1, Q2, Q3, Q4and Q5are each independently selected from N, C-H and C-RQ; andAtty Dkt No.: EVOM-008WOeach RQis independently selected from halogen, hydroxy, cyano, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

25. The compound of claim 24, wherein each RQis independently selected from halogen, haloalkyl and alkyl.

26. The compound of claims 24 or 25, wherein one or two of Q1, Q2, Q3, Q4and Q5is C-RQ, wherein each RQis selected from halogen.

27. The compound of any of the previous claims, wherein R1is alkyl.

28. The compound of any of the previous claims, wherein R1is methyl.

29. The compound of claim 1, wherein the compound has formula (VII):whereinW2is selected from heterocycloalkyl, heterospirocycloalkyl and heterobicycloalkyl.

30. The compound of any of the previous claims, wherein L1is 0.

31. The compound of any one of claims 1 to 29, wherein L1is CH2.

32. The compound of claim 1, wherein the compound has a structure selected from:Atty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WOAtty Dkt No.: EVOM-008WO33. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any of the previous claims, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

34. The pharmaceutical composition of claim 33, wherein the pharmaceutically acceptable excipient is a dermatologically or orally acceptable excipient.

35. A method for treating an inflammatory disorder, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claims 33 or 34.

36. The method according to claim 35, wherein the inflammatory disorder activates MrgprX2 or is consequent to activation of MrgprX2.

37. The method according to claims 35 or 36, wherein the inflammatory disorder is an inflammatory disorder of the skin.

38. The method according to claims 35 or 36, wherein the inflammatory disorder is an anaphylactic reaction, an anaphylactoid reaction, chronic urticaria, systemic itch, rosacea, atopic dermatitis, allergic contact dermatitis, ulcerative colitis and allergic asthma.